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 Prescribing, the first and major decision-making stage in the medication use 
process, has the greatest potential to produce health benefits or cause harm.  However, 
prescribing for the elderly is challenging, especially for medically frail elderly nursing 
home residents (NHRs).  It was hypothesized that innovations of inter-professional 
collaborative practice that leverage on the pharmacists’ role as an “advocator” of 
appropriate medication use may improve prescribing appropriateness (PA) and 
outcomes of NHRs. 
In this thesis, two such practices, namely, the Pharmacist-Led Education on 
Appropriate Drug-use (PLEAD) program and the Psychotropic Use Monitoring (PUM) 
program were developed, implemented and evaluated (reported in Chapters 3 and 4 
respectively) for their impact on reducing inappropriate prescribing/use of laxatives 
and antipsychotics identified from the retrospective cross-sectional background study 
conducted in four NHs (reported in Chapter 2) and optimizing related clinical 
outcomes among elderly NHRs in Singapore. 
 The PLEAD program, spearheaded by pharmacists, engaged the nursing staff 
(NS), physicians and key administrators in behavioral changes to improve the 
appropriateness and outcomes of laxative use by NHRs.  A set of recommendations 
(iPURGE) was thus developed and communicated via a workshop and “Dear 
Healthcare Professional Letter”.  The non-randomized controlled study in two NHs to 
evaluate PLEAD’s impact showed significant increases in the number of laxative 
prescriptions altered and bowel frequencies of residents in the intervention NH.  The 
dosing of laxatives was optimized, with a benefit of reducing the time needed for 
medication administration by the NS.  In addition to PLEAD, the Algorithms for 




prescribing” and “under-use” of laxatives for regular and when-needed use, was 
developed; validation of AALU using laxative use data of 24 NHRs suggested its 
potential in facilitating timely retrospective medication use evaluations and 
prospective use as a guide for prescribing/administering laxatives. 
The PUM program synergized the expertise of the pharmacist, nursing staff 
(NS) and physicians to monitor the use of antipsychotics and other psychotropics to 
manage behavioral and psychological symptoms of dementia (BPSD).  After 
receiving training from the pharmacist, the NS in one NH dementia ward used the 
newly developed Assessment for Psychotropic Prescriptions (APP) scale for PUM 
and provided timely feedback to the psychiatrist, who then adjusted the doses of 
psychotropics for the residents.  From the before-and-after pilot study, the average 
daily doses of antipsychotics, residents’ psychological symptoms, and adverse events 
decreased after PUM implementation; positive changes in the psychiatrist’s 
antipsychotic-related prescribing decisions and the NS’s perceptions towards BPSD 
management, psychotropic side effects monitoring and caregiving stress were also 
reported.  In addition to PUM, feasibility study of computer games as a diversional 
therapy to manage BPSD and reduce inefficacious use of antipsychotics (as a 
secondary effect) was piloted, with encouraging results (Chapter 5); a new criteria 
(JACLY) was developed and used to select suitable computer games for this purpose. 
Future work is needed to evaluate the sustainability, cost-effectiveness and 
feasibility of these innovative collaborative practices involving pharmacists on the use 
of these and other medications within NHs/other care settings in Singapore and 
elsewhere.        
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Introduction and Literature Review 
 
1.1 Medication use process in the nursing homes (NHs) 
 Medication use is a central aspect of medical care for most elderly persons, for 
the treatment of acute (e.g. antibiotics) or chronic conditions (e.g. blood sugar 
lowering medications), prophylaxis or secondary prevention (e.g. antiplatelets), and 
symptom relief or palliation (e.g. painkillers).  Based on a medication safety guideline 
published by the Ministry of Health in Singapore, regardless of the purpose of 
medication use, the processes involved in medication use can be summarized in 
general as four inter-related and continuous stages, namely “prescribing”, “supply”, 
“administration” and “monitoring” (Figure 1.1).1   
  
Figure 1.1  Medication use process in the NHs in Singapore   
The  medication  use  stages  that  take  place  predominantly  within  the  confines  of  a  NH  in  Singapore  are 
“Prescribing”,  “Administration” and  “Monitoring”.    “Supply” of medications usually  takes place at a pharmacy 
outside  the  confines of  the NH.   A  visiting pharmacist’s  role  is  to provide  “monitoring”  at  the NHs,  2   which 




In the NH in Singapore, while the “supply” of medications often take place at 
a pharmacy outside the confines of the NHs, the responsibility of the visiting 
pharmacist in “monitoring” is to provide “periodic (at least six monthly) review of the 
individual resident’s (NHR’s) medical, medication records and prescriptions to 
evaluate his/her progress towards achieving therapeutic outcomes and to ensure that 
his/her drug therapy is appropriately indicated, effective, safe and convenient”.2  The 
pharmacist’s interventions can, therefore, influence medication use at the 
“administration” stage by the nurses and “prescribing” stage by the physicians (Figure 
1.1).     
 
1.2 Caveats of prescribing for the elderly 
Prescribing for individuals in this population group are often complex 
decisions, compounded by issues of age-related pharmacokinetic and 
pharmacodynamic changes, polypharmacy, increased co-morbidities, aged 
heterogeneity, and the lack of evidence-based prescribing information due to under-
representation of elderly in clinical trials and inadequacies in disease-specific clinical 
guidelines.3-5  Hence, the focus on appropriate prescribing has become a cornerstone 
in the practice of geriatric pharmacotherapy.6  Clinical and epidemiological research 
with the aim to improve prescribing appropriateness (PA) among the elderly has also 
become indispensable,7 in view of the concerns about increased costs8 and safety 
issues9 related to inappropriate prescribing (IP). 
  
1.3 Defining and measuring PA 
 In its fundamental pharmacological sense, the term PA implies the attainment 
of maximum health benefits with minimal risks from a chosen pharmacological 
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therapy.10, 11  However, based on this definition, it would be difficult to derive a 
standard measure of appropriateness as patient outcomes often vary widely; this is due 
to the complexity of case mix in the elderly and other issues (such as patient’s choice, 
social expectations, ethics, cost and quality of life) that may influence prescribing.  
Hence, PA has been more comprehensively defined as “the outcome from a process of 
decision-making that maximizes net individual health gains within society’s available 
resources”.12   
Besides simply being “appropriate” or “inappropriate”, inappropriateness in 
prescribing (or medication use in general) can be categorized as: (1) over-prescribing 
(overuse of medication), (2) mis-prescribing (misuse of medication), and (3) under-
prescribing (underuse of medication).  Extending from the definitions of the problem 
categories in healthcare quality,13  over-prescribing can be defined as the prescribing 
of more medications than clinically indicated.  Likewise, mis-prescribing can be 
defined as the incorrect use of a medication (which include incorrect choice of 
medicine, dose, mode of administration, duration of therapy, or the presence of drug 
interactions, inadequate monitoring, and unjustified cost) when an indication is 
present; and under-prescribing can be defined as the omission of medication use when 
it is indicated, where such an omission would be deleterious to the patient’s health.  
From these definitions, “inappropriate” prescribing implies mistakes in planning 
actions.  Hence, it may also be likened to being part of the knowledge-based and rule-
based classification of “medication error”.14 
Tools for assessments of PA can be (1) used to identify gaps in achieving 
optimal medication use,15, 16 (2) incorporated as part of interventions that aim to 
improve medication use and its outcomes,17-19 or (3) applied as outcome measures in 
clinical studies.20  Ideally, comprehensive PA assessment tools should address all 
4 
 
types of IP described above.21  Over the past two decades, numerous instruments 
which contain lists of prescribing quality indicators22 for the assessment/measurement 
of the PA in the elderly population were developed, modified and updated.  Those 
instruments that were developed for use in any setting or specifically in the NH 
setting were identified from PUBMED, using a combination of keywords 
“prescribing”, “elderly”, “measure”, and “appropriateness".  Citations in relevant 
publications identified from the search were also reviewed manually.  Instruments that 
were developed for use specifically in the hospital in-patient23-26 and community27, 28 
were excluded.  The results were summarized in Table 1.1, which was recently 
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PA can be measured by explicit or implicit prescribing quality indicators,11  
from the perspective of the prescribing “process”, or its “outcomes”.  Among the 
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instruments listed in Table 1.1, those which contain “explicit” indicators are usually 
drug or disease-oriented and are derived from published literature and expert opinions.  
Although these can be easily applied in settings where little patient information is 
available, they do not allow for situational flexibility as they may not be able to 
address all pharmacological issues and clinical scenarios, nor do they account for non-
pharmacological factors such as the patient’s and surrogate’s wishes.44, 45  In addition, 
these instruments may become quickly obsolete and irrelevant if not updated 
periodically with new clinical evidence.46  Hence, these may also be time-consuming 
and costly to maintain.   
Conversely, “implicit” indicators allow the assessor to employ his/her clinical 
judgment on available patient information and clinical recommendations to measure 
PA.  These indicators usually focus on the individual elderly person rather than on a 
specific drug or disease, and thus, may account for complex mix of patient factors and 
external factors that may influence prescribing.  However, the use of “implicit” 
indicators such as the Medication Appropriateness Index (MAI)33, 34 is time-
consuming, and may have low inter-rater reliability as its use depends on the users’ 
knowledge and attitudes.47  For example, differences in users’ attitudes towards 
prescribing of analgesics for patients who are not able to verbally communicate 
pain,48  deciding on the dose and duration of long-term active treatment for chronic 
illness in frail elderly,49  and determining the need for pharmacological agent to 
manage behavioral problems among institutionalized elderly with dementia50  may 
give rise to different “appropriateness”, and hence influence the reliability of MAI 
among different users. 
“Process” indicators refer to elements/rationale to be considered during the 
decision-making process of prescribing.  “Outcome” indicators refer to the effect of 
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the prescribing decision on the patient (i.e. NHR).  Assessments of PA based solely 
on “process” measures would not be able to link the process’s impact to patient 
outcomes.  On the other hand, assessments based on “outcomes” measures alone 
would not elucidate the underlying causes of IP or process areas for improvement.  
Hence, evaluations of PA should include both “process” and the “outcomes” 
measurements.51-53   To date, only MacKinnon et al.35 and Morris et al.39 attempted to 
marry both “process” and “outcomes” measurements in an instrument.  However, the 
two teams’ disagreement on a single explicit criteria set emphasized the lack of a 
consensus on what was considered a drug-related morbidity54 and its preventability.55   
Further to this, a review of original publications that reported the prevalence 
of IP measured using PA instruments (published from 1998 to 2008) in the NH setting 
was performed in PUBMED using MeSH terms “inappropriate prescribing” and 
“nursing home”.  The reference lists of review articles of this topic identified from the 
search were also reviewed manually to identify additional publications.  Among the 
nine studies identified (Table 1.2), only two evaluated the relationship between the 
use of Beers criteria medications30 and adverse events (AEs) of all-cause 
hospitalization, emergency department (ED) visit and/or death.56-58  Although 
significant associations were reported by Lau et al. and Perri et al., the predictability 
of actual adverse drug events (ADE) from the use of inappropriate medications 
remain elusive,59 as numerous others,60-65 did not find significant associations between 
































































































































































Among the studies which directly examined incidents of probable adverse 
drug reactions (ADRs) and/or events among elderly NHR,73-77 antipsychotics (8.3% to 
22.8%), diuretics (7.5% to 20.8%) and warfarin (7.5% to 15%) were repeatedly 
reported as the top medications implicated.  In addition to identifying the commonly 
implicated medications, inappropriateness in the prescribing and monitoring stages of 
the medication use process were also identified by Gurwitz et al. to be the major 
contributory factors towards ADEs in this elderly population, over medication errors 
in the supply, storage and administration stages.76, 77  Hence, not only is prescribing 
the first and major decision-making step in the medication use process, it has been 
shown to have the greatest potential to produce health benefits or to cause harm.78   
In another study by Budnitz et al., which evaluated the incidents of ADEs-
related ED visits among older adults in general, Beers criteria-defined inappropriate 
medications were found to be implicated in only 8.8% of the total 4492 incidents.79  
This is a far cry compared to the top single medications implicated, namely warfarin 
(17.3%) and insulin (13.0%).  Interestingly, antipsychotics were not among the top 
medications implicated in ADRs among the elderly in general.  This could be related 
to antipsychotics’ common use among elderly NHR, to manage behavioral and 
psychological symptoms of dementia (BPSD).73, 80, 81   
In summary, to achieve optimal pharmacotherapy outcomes, it is imperative to 
ensure PA.  Although instruments for measuring PA are available, each has their 
limitations and inadequacies in predicting clinically significant adverse outcomes.  In 
addition, interventions that aim to improve clinical outcomes among the elderly NHRs 
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may be more effective from targeting issues related to all aspects of inappropriate 
drug use (i.e. overuse, misuse, and underuse) in specific drug groups or 
diseases/conditions, instead of the focus on the general reduction of IP spelled out in 
these instruments.  However, the use of these instruments in medication use 
evaluation (MUE) studies82    may highlight gaps in achieving optimal medication use 
and issues related to specific drug groups or diseases/conditions for interventions. 
 
1.4 Improving PA – the role and potential impact of pharmacists in 
medication management in Singapore NHs 
   The main role of the pharmacist is providing pharmaceutical care, which is 
defined as “the responsible provision of drug therapy to achieve definite outcomes 
that are intended to improve a patient’s quality of life”.83  Having a professional 
education that focuses on pharmaceutical expertise and development of pharmacists’ 
clinical roles in various healthcare settings, pharmacists are, therefore, in the prime 
position to promote and support the safe, effective and rational use of medications, to 
improve PA and its outcomes.84-86  Furthermore, long-term care facilities such as NHs 
presents ideal opportunities for timely and comprehensive drug regimen reviews.7  
The physical confines of an institution may also bring the prescriber, nursing staff 
(NS), other health care providers and the pharmacist into close proximity of each 
other, and allow greater communications and support for each other to achieve 
optimal pharmacotherapy and continuity of pharmaceutical care for the elderly NHRs.  
In countries such as the USA and Australia, pharmacist-led medication reviews for 
the elderly residing in long-term care facilities have been mandated,87, 88 and have 
undergone rigorous federal-funded research to evaluate its impact.89, 90   
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A literature search was conducted (during January 2009) in PUBMED using 
the keywords “intervention studies”, “intervention”, “medication”, “prescribing”, and 
“nursing homes” (entered as a MeSH term) to identify interventions  published during 
1998 to 2008 that aimed to reduce IP in the NHs.  The publications included for 
discussion were those that reported changes in medication use/prescribing or 
prescribing appropriateness as the primary outcome measure of the intervention, with 
comparisons to a control or baseline estimates.  The reference lists of review articles 
(that described nursing home interventions) identified from the search were also 
reviewed manually for additional publications.  As various study designs may be 
employed to evaluate interventions of different nature, no attempts were made to 
judge the quality of the studies.  All publications that met the inclusion were reported 
and compared descriptively.  Table 1.3 summarized the interventions that aimed to 
reduce inappropriate prescribing in general while Table 1.4 summarized those that 
aimed to reduce inappropriate prescribing of specific pharmacological group/agent.   
It was interesting that nationally mandated drug use reviews by 
pharmacists/surveyors for inappropriate prescribing in NHs did not show significant 
differences in inappropriate prescribing compared to assisted living facilities without 
the mandatory “audit”.91  Specifically, although the presence of guidelines may 
promote safe, rational, and effective medication use, its impact on actualizing 
reductions in inappropriate prescribing may be limited.92, 93  Among the other 
interventions aimed to reduce inappropriate prescribing in general (Table 1.3), six out 
of nine were pharmacist-led medication reviews.94-99  Of these, four studies measured 
and reported high prescribers’ acceptance (59.8 to 91.6%) to the recommendations 
made on NHRs’ medication regimen.94-96, 99  Pharmacists’ reliability and performance 
in medication review were also highly valued by the physicians and nurses as reported 
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by Schmidt et al.100 and Lapane et al.101  In addition,  pharmacists were also shown to 
be a valuable asset in multi-discipline case-conferencing, contributing 42.3% of all 92 
recommendations implemented.102  By comparison, the use of a clinical decision 
support system during computerized physician order entry reported only a modest 
increase in likelihood among the prescribers (relative risk = 1.11, 95% CI = 1.00 to 
1.22) to take appropriate actions when prompted by an electronic alert.103  The same 
intervention was further reported in another study to have no effect on reducing ADE 
rate or preventable ADE rate, possibly related to alert burden.104  In summary, 
pharmacists improve PA.  Although the use of technology may improve operational 
efficiency, the presence of pharmacists seemed to engender a greater effect in 







































































































































































































































































































































































































The identified interventions summarized in Table 1.4 included those that 
targeted changes in the prescribing/use of antibiotics,109-111 drugs for fracture 
prevention,112 calcium and vitamin D supplements,113 non-steroidal anti-
inflammatories,114 drugs for treatment of cardiovascular conditions,115 
psychotropics,116-121 hypnotics,122 benzodiazepines,92, 123 and antipsychotics.124-126  
Most of these interventions involved educational interventions109-114, 121, 122, 124, 125 and 
were multi-disciplinary in nature.109, 110, 112-114, 116, 118, 120, 122, 124, 125  Similar to the 
interventions listed in Table 1.3, most of these reported minimal change in clinical 
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outcomes measured.109-112, 114, 115, 117  By contrast, fewer interventions had 
pharmacists’ involvement,113, 116, 118, 120-122, 124 none involved the use of any PA 
instruments listed in Table 1.1, and five interventions did not elicit positive changes 
on medication use.92, 112, 117, 121, 126  Furthermore, the only medication review by 
external physician specialists115 with a reported acceptance rate of 47.5% of the 
recommendations on NHRs’ medication regimen was lower compared to those 
reported in Table 1.3.  In contrast with the use of federal medication use guidelines,92 
the presence of a triplicate prescribing policy resulted in lower amounts of 
benzodiazepines used in NHs;123 however, no clinical outcomes in relation to this 
change in benzodiazepine use was assessed.  Pharmacists are therefore needed to 
improve PA,86 and to engage other healthcare professionals in the active sharing of 
knowledge and development of specific approaches to prevent or minimize IP of 
specific drug groups for certain diseases/conditions which cannot be addressed 
adequately by the use of general PA instruments127 or general guidelines aimed at 








































































































































































































































































































































































































The same literature search was also re-visited recently to identify articles 
published after 2008; these are summarized in Tables 1.5 and 1.6.  Comparing the 
interventions aimed to reduce IP published before (Table 1.3) and after 2008 (Table 
1.5), there seemed to be an increase in physicians’ and nursing staff’s involvement in 
recent publications.  Conversely, comparing the publications identified before (Table 
1.4) and after 2008 (Table 1.6), pharmacists’ involvement as part of an inter-
professional team or as the primary profession was more apparent in more recently 
published interventions that targeted specific drug groups or disease / condition.  



















































































































































































































































































































































































































































































































































































































































































































In Singapore, national guidelines on the role of physicians, nurses and 
pharmacists in the NHs are available.2, 148  A summary of this is provided in the Brief 
Factsheet on NHs in Singapore (Appendix 1.1). Although the guidelines specified 
pharmacists’ role to provide “pharmaceutical care to residents” and “quality assurance 
of medication management”, there is no data on the impact of pharmacists’ 
medication review on PA.  In addition, the pharmacist’s on-site presence, standard of 
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pharmacy services and level of involvement in the NHs differ across NHs.  
Furthermore, it was observed that the “monitoring” services provided by the visiting 
pharmacists to the NHs were mainly focused on overcoming skill-based medication 
errors (such as slips and lapses14); examples included conducting audits and providing 
reminders on NS’s compliance in proper storage, packing and preparation of 
medicines for administration, and timely documentation on residents’ medication 
notes, and making interventions in retrospect of physicians’ oversight in noting 
existing drug allergies, potential interactions or duplications with residents’ current 
medication regimen when prescribing.  Pharmacist interventions on improving PA or 
appropriateness of  medication administration (which may be likened to overcoming 
knowledge-based errors and rule-based errors14) were lacking or limited; these were 
often left to physicians who conduct routine medical reviews of NHRs.  However, IP 
or “mistakes” may not be picked up as these physicians as they could be the same 
prescribers who initiated the orders.  With the advent of a “silver tsunami”,149 and the 
high prevalence of potentially IP reported by Mamun et al.,66 there is a need for 
pharmacists to assume the role of “advocator” and less as “police” or “auditor” to 
improve PA and patient outcomes.   
 
1.5 Objective and scope of work 
The objective is to develop innovative approaches to improve PA and direct 
patient outcomes from the use of one or more medication groups for specified 
diseases among the elderly NHRs in Singapore in the following steps (Figure 1.2).  
Firstly, the prevalence of medication use, IP, and clinically significant AEs were 
determined using PA instruments and pharmacoepidemiology study methods.  From 
the results of this study, the most compelling IP practices and/or clinically significant 
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AEs were identified.  Next, the gaps in achieving appropriate prescribing of the 
targeted pharmacological groups and/or health conditions were further identified 
through qualitative and quantitative survey methods where necessary.  Lastly, 
innovative inter-professional collaborative practice that leverages on the pharmacists’ 
role as the “advocator” of appropriate medication use and prescribing at the NHs were 
developed.  These were tested at the NH setting using suitable clinical study designs 
to evaluate the (1) feasibility of implementation, (2) feedback from the other 
healthcare professionals, and (3) impact on prescribing, medication use, cost, and 







Prevalence of Inappropriate Prescribing (IP) and Adverse Events (AEs) among 
Elderly Nursing Home Residents (NHRs) in Singapore 
 
2.1 Introduction 
 In Singapore, published information on prescribing appropriateness, adverse 
events, and gaps relating to these among the elderly NHRs was lacking.  Identification 
of the most compelling IP practices and/or clinically significant AEs was crucial in 
directing the limited research and future resources to tackle IP of the relevant 
medication group / disease management and improve specific patient outcomes.  
Understanding the common gaps in the appropriateness of prescribing was also 
imperative for the development of feasible interventions that can be successfully 
implemented at the NHs.  For these purposes, a background study was conducted 
from February 2009 to July 2010, which is reported in this chapter.   
 
2.2 Methodology 
Hence, a retrospective cross-sectional study was conducted to determine (1) 
the prevalence and associated factors of medication use and IP, (2) the impact of 
medication use and IP on AEs, and (3) the gaps in reducing IP and AEs among elderly 
NHRs.  For this study, and all other work in the subsequent chapters, ethics approval 
was obtained from the Institutional Review Board of the National University of 
Singapore, and were was carried out in NHs that are run by Volunteer Welfare 
Organizations (VWOs).  A description of the NHs in Singapore is provided in 
Appendix 1.1.   
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The NHRs’ data sets for this study was obtained from four VWO NHs which 
gave consent to participate in this study and approval to access the original archived 
hardcopy of the NHRs’ administrative, medical and medication records in the NHs.  
These NHs have a capacity of 200-300 beds each and were randomly selected from 
the northern, central, western and eastern parts of Singapore.  The recruitment of four 
NHs was estimated to be able to provide more than the minimum number of data sets 
required for this study.  
The prevalence medication use and IP along with the postulated associated 
factors were determined from the 1-month resident data in December 2008.  The 
prevalence of medication use of all NHRs aged 65 years and above during the month 
of December 2008 was determined using the data from the original hardcopy of the 
NHRs’ medication use records.  Data of the NHRs who had passed away or were 
transferred out of the institution before 31st December 2008 were excluded, as they 
did not yield a full 1-month resident data.  The medication use prevalence was 
reported in Section 2.3.1 according to the World Health Organization (WHO) 
Anatomical Therapeutic Chemical (ATC) classification system.151  Medications that 
were discontinued after taking for less than two weeks and those that were prescribed 
for use on a when-needed basis or a pre-specified short-term basis were considered as 
“short-term medications”.  Conversely, medications that were used regularly for more 
than two weeks were considered as “regular medications”.  These definitions were 
based on the common consensus among pharmacists and physicians who provide care 
at the NHs.  Polypharmacy152 was defined as the use of five or more “regular 
medications”. 
The prevalence of IP for all medications used in December 2008 of the 
included data sets, except for those classified as dermatologicals under the ATC 
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classification system, was determined by reviewing medications using PA instruments 
listed in Table 1.1.  Multiple PA instruments were used to overcome the limitations of 
each individual instrument (discussed in Section 1.3) for determining the true 
prevalence of IP.  These instruments included the Beers criteria,31 Medication Quality 
Indicators derived from the ACOVE project,36 and instruments developed by Oborne 
et al.,40 McLeod et al.,43 and the MAI,33, 34  which had previously been used in an 
unpublished study conducted among local NHs.  The Neuroleptic Appropriateness 
Indicator (NAI)38 was also included in the study, where its use during data collection 
and analysis was included as part of the instrument developed by Oborne et al.40  The 
PDRM was not selected due to the presence of conflicting consensus between 
MacKinnon et al.35 and Morris et al.39 on what should be included in the PA 
instrument.  The STOPP criteria41, 42  was also not included as it was identified after 
the study was underway.   
Documentation of the reviews was made directly on the data collection form 
(Section B of Appendix 2.1).  Additional information required for the medication 
review was obtained from the NHRs’ medical notes and transcribed onto the same 
form.  Clarification with the NS and/or drug references was made when required.  The 
references used for the reviews of IP included the Geriatric Dosage Handbook (14th 
Edition), British National Formulary (BNF, 2009 Editions), the online version of 
MIMS Drug Information System, and online resources from the Health Science 
Authority of Singapore.  These references were also used for the other studies 
reported in this thesis.   
NHRs’ demographic and clinical factors that were deemed to be associated 
with inappropriate prescribing (based on the studies reported in Table 1.2) were also 
listed on the data collection form (Section A of Appendix 2.1) and obtained from the 
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NHRs’ medical records.  These factors, which included age, gender, race, length of 
stay in the NH, functional status, and cognitive status were then evaluated for their 
association with IP observed among this sample population during the data analysis.  
The most recent category rating on the Resident Assessment Form (RAF)148 of each 
NHR, which was reviewed by the nurses every 3-6 months across all NHs, was used 
to represent the NHRs’ functional status.  The RAF categorized the NHRs into four 
categories of increasing physical and mental dependency (Figure 2.1).  NHRs had 
impaired cognitive status if a diagnosis of “mild cognitive impairment”, “dementia”, 
“Alzheimer’s disease” or other forms of dementia were documented on the main 
problem list in the NHRs’ medical records.   

















The 1-month prevalence of IP identified by explicit and implicit instruments 
from the data obtained in December 2008 were reported and described separately in 
Sections 2.3.1.1 and 2.3.1.2.  In order to prevent an over-estimated reporting of IP 
identified by multiple use of explicit PA instruments, the individual IP identified was 
not used as the unit of analysis; simple summation of the total number of IP identified 
from the combined use of all criteria per resident was also not performed.  Instead, 
both (1) individual NHRs and (2) individual medications were used as the units of 
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analysis in reporting of the prevalence and statistical analysis of IP identified using 
explicit PA instruments.  Although these units of analysis were also used in the 
reporting of the MAI index and prevalence of IP identified using the implicit PA 
instrument (MAI), the total number of IP identified by the individual domains of the 
MAI was also reported.  In addition, the concordance between IP identified by 
explicit PA instruments used and the overall prevalence of IP among NHRs during 
December 2008 was evaluated. 
For the determination of the impact of medication use and IP on AEs among 
NHRs, data was collected using the same data collection form (Appendix 2.1), to 
obtain the incidence and the details of AEs that occurred among elderly NHR who 
were 65 years and older residing in the NHs from 1st July 2007 to 30th June 2008.  
Due to constraints in research resources and limited duration (imposed by the NH) for 
accessing the archived records of residents imposed at one NH, data collection for this 
purpose was conducted in three of the four NHs located in the northern, central and 
western parts of Singapore.  AEs included unplanned hospitalizations and ED visits 
identified from the NHR transfer records.57  The details of these incidents (Section C 
of Appendix 2.1) were transcribed directly from filed copies of the discharge 
summaries in the NHRs’ medical records.  Incidents were defined as 
rehospitalizations if the referral was for the same primary or secondary diagnoses, 
within a 30-day period after a previous discharge from hospital stay or ED visit.153  
Rehospitalizations were non-independent and were excluded from data analysis.  The 
independent incident was used as the unit of analysis and were reported in Sedtion 
2.3.2 based on the International Classification of Diseases (ICD-10)154 that is 
available online.  Medication use during the 3-month period prior to each independent 
incident was also noted from the NHRs’ medication use records and assessed for 
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presence of IP as described above.  The prevalence of IP identified from medication 
use during the 3-month period prior to all AEs identified during this 1-year period was 
reported in Section 2.3.2, and compared descriptively to the prevalence of IP 
identified among the general elderly NHRs in December 2008.   
From this, the impact of medication use and IP on AEs that were caused by 
drug-related and falls-related reasons were evaluated further.  These AEs were 
described as “drug-related AEs” and “fall-related AEs” in the rest of this chapter.  In 
order to identify drug-related AEs, the discharge summaries of all the incidents 
(including rehospitalizations) were reviewed for explicit documentations of (1) drug-
related problems (DRPs) as the primary diagnoses, (2) DRPs leading to the primary 
diagnoses, or (3) documentation of changes to the NHRs’ medication regimens at 
discharge, which including dose alterations, discontinuations, or new additions of 
medications, as an outcome of the documented primary diagnoses.  Incidents that 
carry these documentations were then discussed with a US board certified 
pharmacotherapy expert for confirmation as drug-related AEs.  The DRPs related to 
these incidents were reported in Section 2.3.2.1 according to the classification 
(Appendix 2.2) by the Pharmaceutical Care Network Europe (PCNE);155 the 
medications implicated in these drug-related AEs and their identified IP using explicit 
and implicit instruments were also reported.  The significance of these findings on the 
gaps that needed to be addressed in interventions to reduce IP and drug-related AEs is 
discussed in Section 2.4. 
The identification of fall-related AEs was based on explicit documentations of 
“fall” or any unintentional movements to the floor in the discharge summaries of the 
unplanned hospitalizations and ED visits under “reason for referral” to the hospital.  
These documentations were verified against records of fall incidents and instructions 
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for referral to a tertiary care institution by the physician or staff nurse in the NHR’s 
medical records kept in the NHs.  Associations of these fall-related AEs with NHR’s 
demographic and clinical factors, and the use of medications widely reported to 
increase falls156-158 and fall-complications159 were evaluated.  The results from this 
evaluation are reported in Section 2.3.2.2.  From the results, the implications of IP 
(among the medications associated with falls), the significance of the factors 
associated with falls and the corresponding gaps to be addressed in interventions to 
reduce IP and fall-related AEs were discussed in Section 2.4. 
In this thesis, while all other statistical tests were performed on the SPSS 
Statistics version 19.0, the Kappa’s test was performed using online calculators 
available at http://vassarstats.net/.  In this study, the minimum sample of data sets 
required was 368 data sets; this was derived from an online sample size calculator,160 
based on the total patient population in the year 2008 (8600 beds),161 “worst-case-
scenario” prevalence of IP and AEs at 50%, α value of 0.05 and confidence interval of 
95%.  The sample size was calculated based on the total number of beds, and not on 
the number of NHs as VWO NHs are likely to have similar patient demographics 
since admissions into VWO NHs are randomly assigned by a government agency 
unless the resident has specific preferences for the location of a NH and meal plan.  
Comparisons of means were performed using Mann-Whitney U test or Kruskal-Wallis 
One-Way ANOVA where applicable, and adjusted for co-variables using General 
Linear Model with Bonferroni post hoc tests.  Comparisons of proportions were 
performed using χ2 test.  Multiple logistic regressions were used to evaluate 
associations between factors.  In the evaluation of factors associated with 1-month 
prevalence of IP in December 2008, univariate logistic regressions were performed 
using factors (which included age, race, gender, length of stay, functional dependency 
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status, presence of dementia and polypharmacy) individually to obtain the unadjusted 
odds ratios, while the adjusted odds ratios were obtained by keeping all the reported 
factors as they were deemed to be important as reported in the studies in Table 1.2. In 
addition, the NH study-site was included to adjust for potential clustering due to site-
related factors such as prescribing preferences and care culture.  Both the unadjusted 
and adjusted odds ratios of factors associated with IP were reported in Table 2.3.  The 
evaluation of the factors associated with fall-related AEs was also performed similarly 
using univariate and multiple logistic regression; the results of their unadjusted and 
adjusted odds ratios were reported in Table 2.14.  Concordance in this study was 
evaluated using Kappa statistics, where the strength of concordance was based on the 
following: 0.1 – 0.2 = slight, 0.21 – 0.40 = fair, 0.41 – 0.60 = moderate, 03.61 – 0.80 
= substantial, and 0.81 – 1 = almost perfect.162  This reference was also used to 




2.3.1 Medication use trends 
There were 712 elderly NHRs residing at the four NHs during December 2008.  
The data sets for all NHRs were obtained and included in the analyses.  The 
demographic, medical and medication factors of these elderly NHRs were 
summarized in Table 2.1.  The mean age of the NHRs was 80.7 (± 8.76) years’ old.  
There were slightly more females than males (57.2% and 42.8% respectively) in the 
sample population.  The majority of the NHRs resided in the respective institutions 
for more than 2 years (69.4%), were Chinese (86.9%), had functional status of RAF 






































Among the 712 NHRs, only one did not use any medication and 
polypharmacy was present among 62.6% of the NHRs, where the majority took five 
to nine “regular medications” (see Figure 2.2).  The total number of medications 
prescribed was 5922 (mean = 8.3 ± 3.3, range 0 to 25); of which 4019 (mean = 5.6 ± 
2.8, range 0 to 15) were “regular medications” and 1903 (mean = 2.7 ± 1.9, range 0 to 







The prevalence of these medications were reported according to their 
anatomical main groups and pharmacological subgroups of the ATC classification 
system.  Among the anatomical main groups shown in Figure 2.3, medications of the 
alimentary tract and metabolism [ATC code = A] were the most commonly prescribed, 
contributing to 44% of the 5922 medications, and given to 95% of the 712 NHRs.  
This was attributed to the frequent use of laxatives [A06A]; which made up 25% of 
5922 medications prescribed, and was prevalent among 87% of the NHRs.  More than 
two thirds of all laxatives prescribed were meant for use on a when-needed basis.  
Medications of the nervous system [N] were the next most commonly prescribed.  
These medications made up 25% of the medications prescribed, and were prevalent 







Of the 99 pharmacological subgroups identified, the 10 most prevalently 
prescribed were laxatives [A06A], antidepressants [N06A], other analgesics and 
antipyretics [N02B], drugs for peptic ulcer and gastro-oesophageal reflux diseases 
[A02B], calcium [A12A], antithrombotic agents [B01A], antipsychotics [N05A], 
antiepileptics [N03A], plain lipid modifying agents [C10A], and anxiolytics [N05B]; 






2.3.1.1 Types of IP defined by explicit instruments 
 Explicitly defined IP was prevalent among 664 NHRs (93%).  Among these 
NHRs, 32 had inappropriately prescribed medications defined by at least one indicator 












From Table 2.3, the presence of IP was widely prevalent among the NHRs of 
the four NHs.  However, the IP seemed to be more prevalent in some homes, 
compared to the others.  In addition, NHRs who were more likely to have IP were 
noted to be of the male gender, have polypharmacy and higher functional dependency 









    A  160 24.1  -   -  
    B  135 20.3 10.1b (1.3, 78.9) 15.1b (1.8, 125.5) 
    C  103 15.5 7.7  (1.0, 60.3) 10.2b (1.3, 83.2) 
    D  266 40.1 0.6 (0.3, 1.17) 1.0 (0.45, 2.2) 
Length of Stay 
    0 ‐ 6 months  63 9.5  -    -  
    7 ‐ 24 months  132 19.9 0.3 (0.1, 1.1) 0.4 (0.1, 1.5) 
    > 24 months  469 70.6 0.9 (0.3, 3.0) 1.2 (0.3, 4.6) 
Gender 
    Female  371 55.9  -    -  
    Male  293 44.1 2.4b  (1.2, 4.6)  2.3b  (1.1, 5.1) 
Age 
    65‐79 years old  301 45.3  -    -  
    > 80 years old  363 54.7 1.1  (0.6, 2.0)  1.0  (0.5, 2.1) 
Race 
    Chinese  575 86.6  -    -  




    RAF Category 1 & 2  44 6.6  -    -  
    RAF Category 3  250 37.7 3.9b (1.7, 9.0) 4.0b (1.5, 10.7) 
    RAF Category 4  370 55.7 4.4c (2.0, 9.7) 5.3b (2.0, 14.0) 
Cognitive Status 
    No Dementia  248 37.3  -    -  
    Has Dementia  416 62.7 1.0  (0.6, 1.8)  1.5  (0.7, 3.2) 
Polypharmacy 
    Not present  231 34.8  -    -  







Among the four explicit PA instruments, IP measured by the instrument from 
Oborne et al. was the most prevalent (76% of 712 NHRs; Figure 2.5), and had the 
highest concordance with the overall prevalence of IP observed among the 712 NHRs 





















From Table 2.5, the most prevalent IP identified by the individual explicit 
indicators were those from the explicit PA instrument by Oborne et al.  Specifically, 
these were the failure to use generic name in the drug orders (52.1% of 712 NHRs) 
and the failure in documenting the maximum frequency of administration (39.6% of 
712 NHRs).  The medication most commonly implicated with these indicators of IP 








C  Use of generic drug name  371  52.1 
C  Documentation of maximum frequency of administration  282  39.6 
A  Long‐term use of stimulant laxatives  258  36.2 
C  Appropriate Neuroleptic prescribing  142  19.9 
C  Appropriate Benzodiazepine prescribing  117  16.4 
B  Daily aspirin therapy for patient with diabetes  110  15.5 
B  Medication for hypertension if no nonpharmacologic therapy response  100  14.0 
A  Daily Fluoxetine  92  12.9 
B  Aspirin for patient with coronary artery disease  89  12.5 





Of the 5922 medications, 31% of them were deemed to be inappropriately 
prescribed by one or more explicit instruments.  A breakdown of the prevalence of 
inappropriately prescribed medications according to the anatomical main groups and 











Besides being the most widely prescribed medications among the elderly 
NHRs (Figure 2.4), laxatives [A06A] also topped the chart as the most common (10% 
of the 5922 medications) and widely prevalent inappropriately prescribed medications 
among 443 (62%) NHRs.  Inappropriateness of laxatives were mostly related to the 
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prescribing of stimulant laxatives for long-term use, and failure to document the 
maximum frequency of administration (Table 2.6).   
The four other most prevalent inappropriately prescribed medications were 
antidepressants [N06A], antipsychotics [N05A], anxiolytics [N05B], other analgesics 
and antipyretics [N02B], each contributing 3.7%, 2.9%, 2.8% and 2.6% of all 
prescribed medications respectively (Figure 2.7).  Among the PA indicators that were 
applicable for these pharmacological subgroups, the NAI38 produced the highest count 
of IP (Table 2.6).  Among the 156 counts of inappropriately prescribed antipsychotics 
identified by this indicator, 26 were related to the absence of documented indications, 
39 were due to inappropriate indications of unspecified symptoms of agitation, 
restlessness and uncooperativeness related to dementia, 24 did not have objective 
documentations regarding the frequency of behavioral indications, and 67 were 
prescribed prior to June 2008 with no records of attempted dose reduction during the 















A  Long‐term use of stimulant laxatives   265  4.5 
D  Documenting maximum frequency of administration  263  4.4 
D  Use of generic drug name  214  3.6 
C  Bowel regimen to prevent constipation for patient taking opiate  3  NA 
Antidepressants 
[N06A] 
D  Use of generic drug name  121  2.0 
A  Fluoxetine  92  1.6 







A  Amitriptyline  7  0.1 
B  Tricyclic antidepressant with active metabolites   7  0.1 






D  NAI   156  2.6 
C  Avoid strongly anticholinergic medications if alternatives exist  17  0.3 











A  Conventional antipsychotics with Parkinson disease  6  0.1 
D  Documenting maximum frequency of administration  4  0.1 
Anxiolytics 
[N05B] 
D  Use of generic drug name  154  2.6 
D  Benzodiazepine Prescribing Indicator (algorithm)  114  1.9 
A  Anticholinergics and antihistamines  49  0.8 
D  Use of generic drug name  41  0.7 
A  Benzodiazepines with syncope or falls  26  0.4 
A  Benzodiazepines with depression  13  0.2 
C  Avoid strongly anticholinergic medications if alternatives exist  10  0.2 








D  Allowing paracetamol doses >4g/24 hours  2  0.03 














At least 50% of NHRs of these 4 NHs who were prescribed antipsychotics had 
one or more IP measured by the NAI (Table 2.7).  These showed a legitimate concern 
for the lack of proper assessment, monitoring, and/or documentation with regards to 















A  78  10  68  87.2 
B  28  7  21  75.0 
C  15  7  8  53.3 






2.3.1.2 Types of IP defined by the implicit instrument – MAI 
 Of the 712 NHRs, 96% had IP measured by one or more domains of the MAI.  
The mean MAI index scores for prescribing inappropriateness per NHR was 1.4 (± 
0.82, range 0 to 4.7), 1.8 (± 1.08, range 0 to 6.0) and 0.5 (± 1.16, range 0 to 8.0) for 
all medications, “regular medications” and “short-term medications” respectively.  
The average index scores for IP of all medications for NHRs were significantly varied 
across the four NHs, with the exception of NHs B and D (Table 2.8).  After adjusting 
for the NHRs’ demographic, clinical and medication factors (that were reported 

























From the analysis, several NHRs’ factors were also found to be associated 
with higher MAI index scores for PA.  Similar to that reported for explicit instruments, 
higher burden of IP measured by the MAI implicit PA instrument was also associated 
with the male gender (compared to females, p-value = 0.001) and with polypharmacy 
(compared to no polypharmacy, p-value < 0.001).  Other associated NHRs’ factors 
included being 80 years and older (compared to younger than 80 years old, p-value = 
0.023) and with dementia (compared to without dementia, p-value = 0.017).   
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 Of the 5922 medications, the ten pharmacological groups most commonly 
implicated with IP identified by MAI were laxatives [A06A], anxiolytics [N05B], 
drugs for peptic ulcer and gastro-oesophageal reflux diseases [A02B], calcium 
[A12A], antidepressants [N06A], iron preparations [B03A], lipid modifying agents 
[C10A], vitamin B12 and folic acid [B03B], blood glucose lowering drugs excluding 
insulin [A10B], and antipsychotics [N05A] (Table 2.9).  These made up 73% of the 
4468 counts of IP identified by the 10 domains of MAI; and  contributed to 86%, 83%, 
75%, and 52% of the IP identified within their respective anatomical main groups for 
the alimentary tract and metabolism [A], blood and blood forming organs [B], 









counts 1  2  3  4  5  6  7  8  9  10 
n n  n  n  n  n  n  n  n  n  n 
[A06A] Laxatives  248 261 1  4  1  0  0  3  235  229  982 
[N05B] Anxiolytics  41  115 1  12  1  1  72  5  132  40  420 
[A12A] Calcium  0  0  0  311 0  0  0  0  1  0  312 
[A02B] Drugs for peptic ulcer and gastro‐ 
              oesophageal reflux diseases 
76  0  1  84  0  4  0  2  67  127  361 
[N06A] Antidepressants  17  103 1  1  0  29  52  13  15  60  291 
[B03A] Iron preparations  23  0  0  150 0  0  0  1  20  55  249 
[C10A] Lipid modifying agents, plain  16  0  1  192 0  2  0  0  10  12  233 
[B03B] Vitamin B12 and folic acid  53  2  1  0  0  0  0  11  49  48  164 
[A10B] Blood glucose lowering drugs,  
              excluding insulins 
0  0  0  127 0  2  0  1  1  0  131 





As observed in Figure 2.8, the most common types of IP identified among 
these four anatomical main groups were issues related to indication, effectiveness, 
direction of use, duration of use, and cost.  Specifically, IP related to duration of use 
and cost were most prevalent among laxatives, which were prescribed as part of the 
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post-discharge medications from the hospitals or at admission to the NH for short-
term management of acute constipation related to transfers and medical stress but 
were commonly left on the medication charts without proper documentation of 
indications for long-term use.  In addition, IP related to inappropriately long duration 
of use was also commonly reported for anxiolytics, and was the most pertaining IP 
issue for antipsychotics.  The lack of indication was most prevalent with the 
pharmacological groups of vitamin B12, folic acid, drugs for peptic ulcer and gastro-
esophageal reflux diseases as well as laxatives.  IP related to effectiveness was most 
prevalent for laxatives, specifically, the long-term use of senna was deemed to be 
inappropriate under the domain for effectiveness defined by MAI, where according to 
the 2003 Beers Criteria, the potential risks from its use outweighed its potential 
benefits.  Besides laxatives, large numbers of IP related to the issue of effectiveness 
was also found among the pharmacological subgroups of anxiolytics and 
antidepressants, specifically with the long-term use of long-acting benzodiazepines 
and fluoxetine.  Lastly, the issue related to inappropriate directions of use was mostly 
due to the lack of documenting proper instructions on the timing of administration 
with regards to food and other interacting medications; this was common among 
many pharmacological groups including calcium, iron preparations, lipid modifying 







2.3.2 Prevalence and types of AEs, prior medication use and IP 
 Of three of the NHs included in this retrospective study, the 504 NHRs present 
from 1st July 2007 to 30th June 2008, and aged 65 years old and above, were screened.  
Of these, 196 NHRs had one or more incidents of unplanned hospitalizations and ED 
visits, leading to a total number of 345 recorded incidents, and 36 of these identified 
as rehospitalizations, were excluded from the subsequent analysis.   
Of these 309 independent AEs, 275 were hospitalizations, and 34 were ED 
visits.  The average length of stay for the 275 hospitalizations was 8.19 ± 7.16 (range 
2 to 53) days.  From the summary of the NHRs’ demographic, clinical and medication 
factors of the 309 independent incidents (Table 2.10), the majority of these unplanned 
hospitalizations or ED visits seemed to occur among NHRS’ who were Chinese, older, 
had functional dependency of Category 3 and above, had cognitive impairment, 
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resided in the homes longer than 2 years, and had polypharmacy.  When compared 
against the distribution of these factors among the general elderly NHRs staying at the 
NHs during December 2008 (reported in Table 2.1), it was noted that AEs occurred 
more significantly among NHRs who were male, older, had polypharmacy, and had 
been NHR longer than six months but shorter than two years (χ2 test for goodness of 
fit, p-value < 0.05).  When compared to the proportion of non-Chinese (versus 
Chinese) present in the general elderly NH population, the proportion of AEs 
occurring among non-Chinese was also significantly larger (χ2 test  for goodness of  fit, 




































The most common diagnoses documented in the discharge summaries were 
related to diseases of the respiratory system [ICD-10 Code = X].  Of these diagnoses, 
90% were chest infections and pneumonia, which contributed close to a quarter of the 
309 independent AEs recorded.  The number of diagnoses related to injury, poisoning 
and other consequences of external causes [XIX] were a distant second.  Among these 
48 diagnoses, 15 were fractures of the femur, forearm, pelvis, and spine, which 
contributed about 5% of 309 independent AEs.  The other 33 were related to 
complications of genitourinary prosthetic devices, implants and grafts, and injuries 
and open wounds involving various body parts, including the head.  The types and 
prevalence of all other diagnoses documented in these hospital and ED discharge 




























The average number of total medications used by the NHRs during the 3-
month prior to each of the 309 AEs was 12.0 (± 4.9, range 2 to 29); the average 
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number of “regular medications” and “short-term medications” were 7.3 (± 3.0, range 
1 to 20) and 4.6 (± 3.4, range 0 to 19) respectively.  Among the pharmacological 
subgroups identified, the 10 most prevalently used prior to unplanned hospitalizations 
and/or ED visits were laxatives [A06A], drugs for peptic ulcer and gastro-oesophageal 
reflux diseases [A02B], other analgesics and antipyretics [N02B], beta-lactam 
antibacterials, penicillins [J01C], antidepressants [N06A], calcium [A12A], 
antithrombotic agents [B01A], iron preparations [B03A], antiepileptics [N03A], and 
anxiolytics [N05B] (Figure 2.9).  Compared with the medication use trends among all 
elderly NHRs in December 2008, the most observable difference was the higher 
prevalence of antiinfectives for systemic use [J] during the 3-month prior to the 309 






IP defined by explicit PA instruments was present during the 3-month prior to 
306 (99%) of these AEs.  The total number of medications implicated with IP was 
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1329 (35.9%).  The five pharmacological subgroups which contributed to the most 
number of IP shown in Figure 2.10 were the same as those for the general elderly 
NHRs during December 2008.   
 




Of the independent AEs, almost all (n = 305, 99%) were accompanied with IP 
measured by one or more domains of the MAI during the 3-month prior to the 
incidents.  IP for “regular medications” and “short-term medications” was present 
during the 3-month prior, among 99% and 81% of the cases respectively.  The mean 
MAI index score for IP for all medications was 1.6 (± 0.84, range 0 to 8.0), and that 
for “regular medications” and “short-term medications” only 2.1 (± 1.08, range 0 to 
8.0) and 0.88 (± 1.15, range 0 to 8.0).  By comparison, the prevalence and MAI index 
score of IP for “short-term medications” was visibly higher than that observed among 
the general elderly NHRs during December 2008.   
Among all the medications used during the 3-month prior to the incidents, the 
10 pharmacological subgroup with the largest total counts of IP were laxatives 
[A06A], drugs for peptic ulcer and gastro-oesophageal reflux diseases [A02B], 
49 
 
anxiolytics [N05B], antidepressants [N06A], iron preparations [B03A], antiepileptics 
[N03A], antihistamines for systemic use [R06A], antipsychotics [N05A], calcium 
[A12A], and beta-lactam antibacterials, penicillins [J01C] (Table 2.12).  Compared to 
that reported among the general elderly NHRs during December 2008, IP was more 
common among medications of the respiratory system [R] and antiinfectives for 
systemic use [J].  This was probably attributable to the increased “when needed” use 
of antihistamines and antibacterials for managing acute conditions, some of which led 








counts 1  2  3  4  5  6  7  8  9  10 
 [A06A] Laxatives  131  1  2  1  0  0  0  5  164  148  452 
 [A02B] Drugs for peptic ulcer and GRD  76  0  9  71  3  0  0  2  77  101  339 
 [N05B] Anxiolytics  50  94  1  0  0  2  64  2  48  46  307 
 [N06A] Antidepressants  33  56  2  0  0  8  33  14  39  49  234 
 [B03A] Iron preparations  7  0  2  98  1  0  0  0  28  37  173 
 [N03A] Antiepileptics  47  6  5  8  0  2  0  0  51  42  161 
 [R06A] Anstihistamines for systemic use  11  54  5  2  1  1  44  5  17  9  149 
 [N05A] Antipsychotics  50  0  0  0  1  2  1  5  45  40  144 
 [A12A] Calcium  0  0  0  117  0  1  0  0  0  0  118 




2.3.2.1 Prevalence of drug-related AEs and types of medications implicated 
 Of the 345 AEs (including rehospitalizations), the discharge summaries of 
three unplanned hospitalizations carried documentations of DRPs suspected to be 
linked to the primary diagnoses, 23 carried documentations of changes in medication 
regimen at discharge.  Of the latter, 15 incidents were excluded as the NHRs’ 
medication regimens at discharge were not deemed to be directly resulting from the 
primary diagnosis documented, nor did the DRPs (which prompted the changes in 
medication regimens) appear to have contributed towards the primary diagnosis.  
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In total, 10 (2.9%) drug-related AEs were identified; of which, nine were 
hospitalizations (mean duration of stay = 7.2 ± 8.7, range 2 to 30 days) and one was a 
























































































































Among these drug-related unplanned hospitalizations and ED visits, four 
observations were made.  Firstly, medications implicated were mostly from the 
anatomical main groups of alimentary tract and metabolism [A] and nervous system 
[N].  Secondly, all the related DRPs were attributed to IP.  Specifically, inappropriate 
drug/dose selection [C1] was implicated in nine drug-related AEs and the lack of 
proper instructions for drug administration [C3.5] was implicated in two of the 10 
drug-related AEs.  Thirdly, the use of MAI identified IP in four medications, while 
explicit PA instruments identified IP in two medications that were implicated with 
drug-related AEs; however these were not relevant to the DRP reported.  Lastly, lack 
of monitoring/recognition of and continued evaluation for new indications, 
pharmacotherapeutic responses and adverse drug use outcomes were noted to possibly 
contribute towards these adverse drug-related events.  The limitation and detailed 
discussion of the implications of these findings are reported in Section 2.4. 
 
2.3.2.2 Prevalence of fall-related AE and the associated medication use and IP 
  Of the 309 independent unplanned hospitalizations and ED visits, 27 (9%) 
were referred due to fall-related reasons of 23 NHRs, and four of these NHRs were 
referred more than once during the 1-year period of our study.  Of these 27 fall-related 
AEs, 14 were hospitalizations (mean duration of stay = 9.9 ± 7.2, range 3 to 25 days) 
and 13 were visits to the ED.  The majority of these fall-related AEs resulted in 




      
Figure 2.11  Diagnoses resulting from the fall‐related AEs  
 
From Table 2.14, it was observed that the NHRs’ factors such as female 
gender, absence of dementia, lower functional dependence, fall history, absence of 
polypharmacy, and regular use of antidepressants, selective serotonin reuptake 
inhibitors (SSRI) and hydroxyzine were more likely to lead to an AE related to falls.  
Particularly, the presence of fall history and lower functional dependency status were 
singled out as independent risk factors for fall-related AEs.  The prevalence of fall-
related AEs also appeared to be independently associated with a particular NH.  The 
plausible explanations and implications of these associations are discussed in details 











    A  21  77.8  1.0  ‐  1.0  ‐ 
    B  5  18.5  0.3  (0.09, 0.68)f 0.1  (0.02, 0.36)f
    C  1  3.7  0.1  (0.01, 0.52)f 0.1  (0.01, 0.50)e
Length of Stay 
    0‐6 months  3  11.1  1.0  ‐  1.0  ‐ 
    7‐24 months  7  25.9  0.7  (0.18, 3.03)  2.3  (0.43, 12.12) 
    >24 months  17  63.0  0.8  (0.22, 2.93)  1.4  (0.31, 6.59) 
Gender 
    Male  11  40.7  1.0  ‐  1.0  ‐ 












    ≥80 years old  14  51.9  1.0  ‐  1.0  ‐ 
    65‐79 years old  13  48.1  1.7  (0.78, 3.80)  3.1  (1.00, 9.75)
Race 
    Chinese  23  85.2  1.0  ‐  1.0  ‐ 
    Non‐Chinese  4  14.8  0.6  (0.18, 1.64)  0.6  (0.13, 2.39) 
Functional Status 
    RAF Category 1 & 2  7  25.9  1.0  ‐  1.0  ‐ 
    RAF Category 3  17  63.0  0.2  (0.08, 0.71)e 0.2  (0.04, 0.83)e
    RAF Category 4  3  11.1  0.02  (0.01, 0.10)f 0.01  (0.00, 0.06)f
Cognitive Status 
    Has Dementia  11  40.7  1.0  ‐  1.0  ‐ 
    No Dementia  16  59.3  3.0  (1.32, 6.62)f 1.85  (0.62, 5.57) 
History of falls 
    No  17  63.0  1.0  ‐  1.0  ‐ 
    Yes  10  37.0  2.3  (1.01, 5.34)e 9.2  (2.45, 34.94)e
Polypharmacy 
    Absent  7  25.9  1.0  ‐  1.0  ‐ 
    Present  20  74.1  0.5  (0.21, 1.32)  0.2  (0.03, 0.69)e
“Regular Medications” Used 
Antipsychotics  8  29.6  1.23  (0.52, 2.93)  2.46  (0.73, 8.30) 
    Typical antipsychotics  7  25.9  1.38  (0.56, 3.43)  2.33  (0.69, 7.86) 
    Atypical antipsychotics  1  3.7  0.64  (0.08, 5.02)  1.63  (0.10, 27.41) 
Antidepressantsb  17  63.0  2.70  (1.19, 6.11)e 2.11  (0.70, 6.36) 
Selective serotonin re‐uptake  
inhibitors  17  63.0  2.78  (1.23, 6.30)
e  2.34  (0.78, 7.00) 
Sedatives and hypnotics  1  3.7  0.43  (0.06, 3.34)  0.70  (0.06, 7.69) 
    Short‐acting benzodiazepines  1  3.7  0.60  (0.08, 4.69)  0.79  (0.07, 8.91) 
Levo‐dopa  3  11.1  1.29  (0.36, 4.56)  2.70  (0.37, 19.90) 
Antiepileptics  7  25.9  0.77  (0.32, 1.89)  1.58  (0.45, 5.47) 
Hydroxyzine  4  14.8  3.60  (1.09, 11.93)e  1.53  (0.31, 7.48) 
Diureticsc  5  18.5  1.03  (0.37, 2.85  0.40  (0.10, 1.68) 
    Hydrochlorothiazide  1  3.7  0.95  (0.12, 7.63)  0.52  (0.05, 4.92) 
    Furosemide  4  14.8  1.05  0.35, 3.20)  0.41  (0.08, 2.23) 
Beta‐adrenergic blockers  3  11.1  0.85  (0.25, 2.98)  0.28  (0.06, 1.39) 
Calcium channel blockers  4  14.8  0.99  (0.33, 3.02)  0.69  (0.18, 2.67) 
Angiotensin II converting enzyme inhibitors  6  22.2  1.36  (0.52, 3.54)  1.36  (0.38, 4.86) 
Digoxin  1  3.7  0.36  (0.05, 2.78)  0.29  (0.03, 3.43) 
Nitrates  3  11.1  0.57  (0.16, 1.95)  0.43  (0.09, 1.98) 
Narcotic analgesics  1  3.7  2.67  (0.29, 24.81)  2.73  (0.10, 72.98) 
Non‐narcotic analgesicsd  2  7.4  2.18  (0.45, 10.49)  1.57  (0.23, 10.66) 
Alpha‐receptor blockers  3  11.1  1.73  (0.48, 6.27)  1.44  (0.27, 7.67) 
“Short Term Medications” Used 
    Short‐acting benzodiazepines  3  11.1  1.34  (0.38, 4.79)  1.98  (0.34, 11.68) 
    Narcotic analgesics  3  11.1  1.41  (0.39, 5.03)  1.40  (0.18, 10.86) 
    Non‐narcotic analgesicsd  1  3.7  0.48  (0.06, 3.70)  0.15  (0.01, 2.65) 
    Hydroxyzine  4  14.8  1.58  (0.51, 4.89)  1.94  (0.37, 10.22) 
Drowsy antihistamine‐ / codeine‐based  















In Section 2.3.1.1, the differences in IP prevalence observed between the 
participating NHs could be attributed to the varied prescribing habits and 
documentation styles of the different physicians who cared for the NHRs.  The 
association reported between polypharmacy and the presence of IP identified by 
explicit PA instruments in December 2008 was in keeping with the findings of other 
studies.58, 163  This association may be related to the presence of higher number of 
NHRs’ co-morbidities and more complex medication regimens, hence resulting in a 
greater propensity for IP.  Although the association of the male gender with IP was 
also reported in this study, the author could find no reasonable explanation for this 
trend.  Unlike Ma et al.164 who reported a similar association due to the wide use of 
doxazosin, a medication predominantly prescribed among males for its indication in 
benign prostatic hyperplasia, there were little use of such gender-biased medications 
in our study cohort.   
Among the explicit PA instruments used, IP measured by the instrument from 
Oborne et al. had the highest concordance with the overall IP observed among the 712 
NHRs.  Although the kappa statistics of 0.372 reported in Table 2.4 seemed low, this 
value was the highest compared to that obtained from the other instruments, and could 
be due to the high prevalence of the failure to use generic name in the drug orders and 
the failure in documenting the maximum frequency of administration reported from 
the use of this PA instrument.  Although the failure to use generic drug name of 
prescribed medications was commonly implicated among the five most prevalent 
inappropriately prescribed pharmacological subgroups as seen in Table 2.6, this was 
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not regarded as a “misuse of medication” and hence was not an IP within the 
definition used in this thesis.  Yet, the failure to use generic names during prescribing 
could lead to potential medication errors, specifically skill-based medication errors,14 
during the medication supply and administration processes.  As this thesis did not set 
out to address medication errors, this gap was not considered in interventions 
(reported in subsequent chapters) aimed at reducing IP.   
In Section 2.3.1.2, the significant differences of mean MAI index scores found 
between the four NHs suggested that site-related factors such as physicians’ 
prescribing habits, documentation systems and even the organization and treatment 
culture of the NH165-168 may influence PA.  In addition, the reported associations of 
higher MAI index scores with age and cognitive impairment may be related to 
clinicians’ inertia to actively review and change the medication regimens of these 
NHRs, especially if these were prescribed from a hospital.  Such prescribing attitudes 
may be similar to that observed for NHRs who do not require acute considerations,169 
who are more advanced in age,170 or who lack the ability to make decisions.171   
From Sections 2.3.1.1 and 2.3.1.2, laxatives were identified as the top most 
prevalent inappropriately prescribed medication. This prevalence was contributed by 
the Beers Criteria,31 which defined the long-term use of stimulant laxatives to be 
inappropriate at all times among the elderly.  Although this criterion had been 
removed in the recent 2012 update of the Beers Criteria32 due to the lack of evidence 
in supporting the concerns on the exacerbation of bowel dysfunction with long-term 
use of stimulant laxatives,172 the uncertain risks versus benefits of their long-term use, 
high prevalence of laxative use in the NHs, prescribing of multiple laxatives per NHR 
(mean number of laxatives per NHR = 2.1), and the large number of laxatives 
prescribed for use on a when-necessary basis with a lack of proper instructions to 
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guide their administration by the NS continue to be pertinent concerns with regards to 
the appropriateness of laxative use among elderly NHRs.  In addition, the lack of 
documenting and/or reviewing indications for its long-term use, identified using the 
MAI, added to this list of inappropriate prescribing concerns for laxatives in the NHs. 
Among the other top prevalent inappropriately prescribed medications 
reported in Sections 2.3.1.1 and 2.3.1.2, the nature of inappropriate prescribing of 
antipsychotic identified were deemed to have more worrying implications compared 
to that of antidepressants, anxiolytics and analgesics and antipyretics.  Specifically, 
inappropriate antipsychotic prescribing was related to the lack of proper assessment, 
monitoring and documentation of the use indication and outcomes in more than two-
thirds of all NHRs prescribed with antipsychotics, resulting in concerns of 
inappropriately long duration of antipsychotic use and the unnecessary exposure to 
SEs and adverse NHR outcomes.   
In Section 2.3.2.1, 10 drug-related AEs were reported.  This was probably an 
underestimate of the true prevalence in view of the retrospective nature of this study.  
As such, the identification of drug-related AEs was based on the presence of explicit 
documentation in the discharge summary at best, despite limitations in missing 
documentation and potential under-identification of cases during hospital stays or ED 
visits.  Although attempts were also made to identify drug-related AEs through 
retrospective evaluation of the medications used and the presence of IP during the 3-
month prior to the incidents, the absence of documented details in the NHRs’ medical 
notes posed uncertainties in (1) establishing the causes of the DRPs, (2) ascertaining 
the causal relationship of the DRP and actual AE,  and (3) specifying the medication 
implicated, especially when multiple medications were potential causes, as in the case 
of a fall-related AE.  Nevertheless, four points to be considered in interventions aimed 
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at improving PA and medication use outcomes among elderly NHRs were derived 
from the drug-related AEs reported.  Firstly, six drug-related AEs involved laxatives, 
antidepressants, antipsychotics and benzodiazepines, which had been consistently 
highlighted in the previous sections as having the highest numbers of IP.  This echoed 
the need to ensure the appropriate prescribing of these medications.  Secondly, the 
nature of the DRPs implicated in these AEs were similar to that reported by Gurwitz 
et al.,76, 77 where inappropriate drug/dose selection was the main (72%) prescribing 
errors contributing to preventable adverse events in NHs.  Like a repeated refrain, the 
finding from our background study offered evidence for the significant impact of 
inappropriateness in the prescribing process (compared to problems in other 
medication use processes) on negative outcomes of drug use.  Hence, it appeared that 
reducing IP may reduce the incident of drug-related AEs.  Thirdly, the general 
mismatch between the identified IPs and the DRPs implicated in the AEs suggested 
that the use of generic PA instruments that cover all types of medications may not be 
adequate for capturing IP that may be clinically significant.  Furthermore, the conduct 
of medication reviews to identify IP, such as that conducted for this study, was a time- 
and labor-intensive task accomplished by a pharmacist; the use of such interventions 
to capture and prevent IP with the aim of reducing adverse outcomes may thus be 
costly, inefficient, and ineffective.  More specific, sustainable, and practical 
interventions/strategies are thus needed, to (1) target the gaps in achieving PA of 
specific therapeutic or pharmacological subgroups, (2) involve other core clinical 
team members such as nurses and physicians, (3) be readily applied and systemically 
incorporated at long-term care institutions and (4) achieve timeliness in minimizing or 
correcting IP, so as to avoid drug-related AEs, and optimize medication therapy 
outcomes.  Lastly, a lack of monitoring for new indications, pharmacotherapeutic 
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responses and adverse reactions were deemed to possibly contribute towards these 
drug-related AEs; this led to the hypothesis that proper monitoring and 
documentations may serve as an integral part of an intervention to improve PA, avoid 
drug-related AEs, and optimize medication therapy outcomes. 
In Section 2.3.2.2, large confidence intervals for the odds ratios of factors 
associated with fall-related AEs were observed; this was possibly due to the small 
number of incidents included in the analysis.  Nonetheless, several resident factors 
were found to be associated with fall-related AEs.  The higher likelihood of elderly 
female NHRs to have fall-related incidents could be related to the physiological 
effects of accelerated bone loss in post-menopausal women compared to men of 
similar age;173 thus, women have higher risk for osteoporosis and are more prone to 
fractures from falls that may require tertiary medical care.  The decreased likelihood 
of elderly NHRs with dementia to have fall-related incidents could be due to the use 
of specialized dementia wards at the participating homes; such arrangements may 
have highlighted the NHRs’ decreased safety awareness (due to dementia) and 
increased fall-prevention measures in these wards.  In addition, similar to NHRs with 
higher functional dependence (RAF categories 3 and 4), NHRs with advanced 
dementia are likely to be bed-bound, less ambulant and less likely to engage in 
physical activities, and hence have lesser opportunities for falls due to the lack of 
mobility.  The lower prevalence of fall-related incidents among NHRs with 
polypharmacy was, however, contrary to that reported in other studies.174  This may 
be due to the increased attention given to NHRs with polypharmacy in the NHs, 
arising from the awareness of the potential association between popypharmacy and 
falls.  Similarly, the author postulated that interventions to improve PA may also 
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induce a ripple effect in reducing fall-related AEs by increased NS awareness of and 
attention to the NHRs.   
Among the medications evaluated in this study, benzodiazepines and 
antipsychotics were not significantly associated with falls that led to referrals for 
hospitalizations and ED visits although they were widely reported risk factors for falls.  
A possible explanation included limitations of the small number of fall-related AEs 
and the resulting large confidence intervals.  Therefore, this lack of statistical 
significance should not undermine the potential of these medications for causing falls, 
and other SEs and the importance of ensuring appropriate prescribing of these 
medications.  Similar to reports of other studies,157, 175, 176 regular use of SSRI 
(unadjusted OR = 2.78, 95% CI = 1.23, 6.30) and hydroxyzine (unadjusted OR = 3.60, 
95% CI = 1.09, 11.93) appeared to be associated with fall-related AEs.  Although the 
adjusted ORs for these were not statistically significant, the evaluation of these 
medications revealed concerns about their potentially inappropriate use.  Specifically, 
no documentation of mood disorders was found among 30% of the 17 incidents that 
recorded prior use of SSRI.  This was also observed for 37% of the 124 independent 
hospitalizations and ED visits (of all causes) that had prior use of SSRI.  Hence, not 
only did this imply that the association of fall-related AE may be unlikely due to the 
underlying reason of clinical depression, it also highlighted the potential issues related 
to IP that could have culminated to the increased odds for these AEs.  In the case of 
SSRI, the issue of inappropriateness was poor documentation (similar to the 
conclusions drawn by Mamun et al.177 on problems in prescribing of psychoactive 
medications), while for hydroxyzine, it was inadequate monitoring for medication use 
outcomes, leading to the failure to discontinue medications used for symptomatic 
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relief when it was no longer indicated.  Hence, these fundamental issues should be 
addressed in interventions to improve PA of psychoactive medications.   
Finally, although the prevalence of fall-related AEs appeared to be 
independently associated with a particular NH, this comparison could be limited by 
the data being collected from only three of the four NHs recruited.  Despite this 
limitation, strategies to target at-risk NHRs and overcome site-related factors such as 
environment and level of staffing should be considered when devising strategies to 
reduce IP and adverse outcomes, as suggested by many publications.174, 175  
 
2.5 Summary 
In the first part of this background work, laxatives [A06A], antidepressants 
[N06A], antipsychotics [N05A], anxiolytics [N05B], other analgesics and antipyretics 
[N02B], drugs for peptic ulcer and gastro-oesophageal reflux diseases [A02B], 
calcium [A12A], iron preparation [B03A], lipid modifying agents [C10A], and 
vitamin B12 and folic acid [B03B] were identified as the top five and 10 most 
prevalent medications with IP measured by the various explicit PA instruments and 
the implicit PA instrument MAI.  Among these, IP among laxatives and 
antipsychotics appeared to be the most prevalent and with the most worrying clinical 
issues of IP and concerns in terms of the potential adverse outcomes.  Therefore, the 
subsequent work was focused on these medications, beginning with evaluations of the 
challenges and other specific external factors that may influence the PA of laxatives 
and antipsychotics, followed by the development and testing of innovative strategies 
and interventions at the actual settings to improve their PA and therapeutic outcomes, 
and reduce AEs.  These are reported in chapters 3 and 4 of this thesis. 
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In the second part of this background work, IP were identified as the main 
causes of DRPs that had culminated directly to AEs of unplanned hospitalizations and 
ED visits.  AEs related to falls also appeared to be influenced in part by the use and IP 
of SSRI and hydroxyzine, which are potentially avoidable.  Successful interventions 
at the NHs may reduce the incidents of total unplanned hospitalizations and ED visits 
by up to 12%.  From the evaluations, the issues in PA and suggestions for new inter-
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Improving the Appropriateness of Laxative Use among Elderly Nursing Home 
Residents (NHRs) 
 
3.1 Identifying gaps in achieving appropriate laxative use 
 In general, constipation is a term that encompasses symptoms which describe 
irregular, infrequent or difficult evacuation of the bowels.  Despite the presence of a 
standardized diagnostic definition for chronic constipation such as the Rome III 
diagnostic criteria for functional gastrointestinal disorders178, many clinicians 
maintained the use of less than three bowel movements per week as a quick indicator 
for constipation.179  Many report constipation as subjective symptoms, which may 
include hard/lumpy stools, straining, bloating, and feeling of incomplete evacuation 
after a bowel movement, regardless of a reduced stool frequency.180  Hence, it was no 
wonder that the prevalence of self-reported constipation was observed to increase 
with age although reduced bowel frequency may not increase with age.181  
Specifically, the prevalence of constipation was known to be higher among the elderly 
residing in long-term care institutions compared to those who are community-
dwelling.  The difference in prevalence between the two settings reported in the 
United States was 74% versus 50%,182 and that in the Netherlands was 53% versus 
16-41%.183  In Singapore, the prevalence of constipation among those aged 60 years 
and above was estimated to be 12%; no data was available for the elderly NHRs.  The 
high prevalence of constipation at NHs was associated with NHR factors such as 
decreased mobility, poor fluid intake, poor dentition, co-morbidities such as 
Parkinson’s disease, dementia, hypothyroidism, arthritis and stroke, polypharmacy, 
and the use of constipating medications.184, 185  These NHR factors may also influence 
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the management of constipation; while improving access to toileting186 and increasing 
physical activity,187 fiber and fluid intake188, 189 may be effective nonpharmacological 
interventions to prevent constipation and decrease laxative use.  Restrictions in fluid 
intake due to renal/heart failure and a decrease in mobility status may also render 
these interventions infeasible for the majority of the frail elderly NHRs.  It is therefore 
not surprising that laxatives are one of the most commonly prescribed medications 
among the elderly NHRs.   
However, the high prevalence of laxative use (which refer to both the 
prescribing and administration processes of laxatives in this chapter) in the NHs is of 
concern in view of the lack of evidence on the appropriate duration of using senna to 
manage chronic constipation,172 the absence of elderly-specific pharmacotherapeutic 
guidelines for appropriate laxative use190 and the highly variable symptoms of 
constipation between individuals.191  From the previous chapter, the identified IP of 
laxatives included the lack of assessment of indications for laxative use, 
documentation of administration instructions (especially for two-thirds of the 
laxatives prescribed for use on a when-needed basis), and review of continual 
prescription of laxatives upon hospital discharge.  Moreover, under-prescribing of 
laxatives also caused two drug-related AEs.  To overcome these challenges in a 
concerted fashion, a communication program, Pharmacist Led Education on 
Appropriate Drug-use (PLEAD) program for laxative use, was developed to improve 
communication and the appropriateness of laxative use by engaging the prescribers 
(physicians), NS, key administrators and NHRs in specific desirable behavioral 
changes.  The details of which are reported in Section 3.2.1.  To the author’s 
knowledge, no interventions aimed at improving the appropriateness of laxative use 
had been attempted or published to date.        
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Before the development of the PLEAD program, it was essential to first 
identify the underlying factors, beliefs and attitudes that may influence inappropriate 
laxative use as well as possible motivators of behavioral change towards laxative use 
appropriateness.  These were the basis for identifying specific gaps and desirable 
behavioral changes towards appropriate laxative use, which in turn formed the content 
and contributed to the design of the message and structural framework of the PLEAD 
program.192  Several factors that may influence inappropriate laxative use and/or serve 
as motivators for behavioral change were postulated.   
Firstly, the prevalence of chronic constipation was generally thought to be 
correlated with the amount of laxatives prescribed.  However, this assumption in the 
NH setting where the majority of laxatives are used without documented indications is 
debatable.  This could be due to the omission of proper documentation or the lack of 
motivation/attention arising from the recurrent NHRs’ complaints and the simple 
routine treatment modes in providing assessment and hence documentation of 
constipation.193  However, the appropriateness of laxative choice and use should be 
one that is suited for the type of constipation symptom manifested and the intended 
pharmacotherapeutic outcomes.194  Hence, it would be important to uncover the 
prevalence of symptoms underlying the NHRs’ complaints of constipation.  Providing 
specific knowledge of these in comparison to the laxative prescribing/use trends may 
serve as a motivation to induce changes in the clinical team to be more attentive in 
ascertaining proper indications and prescribing/use according to actual needs. 
Secondly, it was observed that the prescribers would often add laxatives to the 
NHRs’ medication regimens when suggested by the NS and frequently at the NHRs’ 
first admission to the NH.  As laxatives are easily available over-the-counter 
medications for symptomatic treatment, the prescribers may not pay much attention to 
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its actual use after prescribing it as a when-needed medication for administration at 
the NS’s discretion (as otherwise, no medications could be served unless ordered by a 
physician).  Hence, discrepancies in laxative administration from its prescribed use 
may contribute towards inappropriate duration of laxative use. 
 Lastly, the NHRs’ beliefs about constipation, the impact of constipation on 
their quality of life, their attitudes towards managing constipation and expectations of 
laxative use, may potentially create pressure for prescribing and use of laxatives.195  
In addition, the NHRs’ feedback, negative or positive, after the administration of 
laxatives, may also influence continual laxative use by the same or other NHRs.  
Although allowing laxatives to be used according to the NHRs’ requests may be 
deemed appropriate,10, 196 such laxative use practice would clearly be inappropriate if 
the requests were driven by incorrect understanding of bowel movements and laxative 
use by the health care team and the NHRs themselves.197   
 
3.1.1 Description of the gap-finding studies  
 Thus, three separate gap-finding studies were first conducted to evaluate the 
appropriateness of laxative use, the prevalence of chronic constipation and symptoms 
among elderly NHR, the perceived impact of constipation, laxative use, satisfaction 
with the laxatives prescribed, and the NS’s perception on constipation management 






3.1.1.1 MUE of Laxatives  
Firstly, MUE to assess the appropriateness of laxative use, was conducted 
from September to December 2010.  The study was conducted at two VWO-run 
homes (200-300 beds each), which had been estimated to provide an adequate sample 
size for the MUE study, as well as the resident interviews (Section 3.1.1.2), and pilot 
study (Section 3.2.2) on the outcomes of the PLEAD program (using a non-
randomized controlled before-and-after design).  These NHs were selected at random, 
and were not previously included in the background study.   
Retrospective data on laxative use and bowel movements over a 4-week 
period in October or November 2010 were collected at both NHs using the custom-
designed data collection form (Appendix 3.1).  Information was collected from the 
original hardcopy medication records, medical notes and bowel elimination charts of 
the elderly NHRs held in the respective homes, except those with medical conditions 
and co-morbidities that would influence bowel movements and require special 
management, such as the presence of colostomy, cancer of the gastrointestinal tract, 
neurogenic bowel, megacolon, intestinal volvulus, diverticular diseases, ulcerative 
colitis (including Crohn’s disease), rectal prolapse, intestinal obstruction (of various 
causes) and irritable bowel syndrome.  NHRs with incomplete 1-month data due to 
hospitalization or death were also excluded.   
Evaluation of laxative use appropriateness was defined generally as 
conforming to any recommendations provided in the original product inserts, drug 
references, and published literature in terms of several domains, including indication, 
contraindication, precaution, SEs, dosage, dosing frequency, duration of use, storage, 
and monitoring requirements.  The actual administration of the laxatives was also 
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assessed for compliance to the prescribed frequency and duration of laxative use.   
Figure 3.2 shows the guide that was developed and used for this purpose.   
The minimum data sets required for this MUE was estimated to be 369 based 
on a worst-case scenario of 50% prevalence of inappropriate laxative use among the 
population of  9265 NHRs198 with 95% confidence level.160  The prevalence of 























3.1.1.2 Interviews of NHRs  
Next, surveys were conducted between January to April 2010 among NHRs 
and NS separately, to determine the prevalence of self-reported chronic constipation 
and related symptoms, perceived impact of constipation, laxative use, satisfaction 
with the laxatives prescribed, and the NS’s perception on bowel management.  Elderly 
NHRs with adequate cognitive capacities to provide responses were first identified 
with the help of the staff nurse-in-charge of each ward.  Consent was then sought 
from these NHRs and all NS at the two homes to participate in the study.   
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Available validated structured questionnaires were used for this study in order 
to provide quantitative measures of NHRs’ perception on constipation, its impact, 
laxative use, and satisfaction with the laxatives prescribed.  Specifically, The 
questions for assessing chronic constipation and symptom severity were derived from 
the Chinese constipation questionnaire.199  This was chosen as it was relatively short 
and quick to complete, well-validated and had been tested for use among Chinese, 
who were the major race at NHs in Singapore.  NHRs were identified to have chronic 
constipation if (1) the total score for the six questions under the “Chronic 
Constipation & Symptom Severity” section was above 4 or (2) the non-zero response 
was obtained for Question 1 under the “Perception of Constipation” section.  The 
questions for surveying the perception of constipation were derived in part from a 
survey published by Cheng et al.200  and the PAC-QOL201 questionnaire; these 
questions were worded in order to be understood by both residents with and without 
chronic constipation to be a survey of their general perception, without the intention 
to assess their current quality of life.  The survey questions administered to the NHRs 
and NS are shown in Figure 3.3.  Responses to all the questions were provided on a 5-
point Likert scale consisting of a range of zero to four scores, corresponding to ‘not at 
all’, ‘rarely/a little bit’, ‘some of the time/moderately’, ‘most of the time/quite a bit’, 
and ‘always/extremely’, where appropriate.  The survey questions were pre-tested by 






The surveys of NHRs were administered using face-to-face interviews to 
ensure good response rate and reliability of quantitative responses provided by the 
older residents202 as many older residents may require assistance in reading and 
writing due to physical impairments and illiteracy.  In addition, the face-to-face 
contact also provided opportunities to respond to the participants if help was needed 
in understanding the questionnaire items.  To minimize potential biases imposed by 
the interviewer, the interviews were carried out in a consistent manner as detailed 




other than those related to the questionnaire items.  All the interviews were conducted 
by the same interviewer, in English, Mandarin, or in Chinese dialects namely, 
Hokkien and Teochew, at a quiet and private location of the NHR’s choice.  Prior to 
the start of each interview, five to ten minutes were set aside to introduce the 
interviewer and the survey objectives, ensure anonymity, obtain the NHR’s consent to 
participate, and engage in casual chat.  The interviewer also emphasized the NHR’s 
right to refuse participation or discontinue the interview if he/she wished at any time, 
and that their action and responses will not affect future treatment.  These steps were 
essential in overcoming the potential reporting bias that may arise from the 
participant’s perception of the interviewer.  During the interview, the survey form was 
shown to each NHR while all the questions were read aloud in the same sequence.  
After each question, the response options were repeated, while pointing to the 
corresponding check boxes on the survey form as a visual cue.  Efforts were taken to 
read the questions during the interview slowly and in a low tone according to each 
NHR’s preferences as assessed during the casual chat.  Pauses were also made after 
each question to allow time for the participant to respond in an unhurried manner.  
Questions were repeated/explained when asked, or when the interviewer sensed the 
need to do so.  Each participant was also encouraged to speak freely, think aloud, and 
ask questions if he/she wished.  Each response was noted down on the survey form 
immediately and then shown to the participant.  Qualitative responses were recorded 
in the same manner; these served to supplement the residents’ quantitative responses, 
to allow quick assessments of the reliability and convergence of participants’ 
quantitative and qualitative responses during the interview, and to draw deeper 
understanding of the quantitative findings.203  Throughout the survey, simple gestures 
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by the interviewer such as addressing the participant by name and responding to 
his/her responses with nods and smiles were also made.   
For the interviews, a minimum of 119 NHRs were required (based on the 
recommendations of Bartlett et al.)204 using margin of error = 0.03 and α = 0.05.  The 
demographic, clinical and medication factors of the participants were obtained from 
their medical and medication records and reported.  The estimated prevalence of 
chronic constipation was reported and compared with that in the physician-
documented medical summary for each NHR.  Discrepancies in the reported laxative 
use from that recorded in the medication administration charts were reported.  The 
relationships between the perceived constipation, its symptoms, impact, laxative use, 
and other treatment modes were evaluated.  Responses between residents identified 
with and without chronic constipation were also compared.  Comparisons of 
categorical data were made using χ2 test while comparisons of continuous data and 
survey responses (ordinal data) were performed using Mann-Whitney U test.  
Correlation and association of domains and factors were tested using Spearman’s 
correlation test and logistic regression, while agreement was tested using Kappa 
statistics.  Factors associated with In addition, qualitative data was encoded using 
Microsoft Word and analyzed for emergent themes of NHRs’ concerns for the 
relevant individual questionnaire items using an inductive content analysis.205   
 
3.1.1.3 Self-administered survey of NS 
In view of the busy workload and changing shift hours of the NS, the use of a 
self-completed paper-and-pen survey questionnaire was postulated to overcome the 
potential limitation of a poor response rate as it can be readily completed per the 
participants’ convenience without the need to schedule for face-to-face contact with 
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the interviewer.  As such, personal invitations168 were made to all the NS of both NHs 
to fill out a 1-page self-administered form together with the consent form 
independently in January – April 2012.  The participants were given up to one week 
to return the completed forms to the interviewer, who provided clarifications on the 
survey questions if necessary, to minimize biased reporting and to ensure reliability of 
the data.  No names were required on the forms and the participants were assured of 
their anonymity.  However, the designations of the participants were obtained.   
The perceptions about constipation, its impact, laxative use, other treatment 
modes, and bowel management at the NH between the NS of different designations 
were compared.  These responses were also compared to those of the NHRs.  Testing 
of relationship between the different questionnaire domains were performed using the 
Cohen’s Kappa test of concordance, Spearman’s correlation test and Chi-square test.  
Kruskal-Wallis one-way ANOVA was used to compare the responses among the NS, 
and Mann-Whitney U test was used to compare responses between those of the NS 
and the NHRs.  The results and discussion of the NHR interviews and NS survey are 
reported in Sections 3.1.2.2 and 3.1.2.3. 
 
3.1.2 Outcomes of the gap-finding studies 
3.1.2.1 MUE of laxatives 
At the two NHs, 412 NHRs were screened; among whom, 69 did not meet the 
inclusion criteria for age, 21 had co-morbidities that may influence bowel 
management, and 12 had incomplete data.  Of the remaining 310 NHRs, laxatives 
were prescribed for 215 (69%).  Multiple laxatives (up to five) were prescribed for 
109 (35%) NHRs.  The demographic, clinical and medication information of the 310 
NHRs are summarized in Table 3.1.  The total number of laxatives evaluated was 359, 
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where 222 were “regular medications” and 137 were for use on a when-needed basis.  
Senna was the most commonly used laxative on a regular basis, while lactulose was 







  n  %  n  % 
NH Site        A  138  44.5  105  33.9 
        B  172  55.5  110  35.5 
Length of Stay        0‐6 months  28  9.0  24  7.7 
        7‐12 months  11  3.5  9  2.9 
        13‐24 months  27  8.7  20  6.5 
        >24 months  244  78.7  162  52.3 
Gender        Male  145  46.8  102  32.9 
        Female  165  53.2  113  36.5 
Age        65‐79 yo  131  42.3  95  30.6 
        >80 yo  179  57.7  120  38.7 
Race        Chinese  253  81.6  178  57.4 
        Others  57  18.4  37  11.9 
RAF        Cat 1 & 2  20  6.4  8  2.6 
        Cat 3  79  25.5  55  17.7 
        Cat 4  211  68.1  152  49.0 
Mobility (RAF)        Independent  16  5.2  5  1.6 
        Some assistance  102  32.9  71  22.9 
        Frequent assistance  101  32.6  62  20.0 
        Total assistance  91  29.4  77  24.8 
Polypharmacy        Absent  126  40.6  72  23.2 
        Present  184  59.4  143  46.1 
Dementia 
(Documented) 
      Absent  209  67.4  145  46.8 
        Present  101  32.6  70  22.6 
Chronic Constipation 
(Documented) 
      Absent  281  90.6  189  61.0 








As reported in Table 3.2, the identified inappropriate laxative use were 
absence of documented monitoring outcomes of laxative use (100%), absence of 
indication for use (67.4%), inappropriate duration of use (51.8%), presence of 
precaution for use (38.2%), inappropriate dosing frequency (32.9%), discrepancy 
between actual laxative administration and the prescribed directions for use (24.8%), 















n  %  n  %  n  % 
Prescribing 
    Indication  242  67.4  151   68.0  91   28.5 
    Duration of Use  186  51.8  186  83.8  0  ‐  
    Precaution  137  38.2  71  32.0  66  48.2 
    Dosing Frequency  118  32.9  44  19.8  74  54.0 
    Dosage (per day)  4  1.1  2  0.9  2  1.5 
Post‐prescribing 
    Monitoring  359  100.0  222  100.0  137  100.0 
    Administration  89  24.8  7  3.2  82  56.9 
 





Specifically, 151 of the 186 regular laxatives with inappropriately long 
duration of use were related to absence of documented indication for regular laxative 
use, while 35 were related to insufficient evidence to support the benefits of 
prescribing senna and bisacodyl tablets for use on a regular basis.  Among the 137 
laxatives prescribed for “short-term” use, 82 were administered on a regular basis, 
deviating from the prescribed intention of use.  Of the 118 laxatives with 
inappropriate prescribed dosing frequency, lactulose was implicated 94 times, for 
administration “three times daily” instead of the recommended dosing frequency of 
“one or two divided doses” for total daily doses of up to 30 milliliters.  Of the four 
counts of inappropriate prescribed total daily dose of laxatives, three involved under-
dose of senna; NHRs’ outcomes were not monitored in two cases, while bowel 
frequency outcome was clinically unsatisfactory (less than three per week) in the third 
case.  In the fourth case, the dosing frequency of lactulose was unspecified, with a 
potential for over-use.  In addition, it was observed that 17 of the 95 NHRs who were 
not prescribed with laxatives had indications for laxative use (bowel frequency < 3 
per week and/or use of opioid medications), while the other 64 NHRs were not 
actively monitored for their bowel movements nor assessed periodically for 
constipation symptoms.  The gaps and recommendations from these results are 
discussed in detail in Section 3.1.3. 
   
3.1.2.2 Interviews of NHRs 
Among the 110 NHRs identified as potential participants for the survey by the 
staff nurses-in-charge, 95 of them expressed interest and provided verbal consent to 
be interviewed when approached by the interviewer.  However, 10 NHRs were 
subsequently excluded due to language barrier and another two due to inability to 
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hold prolonged conversations.  The remaining 83 NHRs provided written consent and 
were interviewed.  Of these, three were excluded from the analysis as they had 
difficulty in answering more than half of the questions.  Another three NHRs opted to 
discontinue the interview citing reasons that they did not have any useful information 
to offer.  The number of interviews completed and included in the analysis was 77. 
Compared to that of the general cohort of elderly NHRs (Tables 2.1 and 3.1), 
the interviewees were made up of more males, younger (65 to 79 years old), had 
higher mobility (independent or require some assistance), and presented with 
polypharmacy.  The proportion of these NHRs with diagnosed and documented 
chronic constipation (7.8%) was similar to that determined in the MUE (9.4%, 
reported in Table 3.1).  The average time taken for the interviews was 14.4 (± 5.6, 





NH Site  A  47  61.0 
  B  30  39.0 
Length of Stay  0‐6 months  5  6.5 
  7‐12 months  4  5.2 
  13‐24 months  4  5.2 
  >24 months  64  83.1 
Gender  Male  47  61.0 
  Female  30  39.0 
Age  65‐79 yo  45  58.4 
  >80 yo  32  41.6 
Race  Chinese  64  83.1 
  Others  13  16.9 
RAF  Cat 1 & 2  11  14.3 
  Cat 3  34  44.2 
  Cat 4  32  41.6 
Mobility (RAF)  Independent  9  11.7 
  Some assistance  37  48.1 
  Frequent assistance  16  20.8 
  Total assistance  15  19.5 
Polypharmacy  Absent  22  28.6 








Of the 77 NHRs, 33 (42.9%) were identified as having chronic constipation; 
28 of them were identified using the questions under the “Chronic Constipation & 
Symptom Severity” section of the questionnaire, and 27 NHRs gave a non-zero 
response for Question 1 under the “Perception of Constipation” section.  This reported 
prevalence was higher than that diagnosed and documented in the NHRs’ medical 
records.  In addition, good agreement was observed between these two methods of 
identifying chronic constipation (Kappa = 0.7, 95% CI = 0.52 to 0.86; rs = 0.7, p-
value < 0.001), suggesting that the responses provided by the interviewed NHRs were 
reliable.  These 33 NHRs will be referred to as “residents identified with chronic 
constipation” (RCC), and the other 44 will be referred to as “residents identified with 
no chronic constipation” (RnCC). 
 From Figure 3.5, the number of constipation symptoms reported by 
RCC was significantly higher compared to RnCC (Mann-Whitney U test, p-value < 
0.001).  Each of the six symptoms was also more prevalent among RCC (χ2 test, p-
value < 0.05), where the most commonly reported symptom was “difficulty in passing 















Difficulty in bowel movements  30  4  < 0.001 
Used laxativesb  27  26  0.033 
    Prescribed with laxativesc  24  27  0.297 
Prescribed with laxatives (R)d  20  14  0.012 
    Laxative use recall discrepancy  16  17  0.387 
Hard stools  22  4  < 0.001 
Incomplete bowel movements  19  6  < 0.001 
< 3 bowel movements a week  16  4  < 0.001 






Among the 44 RnCC, more than 50% of them reported using laxatives during 
the past 3 months.  This prevalence had overshadowed that of other constipation 
symptoms.  Of the 27 (61%) RnCC prescribed with laxatives, 14 (32%) of them were 
prescribed with laxatives for use on a regular basis.  When verifying the NHR-
reported laxative use against that recorded in the medication administration and order 
charts, it was noted that 43% of the 77 NHRs had a recall discrepancy; the numbers of 
NHRs with recall discrepancy between RCC and RnCC (16 and 17 respectively) was 
not statistically significant.  This was not likely due to poor memory of the NHRs, but 
to a lack of awareness if laxatives were administered to them. 
Among the five domains of impact of constipation (Questions 2 to 6 under the 
section “Perception of Constipation”), RCC reported higher total numbers of domains 
affected by constipation compared to RnCC (Mann-Whitney U test, p-value < 0.001, 
Figure 3.6).  Constipation’s negative impact on each of these domains (except 
symptom controllability, which was not statistically significant) was also more likely 
to be reported by RCC; the severity of impact was also somewhat correlated to the 
overall symptom severity score obtained from the section “Chronic Constipation & 














Is bothersome  26  13  < 0.001  0.53e
Affects mood  21  9  < 0.001  0.54e
Affects health physically  19  4  < 0.001  0.51e
Affects life  14  8  0.020  0.29d









It was interesting to note that the most commonly reported impact of 
constipation was that “constipation is bothersome”, for both groups of RCC and 
RnCC.  The negative impact “constipation symptoms cannot be controlled” was the 
least reported by both groups of NHRs, and many did not provide any rating.  It was 
interesting to note that among those who did not provide any rating, 21 NHRs (18 
RnCC and three RCC) replied with “I don’t know”.  Among these 21 NHRs, 10 of 
them had a laxative use recall discrepancy from the medication administration charts, 
where nine NHRs (seven RnCC and two RCC) had under-recalls.   
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Satisfaction with the frequency and regularity of their bowel movements were 
reported among 23 and 24 RCC, and among 42 and 43 RnCC respectively.  The 
difference between the proportions of satisfied NHRs from both groups was 
statistically significant (χ2 test, p-value < 0.05).  This was expected, as constipation is 
a chronic problem.  From the NHRs’ qualitative feedback, satisfaction with bowel 
movements was discounted by presence of abnormal increases rather than a decrease 
in toileting frequency as well as being dependent for toileting needs due to 
dependence of mobility; only one NHR commented about the absolute need to have 
bowel movement daily.  It was further noted that six of the NHRs who provided a 
non-zero rating on being satisfied seemed to be nonchalant about the state of their 
bowel movements.  Such comments included, “…no issues even if not regular…”, 
“…it’s okay to go only 3-4 days a week as I don’t eat much.  Don’t have to go 
daily…”, “…can’t be bothered…”, “…no (about satisfaction), but what to do? ...”, 
and “…no complains…”.   
During the interview, NHRs commented on the negative impact of 
constipation and their satisfaction with bowel movements, as reported in Tables 3.6 
and 3.7.  To the author’s surprise, one RCC who was taking senna and lactulose on a 
regular basis lamented, “…constipation is especially bothersome, having to deal with 
side-effects of watery stools from the use of laxatives…” and further elaborated that 
he would soil his pants if he couldn’t get to the toilet in time.  Other NHRs also 
commented on having experienced diarrhea-like SEs from laxatives, specifically 

















































Of the 26 NHRs who reported having “watery stools”, five were RCC, and 21 
were RnCC.  Results from the logistic regression tests to identify factors associated 
with the NHRs’ responses of “watery stools” when asked if lumpy or hard stools were 
present (Question 4 under the “Chronic Constipation & Symptom Severity” section)   
showed that the reporting of “watery stools” occurred seven times (unadjusted OR) 
more frequently among NHRs who were using lactulose daily.  Despite the wide 
confidence interval observed, this association remained statistically significant even 
after adjusting for the presence of other factors such as the presence of chronic 
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constipation (which may imply spurious incontinence due to stool impaction) and the 





OR  95% CI  OR  95% CI 
NH Site 
A  1.0   ‐   1.0   
    B  5.7  (1.7, 19.0)b 3.8  (0.8, 18.3) 
Age 
65‐79 years’ old  1.0   ‐   1.0   ‐  
    80 years’ old and above  1.0  (0.4, 2.7)  1.1  (0.3, 4.0) 
Gender 
Male  1.0   ‐   1.0   ‐  
    Female  0.4  (0.2, 1.3)  0.5  (0.1, 1.6) 
Race 
Chinese  1.0   ‐   1.0   ‐  
    Non‐Chinese  0.5  (0.1, 2.1)  1.2  (0.2, 7.5) 
Mobility 
Independent  1.0   ‐   1.0   ‐  
    Requires some assistance  1.5  (0.3, 8.3)  0.8  (0.1, 6.7) 
    Requires frequent assistance  0.8  (0.1, 6.0)  0.2  (0.02, 2.7) 
    Requires total assistance  7.0  (1.0, 46.9)b 1.8  (0.2, 16.8) 
Chronic Constipation (identified) 
Absent  1.0   ‐   1.0   ‐  
    Present  1.0  (0.4, 2.5)  0.9  (0.3, 3.4) 
Lactulose administered daily 
Absent  1.0   ‐   1.0   ‐  
    Present  7.2  (2.5, 20.8)c 8.7  (1.9, 40.5)b
Laxatives (non‐lactulose) administered daily 
Absent  1.0   ‐   1.0   ‐  







With regards to the NHRs’ perceived need to use laxatives, weak correlations 
with the severity of constipation symptoms (rs = 0.3, p-value = 0.009) and the active 
use of laxatives (Kappa = 0.3, 95% CI = 0.1 to 0.5) were observed.  Similar trends 
were also noted with regards to the NHRs’ perceived need to use non-
pharmacological interventions to relieve constipation (with severity of constipation 
symptoms, rs = 0.2, p-value = 0.036; with active use of laxatives, Kappa = 0.1, 95% 
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CI = 0, 0.4) as illustrated in Figures 3.7 and 3.8.  The non-pharmacological 

























Of the 33 NHRs who responded that they needed to use laxatives at least 
“rarely”, 14 were RnCC but six of them reported “always” needing to use laxatives 
(Figure 3.7b) due to reasons such as having fear of not being able to pass motion if 
laxatives were stopped and wanting to be compliant with medication instructions from 
healthcare professionals.  Of these 14 NHRs, seven perceived non-pharmacological 
methods to be effective at least “some of the time”, but only three reported the need to 
use non-pharmacological interventions to relieve constipation symptoms.  From the 
NHRs’ comments, barriers to using non-pharmacological interventions included 
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institutional restrictions and lack of knowledge.  Comments alluding to these included, 
“…will ask for more fruits (at mealtimes), however it’s up to the nurses to give…”, 
“…everybody (is being) treated the same, (so there’s) no means to use other 
methods…”, “…(I) don’t know what were the other methods, so did not try…”, and 
“…the nurses know what to do, (I have) no comments…”.   
On the other hand, of the 44 NHRs who reported that they did not need to use 
laxatives at all, 14 had chronic constipation (Figure 3.7a); the reasons provided by 
these NHRs included the preference to non-pharmacological interventions and the 
ineffectiveness of laxatives.  Among these 14 NHRs, one was “not at all” satisfied 
with the laxatives used and another 11 chose to sit on the fence; reasons for these 
included the lack of effectiveness in relieving constipation, and the presence of SEs 
such as “watery stools”.  However, among these 12 opponents of laxative use, five of 
them were enthusiastic when asked about the use of non-pharmacological 
interventions to relieve constipation, and reported being “always” conscious about 
maintaining their bowel movements through increasing dietary fiber intake (in the 
form of fruits and vegetables, specifically bananas and papayas); these same NHRs 
also perceived this non-pharmacological method to be effective and satisfactory at 
least “most of the time”.   
In addition, among the 26 RnCC who were using laxatives, 13 (50%) did not 
perceive any need for them, citing reasons of side-effects (frequent need to “go” from 
lactulose), and savviness to ask for laxatives when required.  On the other hand, 
misconceived beliefs and attitudes of “always” needing laxatives were present among 
six RnCC (shown in Figure 3.7b).  The gaps and recommendations derived from the 




3.1.2.3 Self-administered survey of NS 
93 of 150 NS at the two homes returned the completed consent and survey 
forms, yielding a 62% participation rate.  Amongst these participants were one 
nursing officer, eight staff nurses, 12 enrolled nurses, 51 nursing aides, and 21 health 
attendants.  Their responses on their NHRs’ “Perception of Constipation” are shown 
in Figure 3.9.  The responses of the NS were significantly higher on constipation’s 
severity, controllability of symptoms, how bothersome constipation is and 
constipation’s impact on life, physical health, and mood (Mann-Whitney U test, p-






With regards to the need for, effectiveness of, and satisfaction with laxative 
use by the RCC, there is no statistical difference between the ratings of the NS and 
that of RCC.  The NS responded with a higher mean rank for the RCCs’ preference 
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for non-pharmacological intervention to relieve constipation (Mann-Whitney U test, 
p-value = 0.003), despite no statistical significance on the perceived effectiveness of 
non-pharmacological interventions between RCC and NS.  With regards to acute 
methods for relieving constipation, although no statistical difference in the mean rank 
was provided on the perceived need to administer these on the NHRs, those NS with 
nursing ranks of enrolled nurses and above reported higher mean rank for their 
effectiveness of use (Kruskal-Wallis ANOVA test, p-value = 0.032).  A lack of 
knowledge was also observed among the NS of lower nursing ranks, who included 
“high-fiber diet”, “increase in water intake”, and “lactulose” as acute methods, 
whereas those of higher nursing ranks accurately reported these as the use of enemas, 
suppositories, and manual evacuation procedures. 
More than half of the 93 NS (60.2%) reported the importance of bowel 
management among elderly NHRs as being “extremely” important; none of the NS 
reported “zero – not at all”, and two did not respond.  By comparison, only 51.6% of 
the NS thought that bowel management was “not at all” neglected in the NHs.  In 
addition, although there were no written bowel management protocol/guidelines 
present in the two NHs, 69 (74%) of the NS responded “yes”, and 13 (14%) did not 
respond to the availability of such protocol/guidelines.  When asked about the 
usefulness of having a written bowel management protocol/guidelines, more than half 
(59%) responded “extremely”.  
 
3.1.3 Discussion of identified gaps and recommendations  
 From the MUE outcomes reported in Section 3.1.2.1, gaps in the assessment 
and monitoring of indications for and outcomes (particularly efficacy and side-effects) 
of laxative use were identified.  The potential over-use of laxatives from these were of 
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concern in view of the almost full compliance to prescribed laxatives, and the absence 
of monitoring (100%) for therapeutic outcomes and potential SEs such as the 
frequency and consistency of bowel outputs and serum electrolyte disturbances 
(especially from regular use of lactulose more than six months).206  Furthermore, the 
absence of SEs reported from laxative use could be under-reported in the MUE due to 
inadequate patient monitoring.  Hence, improving identification of residents with a 
true need for laxatives, monitoring for laxative use outcomes and having proper 
documentation may overcome both over- and under-use of laxatives and improve 
clinical NHR outcomes.  In addition, gaps in optimal duration of laxative use 
(specifically laxatives prescribed for use when necessary) and dosing (particularly of 
lactulose) were present.  Providing education or guidelines for appropriate when-
needed use may effectively address the potential laxative mis-use and over-use while 
maintaining the timeliness of the treatment intended with such prescribing.  Although 
there is no evidence to discourage lactulose dosing frequency of more than three times 
daily for managing constipation, there may be other benefits to advocate consolidating 
lactulose doses to the recommended “one or two divided doses” a day.  Firstly, the 
nursing time spent on medication administration will be reduced, and potentially 
translated to savings in opportunity cost, as the time can be spent on other NHR care-
related duties.  Secondly, with lesser administration frequency, there may be reduced 
likelihood of medication administration errors.  Lastly, the NHRs’ quality of life may 
be improved when medications are taken less frequently.207   
From the outcomes reported in Section 3.1.2.2, a good participation rate (70%) 
in the interviews was obtained despite excluding 33 NS-identified NHRs.   
Furthermore, the demographics of the participants summarized in Table 3.3 showed 
that the exclusion of these NHRs did not result in under-representation of the minority 
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races residing in nursing homes.  Hence the potential limitation in the generalizability 
of the outcomes to all NHRs may be minimal.  From the interviews of NHRs, several 
gaps and recommendations to overcome inappropriate laxative use were identified.  
Firstly, the NHRs lacked empowerment with regards to managing constipation.  This 
was evident from the NHRs’ lack of awareness if laxatives were administered to them, 
and understanding of constipation, its treatment options (including non-
pharmacological interventions), and the effects that laxatives can produce.  Secondly, 
while misconceived beliefs and attitudes towards laxative use existed among some 
NHRs, barriers to use non-pharmacological interventions to manage bowels were 
perceived by others.  Hence, recommendations to overcome these gaps may include 
providing education and counseling to improve NHRs’ knowledge on the appropriate 
use of laxatives and non-pharmacological interventions in managing constipation, as 
well as addressing NHRs misguided beliefs about constipation and laxative use, and 
increasing the NS’s support towards the use of non-pharmacological interventions to 
manage bowels.  Thirdly, there was inadequate assessment of NHRs’ need to use 
laxatives and monitoring for the outcomes of laxative use (particularly side-effects of 
lactulose).  This was evident from the serendipitous reporting of “watery stools” 
among many NHRs interviewed, particularly among the RnCCs who were using 
lactulose on a daily basis.  These complaints were not previously detected by the NS, 
neither were the laxative use flagged up for review by the physicians.  Although 
lactulose’s mechanism of action and the resultant soft stools makes it an effective 
laxative for the elderly,206 administration of lactulose within the daily recommended 
doses among residents who do not require laxatives on a regular basis may easily 
induce diarrhoea-like SEs, hence explaining the complaints of “watery stools”.  
Increasing the awareness of the NS towards assessment for needs, monitoring for 
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laxative outcomes and SEs, and timely referral to prescribers for optimizing laxative 
doses, dosing frequency, and change of laxatives may thus improve the 
appropriateness of laxatives use and NHRs’ outcomes.  Specifically, adoption of a 
quick, easy to use and reliable screening tool in the NHs, such as the Chinese 
constipation questionnaire used in this study, may improve the assessment and 
documentation of constipation symptoms and the need for laxative use.  This may be 
especially useful for NHRs who are more independent, require minimal assistance 
with toileting (hence excluded from bowel elimination monitoring), or embarrassed to 
seek help. 
 Finally, from the outcomes of the self-administered survey of NS reported in 
Section 3.1.2.3, disparity in knowledge on bowel management was noted between NS 
of different ranks.  However, most of them agreed that standard guidelines for use of 
laxatives would be useful.  In addition, the NS appeared to be keen to follow 
guidelines and promote appropriate use of laxatives among NHRs under their care. 
 
3.2 Development, implementation and evaluation of a Pharmacist Led 
Education on Appropriate Drug-use (PLEAD) program for laxatives 
 
3.2.1 Program description 
 The identified gaps and recommendations reported in Section 3.1.3 were 
summarized using the mnemonic iPURGE (Figure 3.10), thus forming the content to 













The development of the PLEAD program framework was based on the 
theories of community mobilization208 and communication for participatory 
development,209 which describe behavioral change occurring at the population level.  
When applied in this instance, communication strategies beginning with creating 
awareness of a problem and potential solutions followed by dialogue and participation, 
can allow information sharing, mutual understanding and agreement, and accounting 
for conflict and its management, hence create cultural identify, trust, commitment, 
local ownership and empowerment to foster collective action and cooperation 
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between the various healthcare professionals working in the NH towards the goal of 
improving inappropriate laxative use and NHRs’ clinical outcomes.   
Hence, communication of the content (iPURGE) by the pharmacist is aimed to 
create awareness of existing inappropriate laxative use and foster recommended 
behavioral changes.  In addition to the theories stated above, the delivery of the 
message for the PLEAD program (iPURGE) was designed to increase the audience’s 
self-efficacy,208 which is defined as a person’s confidence in performing a particular 
behavior.  Thus the emphasis of the delivery was to persuade the audience that 
achieving appropriate laxative use would be possible.  As such, the audience may also 
be bolstered to add to the discussion and participation for the desirable behavioral 
changes. 
Therefore, a 2-hour workshop (to be conducted at the NH premise) was 
chosen as a platform to communicate and create awareness of the gaps in appropriate 
laxative use, share recommended behavioral changes to overcome the gaps, stimulate 
dialogue, resolve queries and conflict, and encourage audience participation in 
planning collective action for change.  The workshop’s target audience was the key 
administrators (including the executive director and nursing manager) and the NS 
who are employed by the NH.  The flow of the workshop included a 10-minute ice-
breaker and 5 minute pop-quiz on topics related to constipation and laxative use to 
first gain the audience’s attention.  This was followed by a one-hour PowerPoint 
presentation (by the pharmacist researcher) of the findings of the three gap-finding 
studies and the identified gaps and recommendations (iPURGE) derived from these.  
The presentation was structured to deliver each gap of iPURGE one at a time.  The 
gap was first introduced with reference to the gap-finding studies, then the potential 
impact on the NHRs the need to take action were explained using visual anaglogies to 
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trigger connection with the audience’s overarching values and relevance to 
performance,210 and lastly, the recommendations were provided with specific and 
measurable examples where appropriate.  After the presentation, the leader among the 
audience (executive director and/or nursing manager) facilitated a 45-minute open 
discussion session with the NS, in the presence of the presenter, to resolve queries and 
potential conflicts, decide on the achievable target and strategic behavioral changes, 
and set the date for initiating these changes.   
 The visiting physicians were not included as part of the target audience in the 
workshop, as they are usually volunteers or under institutional/private contract with 
the NH to provide consultative services to the residents; their short visit hours at the 
NH and tight schedules may limit their attendance at the workshop.  Hence, a more 
appropriate communication channel was chosen, where the relevant content of the 
PLEAD program was communicated concisely to the visiting physicians through a 
mailed “Dear Healthcare Professional Letter” as shown in Appendix 3.2.   
 
3.2.2 Prospective pilot implementation and evaluation of PLEAD program for 
laxatives 
 A pilot implementation and evaluation of the PLEAD program were contucted 
at the same two NHs using a non-randomized controlled before-and-after study design, 
where one NH was randomly chosen for implementation of the PLEAD program 
while the other NH was used as a control NH.  The workshop was conducted twice by 
the pharmacist (author) as described in Section 3.2.1, which took place at a meeting 
room of the intervention NH.  A duplicate workshop session was scheduled so that all 
NS could attend.   
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The target behavioral changes decided by the audience during the stake-holder 
facilitated discussions were reported as an outcome of the pilot implementation of 
PLEAD.  The physicians’ feedback on the recommendations provided in the Dear 
Healthcare Professional Letter was obtained by the author using the feedback form 
shown in Appendix 3.3, through individual face-to-face meetings held within two 
weeks after the letters were sent.  For this purpose, the physicians were contacted via 
email, to seek their consent and arrange for the meetings.  During the meeting, they 
were asked to rate their responses to the individual recommendations using “agree”, 
“neutral”, or “disagree”, and to provide comments explaining their responses.  
Additional informal and spontaneous feedback from the NS, key administrators to the 
author subsequently was also noted.   
 The mean changes of the actual amount of laxatives administered, the number 
of prescriptions for laxative altered, and the NHRs’ bowel frequency before and after 
the set behavior change date were evaluated retrospectively during December 2011 
and January 2012.  The relevant data was from the medication and medical notes, and 
the monitoring and elimination charts of the NHRs during the one-month periods 
before and after the set date of the behavioral changes.  A minimum sample size of 85 
residents in each intervention group was estimated, using power = 0.9, α = 0.05, 
standard deviation = 1 and mean difference = 0.5 for comparing means between 2 
samples.211, 212  The difference in changes between the intervention and control homes 
were evaluated using General Linear Model and adjusted for NHR factors that may be 
associated directly with laxative use213, 214 or indirectly through gender-associated 
health-seeking215 and race-associated lifestyle216 behaviors.  These factors included 
age, gender, race, presence of dementia, mobility (subscale of RAF), prior duration of 
stay in the NH, presence of polypharmacy, and the baseline estimates (of the average 
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bowel frequency, number of laxative prescriptions altered and/or amounts of laxatives 
administered).   
 
3.2.3 Outcomes of PLEAD program for laxatives 
 All NS at the intervention NH attended the workshop at least once.  Lively 
discussions ensued between the key administrators and the NS, especially during the 
first workshop, which was attended by most of the senior NS.  During the discussions, 
consensus was achieved between the key administrators and NS to initiate several 
behavioral changes beginning from 31st October 2011.  The behavioral changes 
decided upon were those that could be effected readily and quickly in a structured 
manner; these included (1) alerting physicians to review prescriptions for lactulose if 
the dosing frequency was more than twice daily or if daily dose was more than 30 
milliliters, and (2) improving the “monitoring” stage of laxative use for adequate 
laxative use reviews, through (a) immediate reporting of observations during diaper 
change to the nurse-in-charge at each shift for documentation (b) documenting the 
stool type (using the Bristol Stool Chart)217-219 in addition to the frequency of bowel 
opening, and (c) initiating NHR self-reporting at the nursing station after each bowel 
movement by NHRs who do not need assistance for toileting.  These behavioral 
changes were overseen by the staff nurses-in-charge at each ward, and were executed 
by all NS.  Besides these, the key administrators and NS also expressed interest in 
exploring promotion of non-pharmacological interventions and provision of 
medication education in an informal manner.   
On a separate note, it was also interesting that although the PLEAD workshop 
was not provided to the control home, the conduct of the gap-finding studies 
prompted the nursing manager to initiate elimination charting for the NHRs’ bowel 
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openings in May 2010.  This allowed accurate data of residents’ bowel frequencies 
during the pre- and post-PLEAD intervention periods to be obtained from the control 
home, which ensured unbiased comparison between the control and intervention 
home (where elimination charting was already present). 
 
3.2.3.1  Impact on laxative use trends and NHR outcomes 
 The number of NHRs who remained at the NHs before and after the initiation 
of behavioral changes (October and November 2011) was 112 and 142 in the 
intervention and control NHs respectively.  The NHRs’ demographic, clinical and 
medication use factors were reported in Table 3.10.  The profiles of the NHRs at the 
NHs were similar, except for a higher prevalence of Chinese and NHRs with higher 





















































As the set date for initiating the behavioral changes was 31st October 2011, the 
month of October was taken to be the period before the set behavioral change date, 








Hence, the before-and-after changes in the actual amount of laxatives 
administered and the number of laxative prescriptions altered were calculated using a 
30-day average (November) - 31-day average (October) for each NHR; that for the 
NHRs’ bowel frequencies were similarly obtained using a 4-week average (1st-28th 
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November) - a 4-week average (1st-28th October) for each NHR.  The baseline 
estimates (data from October 2011) of these outcomes were shown in Table 3.11, 
where the NHRs in the control NH had slightly higher mean average bowel 












































During the period after the behavioral changes, the changes in the number of 
laxative prescriptions altered at the intervention NH was significantly higher 
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compared to that at the control NH (Table 3.12).  Among the 53 prescriptions altered 
after the set date of behavior changes, 45 (83%) were for the change of dosing 
frequency of lactulose from “three times daily” to “once every morning”, three were 
for the change of dosing frequency of lactulose from “two times daily” to “once every 
morning”, three were related to prescribing of new laxatives, and two were related to 
discontinuing senna and lactulose.  Among the prescriptions altered for change of 
dosing frequency from “three times daily” to “once every morning”, 44 (out of 47 
possible prescriptions to be altered) occurred in the intervention home while only 1 
(out of 36 possible prescriptions to be altered) occurred in the control home.  In 
addition, the improvement in the NHRs’ bowel frequencies observed at the 
intervention NH were statistically significant compared to the negative changes in the 
NHRs’ bowel frequencies observed in the control NH (Table 3.12), despite no 
statistically significant difference in the mean changes of the average amounts of 














    Mean ± SD  0.38 ± 0.56  0.01 ± 0.17  < 0.001  < 0.001d     Range  ‐1 to 2  ‐1 to 1 
Amount of laxatives administered per NHRa 
    Lactulose (ml/day) 
    Mean ± SD  0.48 ± 6.07  ‐0.21 ± 2.21  0.215  0.408e     Range  ‐23 to 20  ‐26 to 0 
    Senna (mg/day) 
    Mean ± SD  0.19 ± 1.80  ‐0.1 ± 1.18  0.122  0.417e     Range  ‐9 to 14  ‐14 to 0 
    Bisacodyl suppositories (mg/day) 
    Mean ± SD  ‐0.01 ± 0.16  0.03 ± 0.28  0.232  0.267e     Range  ‐1 to 0  0 to 3 
    Bisacodyl tablets (mg/day) 
    Mean ± SD  ‐0.05 ± 0.52  0 ± 0  0.261  0.175e     Range  ‐5 to 0  0 to 0 
    Sodium/phosphate enema (dose/day) 












    Mean ± SD  0.00 ± 0.05  0 ± 0  0.261  0.984e     Range  0 to 1  0 to 0 
NHRs’ bowel frequencyb 
    Average number of days per week 
    Mean ± SD  0.09 ± 1.13  ‐0.42 ± 0.88  < 0.001  0.021f     Range  ‐3 to 3  ‐3 to 1 
    Minimum number of days per week 
    Mean ± SD  0.06 ± 1.43  ‐0.31 ± 1.17  0.023  0.540f     Range  ‐4 to 4  ‐5 to 3 
    Maximum number of days per week 

















3.2.3.2 Feedback from key stakeholders, NS, and physicians 
 During the author’s follow-up visit to conduct data collection for the 
evaluation of the PLEAD program outcomes in December 2011, the nursing manager 
and the NS at the wards commented that the reduction of dosing frequency of 
lactulose cut down the time taken to prepare, serve, and clean up the serving cups.  
The staff nurses also commented that bowel movements of some NHRs were more 
pronounced and consistent when lactulose was dosed all at once in the morning in 
comparison to dosing three times a day.  The NS also reported fewer changes of 
soiled diapers per day for some NHRs.   
   Two of the general physicians who received the “Dear Healthcare 
Professional Letters” offered written and face-to-face feedback on the 
recommendations.  One physician agreed to all recommendations, but disagreed on 
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avoiding the use of lactulose by NHRs who are ambulant, as he had not received 
complaints from them.  However, he also recognized that the NHRs’ description on 
the increased unpleasant urgency to pass motion and “watery stools” induced by 
lactulose could pose as a fall risk if they were to rush to the toilet.  The other 
physician also agreed to all recommendations, but was concerned if the NS could 
conduct the regular reviews of NHRs’ needs for laxatives in addition to their nursing 
duties and general manpower constraints, while suggesting that pharmacists should be 
involved in the monitoring and review of NHRs’ medications to optimize the 
treatment regimens and their outcomes. 
 
3.2.4 Discussion of PLEAD program outcomes 
 From the outcomes of the PLEAD program reported in Sections 3.2.3.1 and 
3.2.3.2, it may be reasonable to conclude that pharmacists can, through the PLEAD 
program, engage the NS and physicians in the NH to collaborate and improve the 
appropriateness of laxative use and outcomes of NHRs.  Specifically, the significant 
increase in the number of laxative prescriptions altered in the intervention home 
suggested that the PLEAD program succeeded in engaging the NS to proactively alert 
the physicians to review prescriptions with inappropriate lactulose dosing during their 
usual interactions when the physicians visited the intervention NH, and possibly 
resulted in significant improvements in residents’ bowel frequencies in the 
intervention NH.  Although the mean change in the NHRs’ bowel frequencies 
observed in Table 3.12 seemed low, it was interesting to note that the residents’ bowel 
frequencies had gotten worse in the control home where PLEAD program was not 
implemented.  In addition, the staff nurses’ comments on the additional benefits of 
consolidated lactulose dose on NHRs’ bowel movements could be related to the 
102 
 
positive effect of flatulence induced by the larger lactulose dose ingested which 
augmented the natural colonic stimulation at morning awakening and after 
breakfast.220   
Hence, compared to the pharmacists’ role as the “police” who conducted 
medication use evaluations at the control home, it seemed that the pharmacists’ role as 
the “advocator” for appropriate laxative use in PLEAD may be the key for these 
desirable outcomes observed in the intervention home.  However, the generalizability 
of these outcomes to other homes may be limited by the non-randomized study design 
employed in this pilot implementation and evaluation of the PLEAD program.  
Although the statistical analyses included adjustments to account for differences 
among the NHR profiles that may confound the outcome of laxative use and bowel 
frequencies, a cluster randomized controlled study will be needed as part of future 
work to evaluate the success of the PLEAD program to facilitate inter-professional 
collaborations to improve laxative use appropriateness.   
 
3.3 Developing a set of algorithms for appropriate laxative use (AALU) 
 As there are no specific criteria/guidelines for assessing the appropriate 
prescribing/use of laxatives in the general elderly NHRs, a set of Algorithms for 
Appropriate Laxative Use (AALU) was developed by the author (apart from the 
PLEAD program), based on the findings reported in earlier Sections 3.1.2 and 3.2.3.  
AALU is limited to assessing laxatives of the elderly residents without other pre-
existing co-morbidities such as irritable bowel syndrome, megacolon, colostomy and 
neurogenic bowels that may affect bowel management. 
AALU consist of two parts (Figures 3.12 and 3.13), where Part (I) assesses the 
appropriateness of laxatives used on a “when-needed” basis; Part (II) assesses the 
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appropriateness of laxatives prescribed for use on a “regular” basis.  Both of these 
algorithms were written as a series of questions to be answered stepwise, in order to 
arrive at the conclusion if the prescribing/use of the laxative was “appropriate” or 
“inappropriate”.  An attempt to answer these questions by retrospective medication 
reviews can be made by the assessor using prior information documented by the 
physicians, nurses and other healthcare professionals (such as physiotherapists) in the 
NHRs’ medical and medication notes, bowel opening monitoring/charting forms, 
institutional transfer notes and hospital/ED discharge summaries, where inadequacies 
in documentation shall be taken as “nil” responses, hence rendering the use of the 












Validation25, 221 for Parts (I) and (II) of AALU was performed by applying the 
algorithm in a pilot retrospective MUE using a data set of 22 “regular” laxatives and 
20 “when-needed” laxatives taken by 24 NHRs, who were chosen at random from the 
intervention NH.  The outcomes of this MUE were reported and their implications on 
the ability of the AALU in identifying the appropriateness of laxative use were then 
discussed in the following paragraphs. 
The average time taken to complete one laxative evaluation using AALU Part 
(I) or (II) of AALU was less than one to two minutes, depending on the number 
questions answered before arriving at being “appropriate” or “inappropriate”.  In all, 
AALU Part (I) was triggered 22 times, where 13 of the 20 “when-needed” laxatives 
were identified to have been inappropriately used and two NHRs with no laxative use 
were not identified to have under-use of laxatives.  The steps in Part (I) that rendered 
“inappropriate” use of “when-needed” laxative were II (absence of indication and 
presence of indication with absence of laxative use), III (existing laxative that did not 
produce desirable therapeutic outcomes was not stopped when the new laxative was 
started), IV (laxative was used continuously for more than a week without achieving 
desirable therapeutic outcomes nor referral to a physician for further review), and V 
(laxative was not stopped despite achieving desirable therapeutic outcomes).  The 
AALU Part (II) was triggered for the 22 “regular” laxatives, of which 14 were 
identified to have been “inappropriately” prescribed.  The steps in AALU Part (II) that 
rendered “inappropriate” “regular” laxative use were II (no prior trial of non-
pharmacological interventions), III (absence of indication), VIII (laxatives continued 
despite the absence of desirable therapeutic outcomes), and IX (presence of frequent 
watery stools).  Hence, use of AALU identified all categories of IP/use, which 
included under-, over, and mis-prescribing/use of laxatives.  In addition, no ambiguity 
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was encountered when assessing the appropriateness of multiple laxatives given to an 
individual NHR.  
From the results of the pilot retrospective MUE, the author noted that steps IV 
and VI of the AALU Parts (I) and (II) for assessing the appropriateness of doses and 
dosing frequencies were not triggered.  The reason for this was that the laxatives had 
been rendered “inappropriate” at earlier steps in the algorithms, for example, at II and 
III of the AALU Parts (I) and (II) respectively, due to the absence of indications.  As 
such, once inappropriateness had been identified, considerations of the subsequent 
steps of the AALU need not be made.  Hence, the use of AALU for MUE appeared to 
be efficient and effective in terms of minimizing the time taken for retrospective 
reviews of laxative use.  In another example of a “regular” lactulose that had been 
transcribed from a hospital discharge medication list (without documentation of 
instructions, diagnoses or indications for continuing lactulose on a long-term basis) 
and used for about two months at the NH with no assessment for its indication, or 
attempts to taper its use although the NHR’s bowel frequency had improved shortly 
after hospital discharge, the inappropriateness of this “regular” laxative use was 
identified in the MUE by AALU Part (II) at step II, where the use of lactulose by the 
NHR should be replaced by a trial of non-pharmacological intervention since the 
NHR was not bed-bound.  In this example, addressing the recommendations provided 
at step II of AALU Part (II) at the first physician review after hospital discharge might 
have avoided an over-use of laxative, without requiring additional time and resources 
to assess for a definite indication for the use of lactulose.  Hence, there may be 
potential to use AALU as a guide for decisions in prescribing and administration of 
laxatives in a prospective manner, to reduce inappropriate laxative use, minimize cost, 
and achieve optimal resident outcomes through the timely recommendations provided.   
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The AALU has several advantages over the existing PA instruments and 
algorithms for use in the NHs (previously reported in Section 1.3 and Table 1.1).  
Firstly, AALU provides a comprehensive assessment for all categories of 
“inappropriate” use of laxatives.  Specifically, Part (I) may detect the presence of 
under-, over- and mis-use of laxatives prescribed for intention of “when-needed” use, 
or for NHRs who were not already prescribed with any laxatives with the assumption 
that nurses would administer laxatives on their discretion.  On the other hand, Part (II) 
may detect the potential over- and mis-prescribing; assessment for under-prescribing 
of laxatives for use on a “regular” basis was covered in Step IV of Part (I).  Secondly, 
AALU also allowed assessment of the use of combination laxatives, with 
consideration of when the use of the individual laxative was introduced.  Thirdly, a 
copy of the explicit descriptions of the definitions of appropriateness, significance, 
issues of inappropriateness, and remedial actions to be taken when inappropriateness 
was triggered at each step was provided to supplement the use of AALU as shown in 
Appendix 3.4.  Hence, similar to the MAI, AALU incorporates both explicit and 
implicit assessments of the appropriateness of prescribing/use of laxatives.  These 
explicit information may guide the healthcare practitioner in decision-making process 
or rectify identified IP/use of laxatives.  Lastly, the order in which the questions in 
AALU were placed complements decision-making during the “prescribing” and 
“administration” processes of laxatives.  Hence, the use of AALU in MUE provides a 
more timely assessment, as the assessor does not need to plough through large 
amounts of information to arrive at the conclusion if the prescribing/use of laxative 
was “appropriate” or “inappropriate”.   
The use of AALU is not without caveats.  Firstly, the explicit descriptions 
regarding the definitions of appropriateness, significance, issues of inappropriateness, 
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and remedial actions if inappropriateness is triggered should be updated to reflect the 
current medical evidence and pharmacotherapy practice.  Secondly, as the use of 
AALU may require implicit evaluations to be made, users of the algorithm may need 
to acquire a basic understanding of the measure of “appropriateness” and sound 
pharmacotherapy principles, in order to ensure reliable outcomes, especially when 
used as a guide for prospective decision-making in the prescribing/use of laxatives.  
Lastly, when used retrospectively, it may be difficult to draft recommendations for 
inappropriateness identified from concurrent use of multiple laxatives.  This could be 
overcome through inter professional collaborative discussions involving the NS who 
provides direct care of the NHRs, the prescribing physicians, and the pharmacists to 
obtain information about the NHR and to achieve consensus on the appropriate 
interventions for the NHR.    
 
3.4  Summary 
 In this chapter, a communication program, Pharmacist Led Education on 
Appropriate Drug-use (PLEAD) was developed based on MUEs, NHR interviews and 
NS surveys, then implemented and evaluated in a pilot study using a non-randomized 
controlled before-and-after design in two NHs.  The content of PLEAD was 
summarized as the iPURGE mnemonic.  Both the PLEAD workshop and the “Dear 
Healthcare Professional Letters” were well-received by the NS, key stakeholders and 
physicians, resulting in interventions that increased the number of prescriptions 
altered and improved the NHRs’ bowel frequencies.   
 In addition, Algorithms for Appropriate Laxative Use (AALU) was also 
derived from the preceeding work, to be used as a retrospective assessment of laxative 
use appropriateness and as a prospective guide in appropriate prescribing and use of 
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laxatives.  Although AALU had been validated for its content and structure as a tool 
for use in retrospective MUEs, its use as a prospective guide is promising as it has 
advantages over the current PA instruments, and increases efficiency of the conduct 
of MUEs and interventional studies for improving appropriateness of laxative use 






Improving the Appropriateness of Psychotropic Use in Managing Behavioral 
and Psychological Symptoms of Dementia (BPSD) 
 
4.1 Identifying challenges in managing BPSD and appropriate prescribing of 
antipsychotics in the NHs 
 In view of the increasing trends in population growth and life expectancy of 
those aged 65 years and above, the prevalence of dementia among Singaporeans is 
projected to increase from the estimated 30,000 in year 2010, to 53,000 by year 2020, 
and 187,000 by year 2050.222  Dementia is marked by features of progressively 
worsening memory impairment and cognitive disturbances.223  As the illness advances, 
the resulting decline in functional capacity naturally exerts its toll on the patient’s 
family, and/or the society, demanding significant expenditure in time, energy, and 
resources in caregiving for extended periods.  This was estimated to amount to some 
USD 391 million in societal cost (direct costs plus informal care) in year 2005.224   
In addition to delaying cognitive and functional decline, research related to 
dementia was reported to be increasingly focused on defining, measuring and 
managing BPSD.225  BPSD is a term that encompasses a heterogeneous range of non-
cognitive symptoms, such as disturbed perception, thought content, mood, and 
behavior;225 and are broadly classified as “behavioral” or “psychological”.226  These 
symptoms were estimated to be present in up to 97% of persons with dementia over a 
five-year period,227 and was reported to be a significant source of patient distress and 
caregiver stress,228, 229 increased costs of care and NH admissions.230  Hence, it was 
not surprising that higher point prevalence were reported in the NHs compared to that 
in the social care setting .231   
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Management of BPSD can be summarized in the following steps: (1) identify 
the target symptom/s to be addressed, (2) evaluate for underlying causes of BPSD, 
and alleviate those that are reversible, (3) optimize the environment, implement 
behavior-response plan, and use of non-pharmacological interventions, (4) use of 
appropriate pharmacologic agent if necessary, (5) monitor for outcomes of 
intervention and return to step 1 if response is not at goal.  Despite the limited 
evidence supporting the efficacy of many non-pharmacological interventions, these 
are clearly recommended over the use of pharmacologic agents, particularly 
antipsychotics, in managing BPSD, particularly symptoms of severe agitation, 
aggression, and psychosis, which often pose a threat to the safety of the NHRs and 
others around him/her.232-234  The obvious reasons are antipsychotics’ inconclusive 
efficacy of use coupled with limited long-term benefits, numerous SEs, and its 
association with higher risks of stroke and death.  Though debatable, antipsychotic 
use in the NHs will likely continue to be prevalent.235, 236  However, NHs face many 
challenges in the appropriate management of BPSD and prescribing of antipsychotics.   
Firsly, dementia is often under-diagnosed or undifferentiated in its diagnoses 
according to the subtypes for many NHRs in Singapore.  Investigations for possible 
dementia, if any, usually take place at the onset of BPSD.  Even then, comprehensive 
workups involving brain scans and electroencephalography are often not performed 
due to limitations in resources and the lack of motivation or inability of the NHRs’ 
families to pay for these procedures; diagnoses are often based on physician 
assessments using brief neuropsychological screening tests.  As such, IP of 
antipsychotics and adverse patient outcomes may ensue.  For example, NS who are 
not informed about the NHRs’ conditions may be less attentive and less likely to 
employ strategies specific for BPSD management during caregiving duties.  As such, 
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frustration among NS during caregiving may arise from nurse-resident conflicts and 
NHRs’ resistance to care, hence, often resulting in ill-managed BPSD, escalation of 
agitation/aggression in the NHRs, hence, risking their safety, and adversely affecting 
the quality of care.  In turn, ill-managed BPSD and the related risks of NHRs’ safety 
may lead to prescribing of antipsychotics,236 exposure of the NHRs to antipsychotic 
SEs and adverse NHR outcomes.  In another example, the lack of proper diagnoses 
may cause antipsychotics to be prescribed unknowingly to NHRs with dementia of the 
Lewy Body type; this dementia subtype accounts for up to 30% of all dementia 
cases237 and has high incidence (up to 60%) of adverse and life-threatening reaction to 
antipsychotics.234, 238  Hence, the prescribing of antipsychotics in these NHRs is 
deemed inappropriate and should be avoided.   
 Secondly, various attributes of the NS may contribute significantly to 
challenges in managing BPSD and potential pressures on physicians to prescribe 
antipsychotics inappropriately.  Currently, 70% of the limited 4,000 NH staff in 
Singapore are drawn from the neighboring countries of the Philippines, Sri Lanka and 
Myanmar.  Two-thirds of them work as nursing aides and healthcare attendants, 
whose core duties involve providing the basic care such as grooming, feeding, 
toileting, and transferring.239  This laborious, time-consuming, low-paying and often 
unappreciated job scope may be a potential recipe for stress and low tolerance to the 
disruptive symptoms of agitation, aggression and psychosis.  Furthermore, deficiency 
in language and cross-cultural differences may create little advantage or motivation 
for the NS to understand and cope with the NHRs’ behaviors and underlying needs.  
The NHRs’ disruptive behaviors and outbursts may inflate feelings of stressfulness in 
caregiving, hence adding to the pressure on physicians to prescribe antipsychotics.  
 Thirdly, the lack of formal healthcare education among many NS and the 
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absence of monitoring programs for treatment outcomes and side-effects of 
antipsychotics across the NHs may contribute to IP of antipsychotics.  Without 
adequate knowledge on BPSD and mandatory training of antipsychotic use 
monitoring, the NS may have variable observational skills, resulting in feedback that 
lack clinical insight, objective details and timely reporting of important 
antecedent/recurring events implicated.  As the physician’s visits are brief and 
infrequent (up to once in 3 months148 and attendance for acute conditions), physicians 
depend on the NS’s input for the report of the NHRs’ well-being and behavior.  
Inappropriateness of antipsychotic prescribing could result from mis-identification of 
target symptoms, and include “mis-prescribing” of antipsychotics when other 
psychotropics are needed, “under-prescribing” of antipsychotics when necessary 
(which may result in AEs related to sub-optimally managed aggression), “over-
prescribing” of antipsychotics when not necessary (which may result in unnecessary 
exposure of NHRs to adverse drug effects and risks for stroke and sudden death), and 
“over-prescribing” of antipsychotics for use over prolonged periods in an unregulated 
manner (which may culminate to debilitating ADEs such as falls, irreversible tardive 
dyskinesia and progressively rapid decline in overall physical functions).  
Lastly, although some non-pharmacological strategies such as music therapy, 
recreational activities and interventions involving sensory stimulation may appear to 
offer some promise in reducing BPSD and hence, the use of antipsychotics, they are 
also complicated to set-up and administer, as the interventions are often 
individualized, time-consuming, labor-intensive, and require high costs.240, 241  Most 
of the NHs in Singapore are run by non-profit volunteer welfare organizations, whose 
operating expenses depended highly on public donations and funding from the 
government (up to a maximum of 50%); a lack in resources, expertise and funding 
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may thus hinder long-term implementation of non-pharmacological strategies in 
managing BPSD, resulting in the reliance of the seemingly cheaper and convenient 
use of antipsychotics in reducing agitation, aggression and psychotic symptoms. 
 
4.2 Identifying strategies to improve appropriate prescribing of 
antipsychotics 
 The first widespread changes in antipsychotic use trends were reported across 
most NHs in the US during the early 1990s.  This was in response to the 
implementation of the OBRA’87 legislation, which aimed, primarily, to restrict the 
unjustified use of antipsychotics as a chemical restraint in the NHs, for managing 
difficult behaviors such as wandering, restlessness, anxiety and uncooperativeness.90  
In tandem with this legislation was the mandatory conduct of routine drug regimen 
reviews by pharmacists.88  Although these brought about remarkable reductions in 
antipsychotic use, evidence on its positive impact on other clinical outcomes (such as 
reduction in AEs among NHRs) was elusive.  Contradictorily, a retrospective cross-
sectional study noted that the NHRs in the US were more likely to sustain falls, 
despite lower prevalence of psychotropic use, compared to those in Denmark, Iceland, 
Italy, Japan and Sweden.242  Furthermore, it appeared that providing adequate levels 
of staffing may be a more crucial ingredient in contributing towards the successful 
reduction of antipsychotic use in the NHs.243, 244  In view of the absence of similar 
legislation in Singapore, and the shortage in NS faced by most of the NHs here, there 
is a need to explore other interventions to improve the appropriateness of 
antipsychotic use among NHR with dementia. 
A literature search was conducted on PUBMED to identify reports of 
interventions for improving the appropriateness of antipsychotic use in NHs.  A 
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combination of terms “intervention”, “medication”, “prescribing”, “antipsychotics” 
(entered as a MeSH term), and “nursing homes” (entered as a MeSH term) was used 
to sieve out original studies that were published in the English language between 2000 
and 2010.  The reference lists of review articles (that described nursing home 
interventions) identified from the search were also reviewed manually for additional 
publications.  Articles included for review were those that reported changes in 
antipsychotic use/prescribing appropriateness as one of the primary outcome/s, in 
comparisons with control or baseline estimates.  Articles that included improving the 
appropriate use/prescribing of antipsychotics among that of other medications as the 
interventions’ aims but did not specifically report the changes of antipsychotic 
use/prescribing appropriateness in the results section were excluded.  Table 4.1 
summarized the seven studies that were identified.  Among these interventions, five 
involved providing education to healthcare professionals and NH care staff,121, 124, 125, 
142, 245 one involved improving medical documentation and inter-disciplinary 
communication,118 and one involved a non-pharmacological intervention for the 
















































































































































































































































































































































From these recent studies, it appeared that the presence of two factors were 
essential ingredients to bring about significant changes in antipsychotic prescribing 
trends.  Firstly, interventions should involve healthcare providers from more than one 
discipline, especially the NS as they were likely to influence physicians’ decisions on 
antipsychotic prescribing.246  Secondly, interventions that involved improving 
healthcare providers’ knowledge on the appropriate use and concerns of antipsychotic, 
with/without active medication review by a prescriber/pharmacist reported desirable 
changes in antipsychotic use.  These findings were consistent with that reported in 
studies published more than a decade ago.116, 247-251   
Of the interventions identified, most of them require additional time of NS, 
pharmacists and clinicians outside of their regular duty/consultation visits for regular 
multi-disciplinary conferencing,116, 118 regular training and support sessions,125 or 
resident-centered psychosocial intervention.126  Such requirement may render these 
interventions unrealistic for long-term implementation in the NHs in Singapore due to 
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shortage of manpower resource as explained in Sections 1.4 and 4.1.  Hence, the 
preferred multidisciplinary approaches are expected to not only produce desirable 
outcomes but also need to be easily implemented without taxing on resources; such 
interventions would be more practical and sustainable in the local NH setting. 
In addition, many of these interventions (and many others reported a decade 
ago) did not measure the impact of changes in antipsychotic use trends on adverse 
outcomes among NHRs.252  In Chapter 1, improvements in both the NHR’s 
therapeutic and reductions in adverse outcomes had been shown to be important 
indicators of medication use appropriateness,10, 11 and should be measured in 
evaluation studies of interventions that aim to improve medication use 
appropriateness.51, 52  Among the seven reported here, only one measured changes in 
the number of NHR falls (an AE widely associated with antipsychotic use).125  
Although most of these studies measured the change in BPSD using various 
instruments,124-126, 245 positive results in this outcome measure may not be attributed 
entirely the appropriateness of antipsychotic use as BPSD, specifically agitation, is 
intermittent in nature.253  Furthermore, it was also noted, that interventions to improve 
the appropriateness of antipsychotic use among NHR with dementia seemed to be 
focused on reducing the use of antipsychotics, which is synonymous with preventing 
an “overuse” and “mis-use” of antipsychotics.  None of these interventions addressed 
the potential “underuse” of antipsychotics due to under- or mis-identification of 
symptoms such as psychosis, which may respond to short-term treatment using 
antipsychotics.233  The use of antipsychotics to manage symptoms of severe agitation, 
aggression and psychosis may be warranted in some cases, especially when these 
behaviors threaten the safety of the NHR and others around him/her.  
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From the above analysis of current local practices and published literature, the 
author opined that timely and objective monitoring and documentation of (1) 
identification of target BPSD for treatment with antipsychotics (and/or other 
psychotropic agents), (2) evaluation of therapeutic outcomes, and (3) monitoring for 
SEs of antipsychotic (and other psychotropic agents) are pivotal steps in preventing 
inappropriate antipsychotic use among NHRs with dementia, via providing critical 
information for physician decisions during the “prescribing” stage of the medication 
use process in the NHs.  Specifically, the information derived from these steps may (i) 
allow targeted use of non-pharmacological interventions or antipsychotics (and/or 
other psychotropic agents) on specific “type/s” BPSD identified, (ii) prevent 
unjustifiable decisions to initiate antipsychotic treatment in managing BPSD, (iii) 
allow timely use of antipsychotics to reduce symptoms of severe agitation/aggression 
and psychosis in order to alleviate safety concerns, and (iv) allow timely prescribing 
decisions to reduce, stop, or switch the antipsychotic in use when the therapeutic goal 
is reached or when SEs interfere with the well-being of the NHRs.  Hence, such 
monitoring may comprehensively address some of the challenges related to “overuse”, 
“mis-use” and “underuse” of inappropriate antipsychotic use and concerns of their 
related SEs and AEs.  Hence, to actualize these steps in a single program and 
overcome the challenges identified above, a Psychotropic Use Monitoring (PUM) 
program which involves an inter-professional collaborative practice model was 
developed.  The development, implementation and evaluation of PUM are described 




4.3 Development, implementation and evaluation of a Psychotropic Use 
Monitoring (PUM) program to improve appropriateness of antipsychotic 
prescribing among NHRs with dementia 
 
4.3.1 Development of the PUM form and the Assessment for Psychotropic 
Prescriptions (APP) scale 
 A PUM form was first developed, to serve as a reference and hard-copy 
documentation of the observations made by the NS during PUM interventions.  The 
form contains 3 sections: (1) an Assessment for Psychotropic Prescriptions (APP) 
scale for the identification and documentation of recently observed changes in the 
different ‘type’ of BPSD, (2) a list of psychotropic agents frequently used for 
managing BPSD, and (3) a checklist for common SEs of the psychotropic agents 
frequently used in managing BPSD.  Figure 4.1(a) and 4.1(b) shows an example of 

























































































































































assessment  of BPSD  aids  in  identifying  target  symptoms  for management  /  pharmacological  treatment more 
readily. 
 
The PUM form was developed by a panel consisting of a senior consultant and 
professor of psychiatry, a pharmacotherapy expert and clinical pharmacist, a 
pharmacy practice research consultant and pharmacist, and the author, who reached 
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consensus after convening over four sessions of half-hour face-to-face meetings.  The 
draft of the PUM form was then shown to a psychiatrist, a geriatrician, and a nursing 
manager, who are familiar with the NH setting for their comments on the face and 
content validity of the PUM form.  A revised version was then piloted by two 
registered nurses at the inpatient psychiatric ward at a tertiary hospital.  All feedback 
and input provided were then considered and a final version of the PUM form was 
then derived by the panel through consensus after a final half-hour face-to-face 
conference.  The developments of these three sections in the PUM form are described 
as follows.  
  
4.3.1.1 APP scale 
The APP scale is a short and simple-to-use tool for objective assessment and 
documentation of BPSD according to its different “type/s”.  This scale is meant for 
routine use by the NS in the clinical setting of a NH, to help with better identification 
of target symptoms for pharmacological treatment.  The development of the APP 
scale was based in part on the Neuropsychiatric Inventory (NPI),254 which by far, was 
the most comprehensive255 and well-validated criteria, which had also been widely 
translated256 and employed in clinical trials for measuring BPSD.257  Although the 
original NPI was a reputable measure of BPSD in clinical trials, it would be 
challenging to operationalize its use in a clinical setting for the purpose of routine 
monitoring as it contained many screening questions (7-9 sub-questions under each 
main screening question for all 12 BPSD domains), which would tax the NS’s time 
significantly (20 minutes or more for each assessment).  Albeit slightly shorter 
versions of the NPI were available, the inter-rater reliability was not optimal;258, 259 
furthermore, the clinical relevance of their use in improving the management and 
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appropriate antipsychotic prescribing in BPSD among the elderly NHRs with 
dementia have not been clinically evaluated.   
 Hence, the consensus panel trimmed the 12 BPSD domains in the NPI to 10 
BPSD “types” for monitoring in PUM, that were deemed to (1) cause much 
disruptions to the nursing/caregiving process and (2) have relevance in influencing 
decisions on psychotropic use.  A comparison of the BPSD domains contained in both 












Appetite and  Eating Disorders  No issues  Included  Appetite Disorder 







Depression/Dysphoria  No issues  Included  Depression 
Elation/Euphoria  No issues  Included  Elation 
Disinhibition  No issues  Included  Disinhibition 
Delusions  No issues  Included  Delusion 








Specifically, “apathy/indifference” and “aberrant motor behavior” from the 
NPI were not included in the APP scale, as these were not main target symptoms for 
pharmacological treatment with antipsychotics, antidepressants, antiepileptics or 
benzodiazepines.  In addition, modifications to the “agitation/aggression” domain 
were made in the APP scale from the NPI.  Where symptoms of agitation and 
aggression were reported to be most disruptive to professional carers,229 and were the 
main reasons for the use of antipsychotics, they were also often vaguely 
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reported/documented as “restlessness” in NHRs’ medical prescribing notes, with little 
objectivity on the severity of the agitation symptom, presence of an eminent potential 
for the NHR to “hit out”, and the potential harm to the NHR or others around him/her, 
where the use of antipsychotics to abate the latter two may be warranted.  The use of a 
single “agitation/aggression” domain in the NPI may not differentiate between 
symptoms of agitation and aggression in a clinically relevant manner.  Hence, this 
domain was regrouped with “irritability/lability” to produce “agitation/irritability” and 
“aggression” in the APP scale.  As such, “agitation/irritability” symptoms were 
differentiated from “aggression” symptoms where the former describes increasing 
restlessness, and the latter describes increasingly threatening behaviors, with a 
potential to hurt.  The 10 BPSD “types” in the first draft of the APP scale were listed 
by an increasing order of difficulty in assessment.  The severity of each BPSD type 
was rated using a 5-point scale (“0” to “4”).  The descriptions of each severity scale, 
provided by the senior consultant and professor of psychiatry, were printed at the back 
of the PUM form to increase the objectivity and reliability of the symptom severity 
ratings. 
Feedback was made by the nursing manager to provide more space on the 
PUM form for the user to add comments for each BPSD “type” rated.  She also 
suggested improvements on the input to the severity rating scale by changing tick 
boxes to circled options in order to improve the visual and ease of documentation by 
the NS.  These suggestions were incorporated into the final version of the PUM form.  
In general, both the geriatrician and the psychiatrist agreed to the BPSD domains of 
the APP scale.  Specifically, the psychiatrist and the nursing manager concurred with 
the exclusion of the domain “apathy/indifference”, as NHRs who exhibited 
apathy/indifference usually appeared to be quiet and comfortable, hence active 
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pharmacological or non-pharmacological interventions were usually not required; 
whereas active interventions would be recommended however, for behaviors that may 
interfere with the rehabilitation plans for the NHRs.   
In addition to face and content validity, the APP scale was also evaluated for 
its concurrent validity with the NPI and clinical relevance of the BPSD “types” in the 
APP scale.  Inter-rater reliability of the APP scale between (1) pharmacist researcher 
and physician researcher and between (2) the staff nurse, nursing aide, and nursing 
attendant were also evaluated.   
 To evaluate the concurrent validity of the APP scale with the NPI, ratings of 
NHRs’ frequency and severity of BPSD obtained by the author using NPI were 
compared with the staff nurse’s ratings of the same NHRs using the APP scale; both 
of whom were trained on the use of APPs by the professor of psychiatry.  Each pair of 
rating was based on observations of the same nursing aide, who provided information 
on the NHR’s behavior changes in the 2-weeks prior to the assessment and perceived 
level of occupational disruptiveness to each NPI domains rated.  The interviews with 
the nursing aide for the NPI and APPs took place at scheduled meetings where all 
three were present, but were conducted independently by the author and the staff 
nurse respectively.  Spearman’s correlation test was then used to compare the 
individual ratings of each APP scale’s BPSD “types” with the corresponding domain 
scores of the NPI, whereas Pearson’s correlation test was used to compare the total 
rating score of the APP scale with the total score of the NPI.  Cohen’s Kappa test was 
used to evaluate the agreement in the prevalence of BPSD symptoms identified by the 
APP scale and the NPI.  Lastly, McNemar’s test was used to evaluate the differences 
in prevalence of each BPSD “types” identified using the APP scale with the 
prevalence of corresponding BPSD domains identified using the NPI.  Using this set 
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of data, the clinical relevance of the APP scale was also evaluated by comparing the 
occupational disruptiveness ratings with the NPI domain score and severity rating of 
the corresponding BPSD “types” of the APP scale using Spearman’s correlation test 
and Cohen’s Kappa test.    
In all, 18 pairs of ratings were made on 18 separate residents over five 
meetings (each lasting between 30 to 45 minutes).  This sample size was the 
minimum required to detect an acceptable kappa value of 0.6 against a null value of 
0.0 and a correlation coefficient of 0.6 at 80% power and α of 0.05.162, 260  The results 
of the correlation and agreement tests between the ratings and scores obtained from 






















0.50c,e 0.51e 0.53c,e  0.48c,e 
Appetite Disorder  Appetite and  Eating 
Disorders 
‐0.11c ‐0.09 ‐0.11c ‐0.11c 
Anxiety  Anxiety  0.98c,f 1.00f 0.98c,f  0.98c,f 
Agitation / Irritability  Irritability / Lability  0.69
c,e 0.57e 0.66c,e  0.72c,e 
Agitation / Aggression  0.74c,f 0.75e 0.68c,e  0.83c,f 
Aggression  Agitation / Aggression  0.70c,f 0.77e 0.65c,e  0.80c,f 
Depression  Depression / Dysphoria  1.00c,f 1.00f 1.00c,f  1.00c,f 
Elation  Elation / Euphoria  1.00c,f 1.00f 1.00c,f  1.00c,f 
Disinhibition  Disinhibition  ‐0.06c ‐0.06  ‐0.06c ‐0.06c 
Delusion  Delusions  1.00c,f 1.00f 1.00c,f 1.00c,f 
Hallucination  Hallucinations  0.73c,e 0.68e 0.71c,f  0.75c,f 
















The ratings of all individual domains in the APP scale strongly correlated with the 
scores (frequency, severity, and total) of the corresponding NPI domains (r > 0.7, p 
<0.05), except for “sleep disorder”, “appetite disorder”, and “disinhibition”.  Similar 
trends were also observed in the agreement of identified BPSD “types” between the 
use of APP scale and NPI.  In addition, the summated rating score for all BPSD 
“types” in the APP scale strongly correlated with the summated score for all domains 
in the NPI (r = 0.83, p <0.05).  The prevalence of having one or more BPSD “types” 
identified by the APP scale had moderately high agreement with that identified by 
NPI (Kappa = 0.60, p < 0.05).  The results of the McNemar’s test were summarized in 
Table 4.4; there were no statistically significant differences in the prevalence of each 
individual BPSD “types” identified using the APP scale from the use of NPI.   
These findings suggested that the exclusion of NPI domains 
“apathy/indifference” and “aberrant motor behavior” in the APP scale, and the re-
grouping of domains “agitation/aggression” and “irritability/lability” did not 
adversely impact the general measure of BPSD.  Furthermore, the target symptoms 
for antipsychotic use, which included the BPSD “types” “agitation/irritability”, 
“aggression”, “delusion” and “hallucination” in the APP scale, were observed to have 
good correlation and agreement with the corresponding domain measured using NPI, 
in terms of its total, frequency of occurrence, and severity scores.  Hence, the APP 




























Aggression  Agitation / Aggression 10 (55.6)  12 (66.7)
Depression  Depression / Dysphoria  2 (11.1)  2 (11.1)  0 
Elation  Elation / Euphoria  2 (11.1)  2 (11.1)  0 
Disinhibition  Disinhibition  1 (5.6)  1 (5.6)  0 
Delusion  Delusions  3 (16.7)  3 (16.7)  0 
Hallucination  Hallucinations  3 (16.7)  5 (16.7)  ‐2 (11.1) 
‐   Apathy / Indifference  ‐   2 (11.1)  ‐2 (11.1) 
‐   Aberrant Motor Behavior  ‐   4 (22.2)  ‐4 (22.2) 






a  The  difference  in  total  prevalence  of  “agitation/irritability”  and  “aggression”  in  APP  scale  (22  counts) was 
compared against the total prevalence of “irritability/lability” and “agitation/aggression” in NPI (20 counts). 
 
It was noted, however, that the correlation and agreement findings reported for 
the BPSD “types” “sleep disorder”, “appetite disorder” and “disinhibition” with their 
corresponding domains in the NPI may be limited by the small number of NHRs with 
mild and/or infrequent symptoms.  Although these domains were not deemed as target 
symptoms for treatment with antipsychotics, and hence were not likely to influence 
the outcomes in antipsychotic use trends during the prospective PUM implementation 
study, an assessment with larger number of NHRs should be carried out to further 
assess the concurrent validity of these BPSD “types” with their corresponding 
domains in the NPI.   
Of the 52 symptoms identified by NPI, occupational disruption was elicited 
for only 14 of them.  Specifically, occupational disruptions were reported for 
“agitation/aggression”, “anxiety”, “Irritability/lability”, “delusion”, “aberrant motor 
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behavior”, “hallucination”, and “sleep and nighttime behavior disorders” (Table 4.5).  
The agreement between the presence of occupational disruption and positive ratings 
for APP scale’s BPSD “types” “aggression” and “hallucinations” were observed to be 
much higher than that of the corresponding domain scores of NPI.  Furthermore, the 
agreement between the prevalence of occupational disruption and domain ratings for 
APP scale’s domain “agitation/irritability” was observed to be lesser than that of the 











































‐  0  0  ‐  ‐ 
Anxiety  Anxiety  2  0.49a  0.49a  0.69a  0.77b
Agitation / 
Irritability 
Irritability / Lability  2  0.40a  0.40a  0.53a  0.55a
Agitation / Aggressiona 6  0.12 0.27  0.69a  0.77b
Aggression  Agitation / Aggressiona 6  0.57a   0.27  0.61a   0.77b
Depression  Depression / Dysphoria  ‐  0  0  ‐  ‐ 
Elation  Elation / Euphoria  ‐  0  0  ‐  ‐ 
Disinhibition  Disinhibition  ‐  0  0  ‐  ‐ 
Delusion  Delusions  1  0.46a  0.46a  0.61a  0.61a
Hallucination  Hallucinations  1  0.46a  0.27  0.54a  0.47a
‐  Apathy / Indifference  ‐  ‐  0  ‐  ‐ 
‐  Aberrant Motor 
Behavior 





These suggested that use of the APP scale differentiated and identified 
symptoms of aggression from symptoms of agitation, where the former were more 
likely to elicit a perception of occupational disruption and/or treatment with 
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antipsychotics.  Compared to the NPI, the prevalence of “hallucination” identified 
using the APP scale was also more likely to be associated with a presence of 
occupational disruption, which may warrant pharmacological interventions with 
antipsychotics.  As such, the use of the APP scale in the clinical setting could result in 
better identification of target symptom for treatment with antipsychotics, and 
potentially improve the appropriateness of antipsychotic use, compared to using the 
NPI. 
Inter-rater reliability of the APP scale was evaluated between the pharmacist 
researcher (author) and a physician researcher involved in other aging- and dementia-
related studies.  For this purpose, independent ratings were made by both researchers 
on the same set of patients/NHRs with dementia at two clinical sites: (1) the 
outpatient clinic of a tertiary hospital and (2) the dementia ward of the participating 
NH, after permission was obtained from the hospital outpatient clinic and the 
management committee of the NH.  The independent ratings of each BPSD “types” in 
the APP scale from the two raters were compared using Cohen’s Kappa test.  The 
summated rating scores for all BPSD “types” between the raters were compared using 
Spearman’s correlation test.  In all, 76 pairs of rating using the APP scale were 
obtained over 13 hospital outpatient clinic sessions and two visits to the NH.  The 
Kappa statistics for all the BPSD “types” are greater than 0.7 (Table 4.6),   In addition, 
the summated rating for all domains between the raters are highly correlated (rs = 0.97, 























In addition, the inter-rater reliability of the APP scale was also evaluated for 
multiple raters who were NS at the NH.  They included one registered staff nurse, one 
nursing aide and one nursing attendant, all of whom were non-Singaporeans, and 
working at the dementia ward of the NH.  Among these three NS, only the staff nurse 
had formal healthcare training.  After adequate training on the use of the APP scale, 
three sets of independent ratings on 25 NHRs in the dementia ward were provided by 
the NS.  These ratings of each BPSD “types” were compared using the Fleiss Kappa 
(generalized kappa) test using a Microsoft Excel template which was developed to 
calculate a generalized kappa statistic for a maximum of six categories and five raters.  
The template was last downloaded in December 2011, from 
http://www.ccitonline.org/jking/homepage/interrater.html.  The summated ratings for 
all BPSD “types” were compared using the intraclass correlation test (two-way 
random model for evaluating absolute agreement) on the SPSS v.19.  The Kappa 
statistics obtained for all BPSD “types” in the APP scale are > 0.7 (Table 4.7).  A 
high intraclass correlation coefficient (ICC = 0.97, 95% C. I. = 0.94 to 0.98, p-value < 
0.001) was also obtained for the comparison of the summated rating scores for the 
APP scale provided between the registered staff nurse, nursing aide and healthcare 
attendant.  Hence, good inter-reliability of the APP scale has been achieved among 
the NS.  This implied that with adequate training, the APP scale can be reliably used 
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by the NS to provide objective observations and documentations on changes in the 
NHRs’ BPSD, despite having differing background in formal healthcare education 

















4.3.1.2 List of Psychotropics Frequently Prescribed for Managing BPSD 
 Although the focus of the study is to improve the PA of antipsychotics, 
multiple psychotropics with overlapping SEs may be prescribed simultaneously to 
target different BPSD “types”.  Therefore it was necessary to list other psychotropics 
commonly prescribed for BPSD in the PUM form, so that the users of the PUM form 
have comprehensive information to decide if the observations made resulted from the 
desirable or side effects of the treatment.  The list of psychotropic agents, identified 
from the background study reported in Chapter 2 for inclusion in the PUM form were 
“antipsychotics”, “antidepressants”, “antiepileptics”, and “benzodiazepines”.  In 
addition to the primary list, alprazolam was added by the consensus panel.  Further to 
this, both the geriatrician and psychiatrist suggested adding anticholinesterases such 
as memantine; however, the consensus panel deemed that these agents were primarily 
prescribed for treatment of dementia and not for the management of BPSD, and did 
not include this pharmacological group in the list.  The psychiatrist also suggested 
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increasing the maximum dose for haloperidol, risperidone, and fluvoxamine to 5, 2, 
and 150 mg respectively; however, the consensus panel disagreed on these doses as 
they were deemed to be beyond those that were suggested in clinical trials and clinical 
guidelines for managing BPSD.     
 
4.3.1.3 Checklist for psychotropic SEs 
 All the SEs of the common psychotropics used for managing BPSD were first 
compiled by the author from drug references, which included the Geriatric Dosage 
Handbook (14th edition), British National Formulary (61st edition), and DRUGDEX® 
System [Internet database].  The top 20 SEs that were prevalent among most of these 
psychotropics were then short-listed by the author for further discussion, with the aim 
of keeping the final checklist short and simple, so as to encourage its use by the NS.  
Hence, the SEs, deemed to have the most clinical relevance for inclusion in the 
primary draft of the PUM form, were blurred vision, weakness, dizziness, sedation, 
insomnia, tremor, parkinsonism, agitation, headache, dry mouth, dyspepsia, nausea, 
constipation, diarrhoea, urinary retention, and sweating.   
This primary draft was then modified using the feedback provided by the 
geriatrician to add documentation for AEs such as falls.  The geriatrician also 
suggested monitoring for postural hypotension, but further noted that such monitoring 
may not apply to the nursing aides and health care attendants.  Hence, although 
monitoring for postural hypotension was not included in the checklist, it was 
specifically taught to the NS during the PUM-related training (Section 4.3.2.1).  In 
addition, one of the hospital registered nurses who piloted the PUM form noted 
difficulty in assessing subjective SEs such as “dizziness”, “sedation”, “insomnia”, 
“headache”, “dyspepsia”, and “nausea”, as she did not speak the same language as the 
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patient.  Hence, the consensus panel removed the items “blurred vision”, “dizziness”, 
“headache”, “dry mouth”, and “dyspepsia” which relied on verbal assessment through 
interviewing NHRs, as these may be difficult to assess by the majority of the NS who 
do not speak the same language (Mandarin and/or Mandarin dialects) as the NHRs in 
the NHs.  Further to this, the items “weakness”, “sedation”, and “nausea” were 
rephrased as “tiredness”, “sleepy”, and “nausea/vomiting” respectively, in order to 
define the items as simply as possible.  Both nurses also commented that they faced 
some difficulty in terms of ascertaining an observed effect to be a medication-related 
SE; this was noted, and addressed during the PUM training provided for the NS 
(Section 4.3.2.1).  In addition, the consensus panel removed the item “sweating”, as 
the presence of this SE is unlikely to influence changes in the prescribing decisions 
and adverse patient outcomes.  The consensus panel also felt that the items “tremor” 
and “parkinsonism” did not fully represent the spectrum of possible extra-pyramidal 
SEs (EPSE), which are clinically significant with antipsychotic use.  Hence, instead of 
adding to the checklist, these items were removed to keep the checklist short.  
However, the topic on “assessment for EPSE” was specifically introduced to the NS 
during the training session (Section 4.3.2.1).       
 
4.3.1.4 Disruption to care rating scale 
 Initially, a 5-point scale to assess the NS’s general perception of BPSD’s 
occupational disruptiveness was included in the first draft of the PUM form.  
However, this was removed in the final version, as one of the two hospital registered 
nurses who piloted the form feedback that she had difficulty in responding, as (1) she 
did not know the definition of “disruption” and the purpose of rating it, and (2) she 
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did not know how her response will affect her superior’s assessment of her 
performance as a professional caregiver.   
 
4.3.2 Prospective implementation of PUM among NS 
Following ethics approval from the institutional review board of the university 
(where the author is a research student) to carry out the implementation and 
evaluation of the PUM program, consent was sought from the NS in the dementia 
ward of one NH to participate in the 24-week prospective pilot study.  This NH was 
randomly chosen from five VWO NHs, with one or more specialized dementia wards 
each and are under the purview of the Ministry of Health. 
 
4.3.2.1 Description of PUM-related training 
 PUM-related training of the NS was provided by the pharmacist (author), 
under the supervision of the professor of psychiatry.  All the participating NS 
underwent one main teaching and case discussion during the introductory session.  
This was followed by 2-week pilot for the NS to apply the knowledge gained through 
hands-on-practice before the formal implementation of PUM.  After implementing 
PUM, three review and further learning sessions were provided at Weeks 4, 8 and 12.  
A copy of the schedule, objectives and content outline of the training is provided in 
Appendix 4.1.   
During the introduction session, the NS was first introduced to the clinical 
significance of performing PUM.  Then, specific observational and assessment skills 
needed for the identification and differentiation of the BPSD “types” using the APP 
scale and SEs of psychotropic agents were taught and demonstrated.  Specifically, 
they were also taught to observe NHRs’ behavioral changes and note their onset with 
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relation to events that had occurred and  to the timing of medication regimen changes; 
where in general, (1) behavior changes that recur in a consistent pattern or with 
increasing frequency or intensity for at least a week were likely to be related to an 
onset/changes in BPSD, (2) those that had occurred within days to a few weeks from a 
recent change in medication regimens were likely to be medication SEs.  As 
mentioned in the earlier Section 4.3.1.3, the assessment, identification and 
management of drug-induced postural hypotension and EPSE were further elaborated 
in separate review sessions at week ‘8’ and ‘12’ respectively, in order to emphasize 
the clinical significance of these SEs on adverse consequences such as falls.  A copy 
of the handouts provided during the introduction and review sessions were inserted as 
Appendix 4.2 to 4.4. 
Case discussions (using actual NHRs as examples) were used to facilitate 
learning.  In addition, the introduction and review sessions were conducted in groups 
of about eight to 10 NS to encourage participation and enhance the learning 
experience.  During the 2-week pilot, the NS were randomly paired, and assigned to 
different NHRs each day to practice and apply the principles and observational skills 
acquired from the introduction session.  In order to accommodate for shift duty and 
NH activities, repeat sessions were provided within the scheduled study week as 
much as possible, for individuals who were unable to attend the sessions on the 
original scheduled dates and time.  Make-up sessions were also provided for those 
who had newly-joined the dementia ward during the period after PUM was 






4.3.2.2 Description of PUM intervention protocol 
PUM intervention was carried out by the NS at the dementia ward using the 
protocol shown in Figure 4.2 for a period of 24 weeks, where the NS applied the 
acquired observational skills in (1) monitoring to identify target symptoms for 
treatment with psychotropics, and (2) monitoring for therapeutic outcomes and (3) 


















 The use of the PUM form was triggered when changes in behavior (compared 
to how the NHR would normally behave) were observed to be recurring in a 
consistent pattern, or with increasing frequency or severity for at least a week.  Based 
on the APP scale, the observed behavior change/s was/were differentiated according 
to one or more BPSD “types” and their severity on the PUM form.  Such observation 
and documentation may be made by one or more of the NS who had firsthand 
observations about the changes or who were affected/implicated by the behavior 
changes.  The documented PUM forms were then filed, collated, summarized and 
reported by the staff nurse to the psychiatrist for further review and assessment, in 
order to better identify the target symptoms and the appropriate 
treatment/management strategy.   
 When a decision was made to initiate treatment with psychotropic agents or 
change the current regimen of the psychotropic agents used by the NHR, use of the 
PUM form was then triggered to monitor for (1) therapeutic outcomes in terms of 
changes in the types and severity of the original target symptoms identified and (2) 
onset of psychotropic SEs.  Specifically, monitoring for the latter was scheduled to 
take place daily for the first three days after the prescribed changes, followed by once 
weekly for two weeks, then once monthly.  For NHRs who were already using 
psychotropic agents with no change in their regimens, use of the PUM form was 
triggered according to the schedule described above, by taking reference from the last 
date of change in the NHRs’ psychotropic regimens. 
 In order to ensure compliance with the scheduled monitoring of psychotropic 
use outcomes, the pharmacist researcher (author) maintained a log, to chart the date of 
change in psychotropic regimen for each NHR and the pre-scheduled dates where the 
monitoring would take place.  The staff nurse then pre-assigned one NS from each 
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shift to carry out the monitoring for the particular NHR on the pre-scheduled dates.  
Input on the log was made after each psychiatrist’s review.  In addition, the 
pharmacist also indicated the SEs that were likely to be observed with regards to the 
psychotropic agent/s implicated.  Documentations on the PUM form were then filed, 
collated, summarized and reported by the staff nurse to the psychiatrist for timely 
review of the psychotropic use outcomes and optimization of the use of these 
medications.  In addition, the NS was also encouraged to use the PUM form whenever 
changes in behavior were observed.  Hence, the pharmacist plays the role as an 
educator and advocator for appropriate use of medications (antipsychotics).  The 
success of which, may be established by the impact of the PUM-related training on 
the NS, degree of engagement by the NS in positive behavioral change, and in the 
outcomes of PUM on antipsychotic use trends and NHR outcomes. 
 
4.3.2.3 Evaluation of PUM 
The impact of PUM and the PUM-related training on the NS were evaluated 
using a structured face-to-face survey at the end of the 24-week intervention period.  
This survey method was chosen as almost all of the nursing staff working in the 
dementia ward was from Myanmar and the Philippines with difficulty communicating 
in written English; face-to-face surveys allowed for validation of the NS’s 
understanding of the survey questions, provision of further explanation, and 
verification of responses when necessary.  Thus, validation of their understanding was 
done by direct probing if the respondent took an unusually long time to respond, or if 
he/she appeared uncertain.  Verification of their responses was done by paraphrasing, 
reflecting of feelings, summarizing long verbal accounts of his/her experiences, and 
direct probing using positive and negative synonyms of neutral key terms provided by 
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the respondent.  As such, the face-to-face method ensured a good response rate and 
reliable responses compared to other methods such as a paper-and-pen administered 
survey.  The survey questions, as shown in Appendix 4.5, aimed to elicit responses on 
the perceived changes in behavior, knowledge, attitudes, ability (application of 
knowledge gained), and feelings of stressfulness of the NS, and the possible reasons 
related to these changes.  The quantitative responses were given on a 5-point scale, 
where options ranged from “0” to “4” of increasing intensity.  A rating above “2” was 
considered strong.  All qualitative responses by the respondents were also noted.  The 
survey questions were also piloted by five NS from the non-dementia wards before 
their use to ensure that the questions were well defined and clearly understood.  In 
order to minimize response bias, namely, respondents giving input based on their 
perception of (1) the investigator’s expectations or (2) the effect on the assessment of 
their work performance, the surveys were conducted individually with each NS at the 
end of the intervention period in a private area of the NH, at a time that was 
convenient for the respondents.  The anonymity of the respondents was also assured.   
In addition, feedback on the prescriber’s perception of PUM’s impact was also 
obtained from the regular psychiatrist who visits the home every fortnightly.  For this 
purpose, a semi-structured face-to-face interview was conducted with the psychiatrist 
at the end of the 24-week intervention period, using the set of questions shown in 
Appendix 4.6.  The psychiatrist’s responses have been reported descriptively. 
 The impact of the intervention on antipsychotic use trends and NHR outcomes, 
which included the overall measures of BPSD and the occurrence of AEs, were 
evaluated using a before-and-after study design, where these outcome measures over 
24-week periods before and after formal implementation of PUM were compared.  In 
addition, the before-and-after changes in the prevalence of other psychotropics used in 
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managing BPSD, including antidepressants, antiepileptics and benzodiazepines, were 
determined as secondary outcomes.  Data collection of these outcome measures was 
conducted retrospectively, and included those of NHRs who were already diagnosed 
with dementia by a physician and were present in the dementia ward during both the 
24-week periods before and after PUM implementation.  The data of NHRs who were 
deceased or transferred out of the dementia ward during the 24-week period before 
PUM implementation was excluded.  Those of newly admitted NHRs during the 24-
week period after PUM implementation were omitted. Specifically, the prevalence of 
antipsychotics and other psychotropics used to manage BPSD were determined from 
the medication notes.  The details pertaining to antipsychotic use were obtained from 
the medical and medication records.  These included the prevalence of use, duration 
of use, prescribed dose, type of prescribing decisions made, and physician-
documented reasons underlying the prescribing decisions.  The RAF subscale rating 
for psychiatric problems and behavioral problems among the NHRs at the start of the 
24-week period before PUM implementation, at PUM implementation, and at the end 
of the 24-week period after PUM implementation were collected from the NH 
administrator’s file, to be used as the overall measure to determine the overall changes 
in BPSD.  Incidents and the details of all AEs that had occurred among the NHRs 
were obtained from discharge summaries of unplanned hospitalizations and visits to 
the ED, and nursing incident reports to the administrator’s office.  The NHRs’ 
demographic, clinical and medication factors at the time of PUM implementation 
were obtained from the summary in the medical notes.   
The duration of antipsychotic use for each NHR was converted to a ratio (the 
number of days with antipsychotics ÷ number of days residing in the ward during the 
study period), and reported as “resident-days”.  All antipsychotic doses were 
144 
 
converted to chlorpromazine equivalent doses for standardized reporting and 
comparison of doses.  Conversions of the doses for depot injections were according to 
the recommendations of Kane et al.261  The conversions for oral antipsychotic were 
obtained from Woods,262 and that for sulpiride was derived from the BNF (61st 
Edition, 2011).  The average daily chlorpromazine equivalent dose of antipsychotics 
used per NHR in each study period is computed using the equation (total dose taken 
during the study period ÷ total number of days during the study period taking the 
medication).  The mean average daily chlorpromazine equivalent dose of 
antipsychotic used in each study period before and after PUM implementation was 
based on the total number of NHRs who were prescribed with one or more 
antipsychotics during the study period.  All prescribing decisions made on 
antipsychotics were categorized by four dose adjustment types, which included “start 
new”, “increase dose”, “decrease dose”, and “discontinue”.  The prescribing decisions 
on antipsychotics were also grouped and evaluated according to their underlying 
reasons, which included antipsychotic dose adjustments which were “BPSD-related”, 
“SE-related” and with “no documented reason”.  The changes in RAF subscales for 
psychiatric problems and behavioral problems over each 24-week period before and 
after PUM implementation were calculated using (scores at PUM implementation – 
scores at start of 24-week period before PUM implementation) and (scores at end of 
24-week period after PUM implementation – scores at PUM implementation) 
respectively.  All AEs of unplanned hospitalizations and ED visits were categorized 
by the documented reasons for referral to a tertiary care institution, and the diagnoses 
of the referrals.  The AEs obtained from incident reports archived in the nursing 
administrator’s office were categorized by the nature of the incidents and their 
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underlying causes (if stated in the report).  Only the AEs related to falls, and injuries 
related to medication use and/or BPSD were evaluated and discussed.   
No sample size calculation was required for this pilot study; however, the 
sample size of at least 20 to 25 was recommended for an efficacy pilot study such as 
this.263  Evaluation of the survey responses was done using Wilcoxon signed rank test, 
binomial test (using test proportion of 0.5) and Spearman’s correlation test w.  
Statistical analyses on all the medication use and resident outcome measures were 
performed using McNemar tests, Wilcoxon signed rank test and Spearman’s 
correlation test.   
 
4.3.3 Outcomes of PUM implementation 
 
4.3.3.1 Impact on NS 
 All 25 NS in the dementia ward during the 24-week intervention period 
provided consent to participate in PUM.  Among them, six NS were transferred to the 
non-dementia wards mid-way through the intervention period (due to the pre-
scheduled internal rotation of staff at the NH), two resigned and one did not 
participate in the training sessions, citing personal reasons.  Thus, only 16 staff 
received the full training and participated in the survey.   
Of these 16 NS, two were staff nurses, one enrolled nurse, six nursing aides 
and seven healthcare attendants.  All of them were foreigners from Myanmar (n = 10) 
and the Philippines (n = 6).  Their years’ of experience in a NH setting and dementia 
ward setting were summarized in Table 4.8.  Among them were four who joined the 
dementia ward half-way through the intervention period; although they did not have 
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prior experience working in a dementia ward setting or managing BPSD, they 















3  5, 13  8.5 (4.3)  8  5a 0, 1  0.4 (0.3)  0.3  0 
Nursing aide  6  2, 8  4.3 (2.4)  4  4  0, 2  1.3 (0.8)  1.5  2 
Healthcare 
attendant 




A summary of the survey results in terms of the perceived changes in behavior, 
knowledge, attitudes, ability and perceived stress were shown in Table 4.9.  Firstly, 
majority of NS reported positive behavior changes after PUM implementation, 
specifically, the frequency of monitoring for psychotropic SEs increased (binomial 
test, p-value = 0.004), suggesting that the NS were motivated and engaged to carry 
out PUM.  However, six (36%) of them did not perceive a change in the frequency in 
managing BPSD.  Thus, the reports of increased frequency in managing BPSD may 
be reflective of an increased prevalence or severity of BPSD among some NHRs 
during the period of intervention and the increase in exposure to BPSD experienced 
by the new NS who had recently joined the dementia ward.  The distribution of 





































1.3 (0.9)  2.4 (0.8)  1.1 (1.1)  84.6  0.004  10  0.454 
2  frequency in 
monitoring SE 
1.3 (1.2)  2.7 (0.9)  1.4 (0.9)  107.7  0.001  14  0.004 
Changes in Knowledge  
5  on BPSD  1.2 (0.8)  2.5 (1.0)  1.3 (0.9)  108.3  0.002  12  0.077 








1.5 (0.8)  3.3 (0.7)  1.8 (1.0)  120  0.001  14  0.004 
Changes in Ability (in applying knowledge)  
3  manage BPSD well  1.4 (0.7)  2.5 (0.8)  1.1 (0.6)  78.6  0.001  14  0.004 
10  differentiate BPSD 
types & severity 
1.0 (0.8)  2.8 (0.8)  1.8 (1.0)  180  0.001  15  0.001 



















The NS reported a significant increase in knowledge on BPSD after PUM 
implementation (Wilcoxon signed rank test, p-value < 0.05).  The distributions of the 
responses to survey Questions 5 and 13 were reflected in Figures 4.5 and 4.6 
respectively.  By comparison, more NS reported an increase in their knowledge on 
psychotropic SEs.  The mean difference in rating reported for the perceived difference 
in knowledge on psychotropic SEs after implementing PUM was also greater 
compared to that for BPSD.  Further to this, almost all NS attributed the increase in 
knowledge to the PUM-related training received (refer to Table 4.10).  Hence, it 








































6  PUM‐related training  on  BPSD  3.3 (0.7)  16  14  0.004 
17  PUM‐related training  on  SE  3.4 (0.7)  16  14  0.004 
Changes in Attitudes  
18  Increase knowledge on SE  on  awareness to monitor SE  3.2 (0.5)  16  15  0.001 
20  Increase knowledge on SE  on  confidence in correctly 
identifying SE  
3.0 (0.7)  16  14  0.004 




on  manage BPSD well  3.3 (0.7)  16  14  0.004 
11  documenting  BPSD 
changes on PUM form 
on  manage BPSD well  3.0 (0.8)  16  14  0.004 











With regards to change of attitudes, almost all the NS reported being more 
aware about monitoring for psychotropic SEs after implementing PUM (Table 4.9).  
The distribution of the responses to survey Question 14 is shown in Figure 4.7.  It was 
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also noteworthy that this change in awareness had the largest positive difference in 
rating after PUM implementation (200% difference).  Furthermore, majority of the 
NS attributed much of this to an increase in knowledge on psychotropic SEs, and the 
presence of a pharmacist-maintained schedule as a reminder to monitor for SEs (Table 
4.10).  In addition, an increase in confidence in identifying psychotropic SEs correctly 
during the PUM intervention period is reported (Table 4.9).  This was perceived to 
have been influenced strongly by the knowledge of psychotropic SEs gained from the 
PUM-related training (Table 4.10).  The distribution of the responses to survey 







Figure 4.8   Distribution of  the  responses  to Question 16 of  the NS  survey on  their perceived  confidence  in 
correctly identifying psychotropic SEs (n = 16) 
 
Further to this, the other changes in attitudes (towards managing BPSD) 
elicited among the NS in their qualitative responses to survey Questions 9, 12 and 23 
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are summarized in Table 4.11.  They include: being more discerning about residents’ 
behaviors, feeling more capable and more confident in managing BPSD, being more 
motivated in managing BPSD by taking more initiative and ownership, being more 
attentive to the NHRs’ needs, being more accepting of the NHRs’ behaviors, and 
showing more patience, gentleness, kindness, empathy and sympathy towards the 
NHRs.  Therefore, it seemed that through the increase in knowledge, the PUM-related 
training had successfully induced positive attitude changes among the NS towards 
managing BPSD.  These positive attitudes could have influenced the desired behavior 
changes reported, and possibly play a role in reducing the stress of the NS when 
managing the NHRs with BPSD.  The use of the APP scale also resulted in a more 
discerning attitude among the NS in observing and reporting NHRs’ behavior such 
that the identification of target symptoms for treatment was more discriminative and 






























































































































After implementing PUM, the NS reported increased abilities in managing 
BPSD, differentiating BPSD types and severity, and recognizing psychotropic SEs 
(Table 4.9); these were perceived to be related to the gain in knowledge from PUM-
related training (Table 4.10).  The distributions of the responses are summarized in 
Figures 4.9 to 4.11.  The perceived increase in ability to manage BPSD was also 
postulated to be indirectly related to the positive changes in attitude.  In addition, a 
handful of the NS also reported that the use of the APP scale helped them to manage 
BPSD better, possibly by enabling the NS to differentiate BPSD types and severity 
















Despite the unanimous response of the NS towards positive changes in 
knowledge, attitude, ability, and behavior related to PUM and PUM-related training, 
there were mixed responses among the 16 NS regarding changes in perceived stress 
before and after implementing PUM (Table 4.9 and Figure 4.12).  While seven of 
them reported feeling less stressful in managing BPSD, three reported no change in 
stress level, and six reported feeling more stressful.  It was observed that majority of 
the NS perceived a reduction in stress level with an increase in knowledge on BPSD 
(Table 4.10), whereas those who reported no change had a low level of stress (“a little 
bit”) at baseline.  Interestingly, among the six who reported feeling more stressful 
after PUM implementation, all of them cited “having an increased sense of 
responsibility towards the NHRs in terms of monitoring as they become more aware 
of the SEs of psychotropics and the amounted fall risk as the reason for the increase in 
stress level.  Hence, both the decrease and increase in stress levels were deemed as 








Lastly, it was noteworthy that all NS responded that they would strongly 
recommend PUM and PUM-related training to other nurses who manage BPSD at a 
NH setting (mean rating = 3.7 ± 0.48; Binomial test, p < 0.001).  When compared 
with the changes in behavior, knowledge, attitude, ability, and stress perceived by NS, 
only the change in stress level was found to correlate significantly with the strength of 
recommending PUM and PUM-related training.  Specifically, decreasing levels of 
stress was strongly correlated with increasing strengths of recommendation (rs = -0.79, 
p < 0.001).   
 
4.3.3.2 Feedback from the psychiatrist 
 The visiting psychiatrist (who was not aware of the details of the intervention 
and outcome measures) did not notice significant changes in the general level of 
disruptions/stress in caregiving reported by the NS, his assessment of psychotropic 
SEs among the NHRs, or the need to use psychotropics among the NHRs.  With 
regards to the NS’s feedback on changes in BPSD and psychotropic SEs, the 
psychiatrist specifically noted the frequency of reporting psychotropic SEs during his 
visits to have “increased moderately” after PUM implementation.  He also observed 
that the frequency of correctly identifying SEs by the NS “increased a little bit”.   
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 With regards to factors that could have influenced his decision to prescribe 
psychotropic agents, the psychiatrist reported that it was not likely to be influenced by 
NS-reported changes in the level of disruptions/stress, but was based on the reporting 
of individual NHRs’ needs by the NS, and that the prescribed psychotropics for 
management of BPSD was likely to be maintained for several months before attempts 
to taper off.  However, he added that reported SEs related to the use of antipsychotics 
and benzodiazepines would, however, prompt him to reduce the medication dose or 
switch to another agent within the same therapeutic class.   
 
4.3.3.3 Impact on antipsychotic use trends 
During the 24-week intervention period after PUM implementation, of the 55 
NHRs at the dementia ward, four were excluded from the analysis as they were newly 
admitted, and data was collected from the rest of the NHRs.  The demographics of 




Factors  N (%)  Mean ± SD  Median (Range) 
Age (years)   ‐   79.8 ± 9.5  79.5 (60.4 to 98.2) 
Gender       
    Male  28 (54.9)  ‐  ‐ 
    Female  23 (45.1)  ‐  ‐ 
Race       
    Chinese  38 (74.5)  ‐  ‐ 
    Non‐Chinese  13 (25.5)  ‐  ‐ 
Duration of Stay (days)       
  [before PUM implementation]  ‐  163.0 ± 21.9  168 (3 to 168) 
  [after PUM implementation]  ‐  150.8 ± 42.0  168 (49 to 168) 
Total Number of Medication  ‐  8.7 ± 4.8  8 (1 to 20) 
Polypharmacy a       
    No   20 (39.2)  ‐  ‐ 
    Yes  31 (60.8)  ‐  ‐ 
RAF       
    Category 1 & 2  0  ‐  ‐ 
    Category 3  16 (31.4)  ‐  ‐ 
    Category 4  35 (68.6)  ‐  ‐ 
Mobility Status (RAF Sub‐scale)       
    Independent  10 (19.6)  ‐  ‐ 
    Requires some assistance  25 (49.0)  ‐  ‐ 
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    Requires total assistance  12 (23.5)  ‐  ‐ 
Feeding Status (RAF Sub‐scale)       
    Independent  28 (54.9)  ‐  ‐ 
    Requires some assistance  12 (23.5)  ‐  ‐ 
    Requires total assistance  6 (11.8)  ‐  ‐ 
    Tube‐feeding  5 (9.8)  ‐  ‐ 
Toileting (RAF Sub‐scale)       
    Independent  6 (11.8)  ‐  ‐ 
    Requires some physical assistance  5 (9.8)  ‐  ‐ 
    Requires commodes/bed pans/urinals  9 (17.6)  ‐  ‐ 
    Incontinent and totally dependent  31 (60.8)  ‐  ‐ 
Psychiatric Problems (RAF Sub‐scale) b      
    Nil  5 (9.8)  ‐  ‐ 
    Mild interference in life  21 (41.2)  ‐  ‐ 
    Moderate interference in life  22 (43.1)  ‐  ‐ 
    Severe interference in life  3 (5.9)  ‐  ‐ 
Behavioral Problems (RAF Sub‐scale) c      
    Nil  4 (7.8)  ‐  ‐ 
    Occasionally: 1‐3 x a week  14 (27.5)  ‐  ‐ 
    Often: 4‐6 x a week  23 (45.1)  ‐  ‐ 
    Always: daily  10 (19.6)  ‐  ‐ 
Diagnosed Schizophrenia       
    No   49 (96.1)  ‐  ‐ 
    Yes  2 (3.9)  ‐  ‐ 
Physician‐diagnosed Dementia Subtypes       
    Alzheimer’s   15 (29..4)  ‐  ‐ 
    Vascular  19 (37.2)  ‐  ‐ 
    Others/Mixed  1 (2.0)  ‐  ‐ 






Ten (19.6%) NHRs were admitted to the dementia ward during the 24-week 
period before PUM implementation, three (5.9%) were transferred to other wards 
during the 24-week period after PUM implementation, and the remaining 38 (74.5%) 
NHRs resided in the dementia ward for both periods before and after PUM 
implementation.  The proportions of male and female NHRs in the ward were almost 
equal, 74.5% were Chinese, and mean age was 79.8 (± 9.5) years’ old.   
When PUM was implemented, the mean total number of medications used was 
8.7 (± 4.8), and polypharmacy was present in more than half of the NHRs.  Although 
the majority of these NHRs were relatively independent in mobility and feeding 
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(68.6% and 78.4% of NHRs were under the categories “independent” and “requires 
some assistance” of the RAF sub-scales for mobility and feeding respectively), most 
of them needed much assistance for toileting (78.4% with categories “requires 
commodes/bed pans/urinals” and “incontinent and totally dependent” of the RAF sub-
scale for toileting).  Psychiatric problems (assessed by the RAF sub-scale) which 
include hallucination, delusions, anxiety, and depression were observed in 46 (90.2%) 
NHRs, and behavioral problems (assessed by the RAF sub-scale) which include 
restlessness, disruptiveness, uncooperativeness, and abscondment were reported in 47 
(92.2%) NHRs.  Only two NHRs had a previous diagnosis of schizophrenia.  
Physician’s documentation of “dementia” were recorded in the summary pages of the 
medical notes of all NHRs included in this analysis, while close to a third of their 
diagnosis were not further specified according to the subtypes. 
 The changes in the prevalence of antipsychotics, antidepressants, 
antiepileptics and benzodiazepines used among 51 NHRs during the 24-week periods 
before and after PUM implementation are shown in Figure 4.13.  Prior to PUM 
implementation, antipsychotic (45%) and antidepressants (47%) were the most 
commonly used psychotropic.  This was followed by antiepileptics (22%) and 
benzodiazepines (22%).  After PUM implementation, the prevalence of antipsychotic 
(53%) use among the 51 NHRs remained high.  However, the prevalence of the use of 
antidepressants (41%) and benzodiazepines (18%) was lower.  These before-and-after 








Of the 23 NHRs who took antipsychotics before PUM was implemented, 20 
continued to do so after PUM.  The number of NHRs who were started on 
antipsychotics during both study periods (seven versus eight) was about the same 
(Figure 4.14).  Of the 30 NHRs who took antipsychotics during the 48-week period, 
13 (25%) used antipsychotics throughout the entire duration.  Twenty-one (41%) of 
the 51 NHRs did not use antipsychotics during the 48-week period.  Although the 
mean duration of antipsychotic use by these 51 NHRs after PUM implementation was 
higher (0.48 ± 0.48 versus 0.39 ± 0.47 resident-days), it was not statistically 







New users were NHRs who were  started with antipsychotics during  the  study period.   Continuous users were 
those who were already using antipsychotics prior to the study period. 
 
The mean absolute number of days of antipsychotic use before and after PUM 
implementation was 127.6 ± 55.3 among 23 NHRs and 150.81 ± 34.4 among 27 
NHRs respectively.  After adjusting for their duration of residence in the ward during 
each study period, the mean duration of antipsychotic use was similar (0.86 ± 0.27 
before PUM implementation versus 0.90 ± 0.20 resident-days after PUM 
implementation).  Among the 23 NHRs who were using antipsychotics, eight NHRs 
remained unchanged, seven used lower average daily doses (mean difference = -38.5 
± 31.8 mg/day), and eight used higher average daily doses (mean difference = 37.0 ± 
40.0 mg/day) after PUM was implemented.  Overall, the mean average daily 
chlorpromazine equivalent dose of antipsychotics used by NHRs prescribed with 
antipsychotics was slightly lower after PUM implementation (67.26 ± 51.84 mg/day 
versus 70.2 ± 63.2 mg/day), but the median average daily dose before PUM 
implementation was slightly lower (48.5, ranging from 16.7 to 249.9 mg/day versus 




 The total number of dose adjustments made by the psychiatrist on 
antipsychotics was higher after PUM implementation (47 versus 34), while the 
average number of dose adjustments per NHR (for those who were using 
antipsychotics in each study period) was higher after PUM implementation (1.74 
versus 1.48).  Hence, it appeared that the PUM intervention could have resulted in an 
increase in dose adjustments of antipsychotics.  Specifically, this higher number of 
dose adjustments made after PUM implementation was contributed by the higher 
number of adjustments to “increase dose” (increased by 2.7 times), and the higher 
number of adjustments to “start new” antipsychotics (increased by 36%).  This was 
evident from the illustration in Figure 4.15 and the positive correlation results from 
Spearman’s correlation test reported in Table 4.13.  The lower mean average daily 
antipsychotic dose used after PUM implementation could be attributed to smaller, 
more frequent, and probably more cautious dose increments of antipsychotics.  It was 
interesting to note, however, that the total number of the adjustment to “decrease 
dose” after PUM implementation was similar to that before PUM implementation, but 
the total number of dose adjustments to “discontinue” antipsychotics was much lower 
after PUM implementation.  These four types of dose adjustment were further 















by Types      Start New  0.647  <0.001 
      Increase Dose  0.560  <0.001 
      Decrease Dose  0.342  0.014 
      Discontinue  0.340  0.015 
by Reasonsa      No reasons documented  0.224  0.114 
      BPSD‐related  0.664  <0.001 





The prevalence of all dose adjustments categorized by reasons for adjustment 
as “BPSD-related”, “SE-related” or with “no documented reason” as summarized in 
Figures 4.16 and 4.17 showed that after PUM was implemented, the absolute number 
of dose adjustments with no documented reasons was reduced by almost 50%, and six 
of the 12 dose adjustments to “discontinue” antipsychotics before PUM 
implementation were made with no documented reasons.  Hence, prescribing 
decisions after PUM implementation were relatively more definite, clear and 








The number of dose adjustments made due to reasons that were “BPSD-
related” and “SE-related” increased by 24% and four times respectively after 
compared to before implementation of PUM.  These were also observed to be 
positively correlated to the before-and-after difference in the total number of all dose 
adjustments (“BPSD-related” rs = 0.66, p < 0.001; “SE-related” rs = 0.60, p < 0.001).  
Therefore, PUM apparently led to more frequent reporting of BPSD changes, 
therapeutic responses to antipsychotics and antipsychotic SEs by the NS, attributed to 
more dose adjustments of these pharmacological agents.  This observation matched 
the feedback by the visiting psychiatrist that more SEs were reported by the NS after 































































Among the “SE-related” adjustments observed after PUM implementation 
(Figure 4.17), the decisions to “discontinue” and “start new” antipsychotics occurred 
simultaneously among five NHRs.  These were due to the switching of antipsychotic 
agents (risperidone, haloperidol and chlorpromazine) to quetiapine, which has less 
propensity to cause SEs – EPSE and tardive dyskinesia.  In addition, three of these 
switches were preceded by dose decreases of the previous antipsychotics.  The 
documented SEs that led to the prescribing decisions in both study periods are shown 



















By contrast, the reporting of SEs before PUM implementation was less 
frequent, and appeared to occur only after AEs had occurred.  After PUM, NS were 
encouraged to report more SEs, which in turn, improved PA, through timely 
adjustments of antipsychotics to prevent possible AEs such as falls, and permanent 
deconditioning of physical functions. 
Before PUM implementation, the “BPSD-related” reasons that led to dose 
adjustments to “decrease dose” and “discontinue” antipsychotics included those that 
were documented as “no BPSD”, “behavior better”, and “no more agitation”.  These 
BPSD-related dose adjustments were not documented after PUM.  The documented 
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“BPSD-related” reasons that led to dose adjustments of “start new” and “increase 




















The “BPSD-related” documentations that led to these dose adjustments before 
PUM implementation were considered vague as they were not clearly linked to 
agitation, aggression and psychosis that required the use of antipsychotics; these 
symptoms and incidents could be related to confusion secondary to dementia and 
symptoms of elation, which would not warrant the use of antipsychotics.  By 
comparison, the documented reasons for dose adjustments to “start new” and 
“increase dose” of antipsychotics after PUM implementation were clearly indicative 
of severe agitation, aggression and/or psychosis and the maintenance of antipsychotic 
use to reduce these symptoms.  Hence, the NS used PUM to provide specific feedback 
to the physicians, with clear identification of target symptoms, proper documentation 
and improved appropriateness of prescribing yielding discriminative use of 
antipsychotics to manage BPSD. 
 
4.3.3.4 Impact on NHR outcomes 
 The mean RAF subscale rating for “psychiatric problems” and “behavioral 
problems” at the start of the 24-week period before PUM implementation, at PUM 
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implementation and at the end of the 24-week period after PUM implementation are 











The mean before-and-after PUM changes of these ratings are summarized in 
Table 4.16.  Overall, the rating for “psychiatric problems” was reduced after 
compared to before PUM implementation (mean difference = -0.06 ± 0.10; Wilcoxon 

























Psychiatric Problems  ‐0.04 (1.96)  ‐0.10 (0.61)  ‐0.06 (0.10)  10  6 













The increase in the number of newly initiated antipsychotics after PUM 
implementation was significantly correlated to the decrease in rating for “psychiatric 
problems” (rs = -0.308, p = 0.028, Table 4.17).  The overall rating for behavioral 
problems did not appear to show any downward trends (Figure 4.18).  The changes in 
the rating of behavioral symptoms also did not correlate with the changes in 
psychiatric symptoms (rs = 0.067, p = 0.642).  Possible reasons for this could be (1) 
the increased awareness and ability of the NS to identify and report the BPSD “types” 
and (2) the intermittent nature of BPSD.  Hence, although PUM did not appear to 
have positive effects on reducing “behavioral problems” of the NHRs, it could have 
contributed to improvement of BPSD in terms of reducing “psychiatric problems”, 
through more targeted and appropriate prescribing of antipsychotics. 












































In addition to positive changes in NHRs’ BPSD, the total number AEs 
reported by the NS to the NH administrator’s office was reduced by half after PUM 
implementation, compared to before.  Specifically, among the 16 AEs reported before 
PUM implementation, 15 were incidents of falls, and one was an incident linked to a 
badly managed BPSD (irritability and accusatory behavior) of one NHR; documented 
details of the latter described a quarrel that broke out between two NHRs which had 
quickly escalated to physical aggression.  After PUM implementation, only eight AEs 
were reported; seven were related to falls and one was related to agitation and 
resistance to care leading to mild injury (superficial skin abrasion).  These incidents 
occurred among 12 and seven NHRs before and after PUM respectively and the same 
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two NHRs suffered AEs during both study periods.  No statistical significance was 
obtained, however, on the McNemar test or the Wilcoxon signed rank test.  
 Lastly, PUM impacted NHRs’ outcomes with regards to unplanned 
hospitalizations and ED visits.  During the period before PUM implementation, 10 
unplanned hospitalizations and ED visits were documented; of these, three were 
related to falls and one was related to  
adverse outcome from antipsychotic use.  After PUM implementation, 13 unplanned 
hospitalizations and ED visits were identified; of these, two were related to falls and 
one was related to antipsychotic use, as summarized in Table 4.18.  The incidents of 
AEs that were excluded from the comparison and discussion had medical-related 
diagnoses, such as “dysphagia”, “subacute intestinal obstruction”, “pneumonia”, 
“constipation (with spurious diarrhoea)”, “deep vein thrombosis of left lower limbs”, 
“vomiting”, “delirium due to sepsis”, “pneumonitis secondary to poor swallowing 
(from cardiovascular accident – acute on chronic subdural hematoma)”, 
“bronchiolitis”, “pyrexia of unknown origin”, “acute cholecystitis”, “acute on chronic 
cholecystitis with multiple gallstones”, “upper urinary tract infection”, “lower urinary 


















































































4.3.4 Discussion of PUM program outcomes 
The PUM had been developed, implemented and evaluated with several 
limitations.  Secondary to the limitation in sample NHRs and BPSD cases, testing of 
the concurrent validity with the NPI was affected, specifically for BPSD “types” such 
as “sleep disorders”, “appetite disorders” and “disinhibition”.  However, this was 
unlikely to affect the outcomes of the implementation and evaluation of the PUM 
program as the occurrence of these BPSD “types” were not common in the NH during 
the study period, and may not lead to the use of antipsychotics; the concurrent validity 
of these domains with that in the NPI can be further evaluated using a larger sample 
size from other NHs. 
Although a cluster randomized controlled trial may be a better study design to 
evaluate the impact of PUM and PUM-related training, it was not feasible due to a 
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lack of time and manpower to run the study at multiple sites.  Furthermore, since this 
is the first time PUM was developed and studied, a pilot study using a simple before-
and-after design was chosen to evaluate the potential impact of PUM.  Based on this 
pilot study, future evaluations on the external validity of PUM applied to NHRs of 
other NHs using cluster randomized controlled study can be designed and carried out.   
In this pilot study, the outcome measures were comprehensive and included 
most of those recommended for evaluating interventions that aim to improve drug 
prescribing and utilization in the NH setting.51  However, these results may be limited 
by the reliability of documentation at the NHs in terms of mis-placed/missing reports, 
mis-entries, and under-reporting.  Hence, limitations of mis-placed/missing reports 
were minimized by conducting data collection every eight weeks after the 
implementation of PUM.  In addition, limitations due to mis-entries and under 
reporting were minimized by retrieving data from original data sources, which 
included medication charts, physician’s handwritten entries in the NHRs’ files, 
hospital discharge summaries, and reports that were submitted and archived in the 
administrator’s office.  The use of descriptive data collection methods also allowed 
for more complete reporting and analysis of the outcomes.  Further to these, potential 
mis-transcribing of the data was minimized by engaging a research assistant to double 
check the data entry from the hard-copy data collection forms. 
 Lastly, during the course of the study, a high turnover of NS was seen in the 
dementia ward, which may have a negative impact on the outcomes of the study and 
threaten internal validity of the study results.264  However, this was anticipated and 
minimized by providing reviews, repeated and make-up sessions for the PUM-related 
training.  Responses and feedback from the participants were also obtained and 
analyzed to ensure the internal validity of the PUM-related training and intervention 
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with regards to the outcomes measured.264  Although the use of a face-to-face survey 
to collect responses and feedback from the NS could have led to response biases as 
mentioned earlier in Section 4.3.2.3, this was minimized by conducting the feedback 
after the implementation period, assuring the respondent of his/her anonymity and 
privacy, and allowing the respondent to give his/her feedback at a comfortable pace 
and setting (such as narrating their actual experience if they had difficulty expressing 
their feelings and attitudes in written format).  In addition, the rapport and 
understanding forged between the interviewer and the respondents during the 
intervention period allowed both the negative and positive responses to be given with 
less inhibition.  This was evident from the results where no post-intervention change 
in knowledge gained and no post-intervention decrease stress levels among two and 
six respondents respectively. 
Despite these limitations, PUM appeared to have potential in improving the 
appropriateness of antipsychotic use and NHR outcomes, through the timely and 
objective (1) identification of target BPSD for treatment with antipsychotics (and/or 
other psychotropic agents), (2) evaluation of therapeutic outcomes, and (3) monitoring 
for SEs of antipsychotic (and other psychotropic agents).  Specifically, the PUM-
related training provided by the pharmacist appeared to have contributed to the 
increase in NS’s knowledge, induced positive attitude changes towards managing 
BPSD, hence leading to the desired behavior changes to perform PUM and reduced 
stress of the NS when managing NHRs with BPSD.  In turn, PUM led to an increase 
in reporting of BPSD changes, therapeutic responses to antipsychotics and 
antipsychotic SEs by the NS to the visiting psychiatrist, attributing to more dose 
adjustments of these pharmacological agents.  
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Although the number of AEs observed were too few to establish statistical 
significance in any statistical tests, the reduction in the prevalence of fall incidents 
after PUM implementation is encouraging compared to that reported in other 
interventions.125, 144  Specifically, reasons for the observed decrease in these AEs after 
PUM implementation could be: Firstly, the increased reporting of SEs by the NS and 
the corresponding increase in prescribing decisions to change the antipsychotic 
regimens of the NHRs may have alleviated SEs such as EPSE, impairment to balance, 
and drowsiness, hence leading to the prevention of fall incidents; secondly, the more 
discriminative and timely reporting of changes in BPSD could have resulted in the 
increased use of antipsychotics among NHRs with severe agitation, aggression and 
psychotic symptoms, hence reducing behaviors that would predispose to falls or pose 
risks of injuries; thirdly, the extension from the NS’s positive feedback on PUM and 
PUM-related training, the vigilance of the NS towards patient safety in general was 
raised, hence the reduced number of falls.  In addition, it was noted that despite a non-
significant increase in the prevalence of antipsychotic use during the period after 
PUM implementation, the numbers of fall incidents that resulted in unplanned 
referrals for medical attention at the hospitals did not increase.  This observation was 
contrary to common pharmacoepidemiological findings of increased falls and injuries 
with increased prevalence of antipsychotic use.157, 265, 266  Hence, it appeared that 
despite the lack of an emphasis to reduce the overall prevalence of antipsychotic use, 
PUM’s emphasis on monitoring to improve appropriate antipsychotic use may prevent 
unrecognized adverse drug effects, adverse events such as falls, and related 
complications, potentially improving NHRs’ quality of life and reducing healthcare 
costs.   
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Due to the limited sample size and small numbers of unplanned 
hospitalizations and ED visits reported, statistical significant conclusion on the effect 
of PUM on reduction of these AEs could not be drawn.  However, it appeared that 
PUM interventions resulted in greater vigilance with regards to reporting and 
managing SEs of antipsychotics as evident from the different referrals for the 
medication use-related incidents reported during both study periods.  In the specific 
example of the medication use related AE reported before PUM implementation in 
Table 4.18, although symptoms of tardive dyskinesia from antipsychotic use in the 
NHR were first noted by a physiotherapist, who then requested for a review to alter 
the antipsychotic prescription in the medical notes before PUM implementation, the 
documentation went unnoticed and no further action was taken.  The antipsychotic 
depot injections were continued for four months before this NHR was referred to the 
hospital when he showed reluctance to eat for two months.  The NHR was then 
diagnosed with drug-induced dysphagia and was subsequently put on tube-feeding.  
By contrast, prompt referral to the hospital for further assessment of suspected 
antipsychotic SE was made concurrently with a decision to withhold the next 
antipsychotic dose during the period after PUM implementation, when another NHR 
was observed to have acute dystonia and hyperextension of the neck area.   
 
4.4 Summary 
This chapter details the development and implementation of a psychotropic 
use monitoring (PUM) program at the dementia ward of a NH through inter-
professional collaborative efforts.  The evaluation outcomes suggested that the 24-
week prospective intervention with PUM had the potential to improve the 
176 
 
appropriateness of antipsychotic use and NHRs’ outcomes, in terms of reduced BPSD 
and incident of falls and other AEs such as unplanned hospitalizations and ED visits.   
An Assessment for Psychotropic Prescriptions (APP) scale was developed and 
validated with good results for its face and content validity, clinical relevance, inter-
rater reliability and concurrent validity with the NPI.  A set of training materials for 
teaching how to use the APP scale and PUM intervention was also developed and 
used to train the NS to increase their awareness, knowledge, and skills to manage 
BPSD and to better identify SEs of antipsychotics.  These prompted the active 
participation of the NS to carry out PUM, and translated to the positive outcomes over 
the 24-week intervention period.   
From the evaluation outcomes, PUM appeared to be effective in encouraging 
more judicious prescribing of antipsychotics in the NH.  Especially in Asia with huge 
patient loads and meager human resources, interventions such as PUM that uses short 
and reliable assessment scales such as APP is much needed, even in busy outpatient 
clinics and inpatient facilities.  Besides validating the external applicability of PUM 
among NHRs at other NHs and clinical settings, future studies could also evaluate the 
application of PUM to improve the appropriateness of other psychotropic drug classes 
including antidepressants, antiepileptics, and benzodiazepines often prescribed for the 







Exploring the use of computer games in managing BPSD in a NH  
 
5.1 Introduction 
In Chapter 4, the pilot implementation and evaluation of the newly developed 
PUM program in a NH appeared to have potential in improving the appropriateness of 
antipsychotic use and NHR outcomes in the management of BPSD, specifically 
through the timely and objective (1) identification of target BPSD for treatment with 
antipsychotics (and/or other psychotropic agents), (2) evaluation of therapeutic 
outcomes, and (3) monitoring for SEs of antipsychotic (and other psychotropic 
agents).  However, in view of the risks of increased incidents for stroke and sudden 
death with the use of antipsychotics in this population group, the need to explore the 
use of non-pharmacological interventions over the use of antipsychotics in managing 
BPSD persists.  Although evidence on the effectiveness of non-pharmacotherapy 
strategies to reduce BPSD have been limited to studies with small samples and of 
limited duration, stimulation-oriented approaches that involve music, recreational 
activities and various sensory stimulation have been identified to be beneficial, 
specifically in reducing behavioral problems and improving mood while they are in 
use.233  However, these may also be complicated to set-up and administer, as these 
interventions are often individualized, time-consuming, labor-intensive, and require 
high costs.240, 241  Given the various limitations at the NHs for implementing these 
non-pharmacological interventions, alternative stimulation-oriented approaches that is 
relatively cheap, simple in set-up and administration, and that requires minimal input 
in terms of manpower resources could be explored.  The use of digital and multimedia 
technology in the form of computer games may hold promise in filling this gap.   
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In a 2010 national survey, 84% of Singapore households had access to at least 
one computer at home.  Among those aged 60 years and above, although only 24% 
and 22% reported to have used computer and internet respectively, a much higher 
percentage of this population group reported having access to a computer (76%) and 
internet (71%) respectively.267  In the US, although seniors were considered to be 
under-represented among the population who play digital games, the percentage of 
gamers over 50 years of age had increased from 9% in 1999 to 26% in 2008.268  
Hence, computers are ubiquitous, readily available at low cost and may require 
minimal training for the NS to facilitate its use.  Compared to interventions such as 
music and massage therapy, interventions using computers also have the advantages 
of being less labor-intensive and relatively less costly to maintain.   
In the past two decades, investigations on computer games as a recreational 
activity in NHs yielded many positive effects among the frail NHRs, such as 
improving socialization, stimulation, feelings of success of achievement, emotional 
well-being, reaction time, hand-eye coordination, and perceptual-motor skills.269, 270  
Although the feasibility of introducing computer games among NHRs with dementia 
has not been studied, another digital and multimedia intervention of using video 
simulated presence of a family member showed positive effects on reducing BPSD of 
a NHR.  Specifically, when the video was played from an iPad during specific care 
tasks, it allowed the care staff to continue with the normal operating procedures of 
care with minimal resistance from the resident, possibly through positive distraction 
provided by the video.271   
Hence, it is postulated that simple yet interactive computers games of suitable 
content, music and graphics can serve as a recreational activity, provide sensory 
stimulation and create positive diversion for the NHRs who have BPSD.  Secondary 
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to these effects, the need to use antipsychotics in the NHs may be reduced as BPSD 
becomes more manageable.  Hence, a pilot study was conducted, with the primary 
objectives to determine the feasibility of using computer games as a diversional 
strategy to manage BPSD among the elderly NHR in Singapore.   
 
5.2 Methodology 
 The study was carried out in three phases, namely, (1) game screening, (2) 
game selection, and (3) feasibility evaluation, in one NH.  A brief summary of the 









5.2.1 Phase 1 – Game screening 
In Phase 1, free to play games from the internet were first screened to identify 
those that were suitable for the study.  This was important as characteristics of the 
games in terms of its interface, task requirements to make inputs, and the gameplay 
may influence participation, play experience, and outcomes of play, particularly for 
the elderly who often have age-related decline in sensory perception, cognitive 
processes (in dementia), motor abilities, and speed of tasks.269, 272  Hence, based on 
IJsselsteijn and team’s report,272 a criteria for elder-friendly games was first 
developed and used as a quick screening tool to short-list six computer games for use 
in Phase 2. 
 
5.2.2 Phase 2 – Game selection 
 Phase 2 involved selecting two of the six short-listed games.  The selections 
were based on survey responses and feedback from the participants after they had 
tried the games.  In particular, the games that were most engaging and have good 
accessibility and usability273-275  were selected.  As such, the ability of the games to 
engage was measured by the time spent on playing the game, NHRs’ preference, and 
experience during gameplay.  Accessibility referred to the extent to which the 
computer games was designed for the elderly with/without cognitive, motor and/or 
physical disabilities; the evaluation of this was based on the feedback of the 
participants and investigators’ observations on each game.  Usability referred to the 
degree of playability by the elderly, and was measured by the number of errors made 
during interaction with the computer mouse and game interface, amount of time spent 
on learning and re-learning the game, and NHRs’ ability to have fun while playing the 
games.  The evaluation on the NHRs’ ability to have fun was based on the 
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participants’ responses while playing computer games as observed by the 
investigators.   
In addition, the general impact of playing computer games on life satisfaction 
of the NHRs was measured.  The measure of life satisfaction is a reflection of the 
NHRs’ psychological well-being.276  As many studies had reported the positive 
benefit of computer games on the psychological well-being of NHRs,269, 270 it would 
be important to determine if this hypothesis holds true among the study sample in this 
pilot study.  As such, improvements in life satisfaction in relation to playing of 
computer games observed in Phase 2 could provide the basis for introducing computer 
gaming as a tool to create positive diversion for NHRs with BPSD with the benefit of 
enhancing their psychological well-being. 
NHRs without dementia were first identified by the nurses in-charge.  After 
obtaining consent from the NHRs, the Elderly Cognitive Assessment Questionnaire 
(ECAQ)277 was administered to ascertain the absence of dementia (score > 6).  
Following inclusion, all the games were introduced and taught to each participant 
individually on day “1”, who was then allowed to play the game/s of their choice once 
daily from days “2” to “5”.  The duration of each play session was not limited, and the 
participant could start and stop playing when he/she desired.  The same two 
investigators were present at all times, who provided technical assistance or to re-
teach the games when required.  These games were played on two similar desktops 
decked with 17-inch flat-screen monitors with non-reflective screens, and the 
computer mouse was used as the game controller.  The set-ups were placed in the 
common area near the nursing station at the NH.  Feedback on the experience during 
gameplay and general impact of playing computer games were obtained through 
administering the In-game version of the Game Experience Questionnaire (GEQ)278 
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and LS276 questionnaire in face-to-face interviews at the end of day “5”.  Evaluation 
of the GEQ focused on the domains for “competence”, “immersion”, “flow”, and 
“tension”, which described the game’s ability to engage the participants at their levels 
of skills, encourage the participants to focus their attention on the game and elicit 
enjoyment in the process,275, 279 and were deemed to be important measures of the 
games’ purpose as a diversional strategy to manage BPSD.  A copy of these 
questionnaires is shown in Appendix 5.1.  In addition, the participants were asked to 
rank the games according to their preferences.  The time spent on learning and 
playing the games, qualitative feedback from the NHRs and observations by the 
investigators were also recorded.  Friedman two-way ANOVA test was used to 
evaluate the responses to the GEQ and the participants’ game rankings; post-hoc 
pairwise comparisons were done using Wilcoxon signed rank tests.  Wilcoxon signed 
rank test was also used to evaluate the responses to the LS questionnaire.   
 
5.2.3 Phase 3 – Feasibility evaluation 
In Phase 3, the two selected games were piloted among NHRs with dementia, 
to determine the feasibility of computer games as a diversional strategy to manage 
BPSD.  Feasibility was based on the ability of the games to engage the participants, 
its accessibility and usability, and the effect of gameplay on those with BPSD; where 
evaluation of the games’ ability to engage was based on the amount of time NHRs 
spent playing and their responses to the games, while evaluation of the game’s 
accessibility and usability was same as that for Phase 2.  Similar to Phase 2, NHRs 
with dementia were identified by the nurses-in-charge prior to recruitment.  However, 
in addition to obtaining the NHR’s consent to participate, consent was also obtained 
from the NHR’s family members or next-of-kin.  The ECAQ was then administered to 
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ascertain the presence of dementia (score < 7).  Following this, the steps to introduce, 
teach and allow the participants to familiarize the two selected games were the same 
as those in Phase 2.  NHRs’ responses and qualitative feedback during gameplay were 
observed and recorded by the investigators.  The time taken for learning and playing 
the games over the five days were also measured.  In addition, nurses-in-charge of the 
NHRs were interviewed at Days 1 and 5 using the NPI254 to measure changes in the 
NHRs’ behavior between 5-day periods before and after introducing computer games.  
Wilcoxon signed rank test was used to evaluate changes in NPI scores.   
 
5.3 Results 
5.3.1 Phase 1 – Game screening 
A JACLY (an acronym which stands for the initials of the investigators 
involved in this study) criteria for elder-friendly games was developed (Figure 5.2) 
and used to screen 300 free online games obtained from 
www.onlinegamesforseniors.com under the category “bubbles”, “puzzles” and 
“shooting” and their related website links.  Games which met all the criteria were 
short-listed and voted by co-investigators.  This resulted in a final six to be evaluated 
by NHRs without dementia in Phase 2.  These games were Bubble Pandy, Linyca, 
Jungle Tower, Color Breaker, Mushroom Madness, and Simon.  The description of 













5.3.2 Phase 2 – Game selection 
Of the 15 NHRs approached for Phase 2, eight provided consent.  Common 
reasons for refusal to participate were “…I am not interested…”, “…I am too busy 
with other activities and have no time to play computer games…” and “…computer 
games are not for old people but for younger kids…”.  Of the eight NHRs willing to 
try playing computer games although they had never done so before, seven completed 
all five days of gameplay and provided feedback for the selection of games, however, 
one dropped out after Day 3 due to medical reasons.  The demographic and clinical 





Age      Mean ± SD  70.3 ± 14.6  81.8 ± 14.9 
Gender      Male  5  1 
      Female  2  3 
Race      Chinese  7  2 
      Others  0  2 
RAF Category      I & II  2  0 
      III  2  1 
      IV  3  3 
ECAQ score      Mean ± SD  8.4 ± 0.8  4.0 ± 1.8 
 
  
The learning and playing duration for the games, outcomes for the GEQ, and 
participants’ ranking of game preference are illustrated in Figures 5.3 to 5.6.  Linyca 
and Jungle Tower were consistently the top three of the six games that required the 
shortest time for participants to learn (4.3 ± 4.1 and 5.4 ± 1.8 minutes respectively) 
and had the longest duration of play (50.2 ± 28.8 and 80.0 ± 26.3 minutes respectively) 
over the 5-day study period (Figures 5.3 and 5.4).  These two games were also ranked 
among the highest in the GEQ in-game domains (Figure 5.5) for competence, 
immersion and flow of the GEQ, and the lowest for tension (Friedman two-way 
ANOVA, p-value = 0.067, 0.001, 0.003, and 0.060 respectively; post-hoc analysis did 
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not yield statistically significant results).  In addition, Linyca and Jungle Tower were 
also ranked as the two most preferred games by the seven participants in Phase 2 

































Additional feedback by the participants on the games and investigators’ 
observations are reported in Table 5.2.  Although positive reactions and responses 
were observed for Linyca, Jungle Tower, Bubble Pandy and Mushroom Madness, the 
latter two were found to be inferior in accessibility to Linyca and Jungle Tower.  
Specifically, the objectives of Bubble Pandy seemed complicated for three 
participants to comprehend and the rapid clicking required during the gameplay in 
Mushroom Madness was problematic for five participants despite repeated coaching 
and practice.  In addition, Simon and Colour Breaker were also deemed to be the less 
accessible games compared to Jungle Tower and Linyca as six participants opted not 
to play Simon after day one as they had difficulty understanding the game’s 
objectives, while the time limit in Colour Breaker was a barrier for five participants 
who played the game slowly to achieve their target high scores.  Based on these, 































































Improvements to the control of the computer mouse and navigation through 
the game website were observed within five minutes into the game play, with much 
initial coaxing and coaching.  By Day 5, five of the seven participants managed to 
manipulate the computer mouse, navigate and play the games independently, without 
the need for verbal cues or physical interventions by the investigators.  In addition, all 
seven participants responded that there was an increase in LS after the 5-day period 





5.3.3 Phase 3 – Feasibility evaluation 
Five NHRs with dementia were approached and recruited successfully for the 
study in Phase 3.  However, only four completed the study; one of them dropped out 
due to a lack of interest after Day 2.  The demographic and clinical factors of these 
four participants are reported in Table 5.1.  Only one was taking an antipsychotic and 
an antidepressant for the management of BPSD, whereas another was taking a 
cholinesterase inhibitor for the treatment of dementia.   
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The learning and playing durations for the games over the five days in Phase 3 
are shown in Figures 4.26 and 4.27.  On the average, the four participants required 
65% more time to learn how to play Jungle Tower compared to Linyca.  Although the 
games had to be re-introduced to the participants each day, the amount of time spent 
on providing instructions for the gameplay were observed to be decreasing over time 
for both games, among all participants (Figure 5.8).  The mean duration of playing 
computer games among these four participants with dementia was 38 minutes per day 
(± 13, range 15 to 63).  Interestingly, participants in Phase 3 seemed to prefer Linyca 
to Jungle Tower, where on the average, Linyca was played almost twice as long 













In terms of the errors made during interaction with the computer mouse and 
game interface, one participant was unable to move and click the mouse 
simultaneously, and required constant assistance; incidentally, he had the lowest 
ECAQ score of 2.  Despite the inability to play the computer games as intended, this 
participant was observed to be fully engaged by the colours and sound effects of 
Linyca, which he played for an average of 22 minutes each day.   
Conversely, the other three NHRs could overcome the initial difficulty in 
handling the computer mouse despite their motor and cognitive impairments.  In 
addition, the ability of these three NHRs to play Linyca and Jungle Tower improved 
over time.  Specifically, they had progressed from stacking less than 10 blocks in 
Jungle Tower on Day 1 to stacking between 15-20 blocks by Day 5, and moved from 
completing levels 4-5 in Linyca on Day 1 to levels 8-9 by Day 5.  The investigators 
also noticed that these participants were generally able to focus their attention during 
the gameplay sessions, especially when playing Linyca.   
191 
 
As shown in Table 5.3, the computer games elicited positive responses from 
the participants.  However, there was no significant difference in the participants’ 
BPSD before and after the study period (mean NPI score of 4.25 ± 2.22 versus 4.00 ± 





























          
5.4 Discussion 
From the results reported in Section 5.3.2, it appeared that with adequate 
coaching coupled with suitable games, elderly NHRs were able to play computer 
games successfully and independently.  As shown by the desirable changes in the 
scores of LS questionnaire of the participants in Phase 2, playing computer games 
seemed to improve general psychological well-being of elderly NHRs.  This was in 
line with that reported by Jung and team who conducted a local study concerning the 
use of Nintendo Wii games among elderly NHRs.280  In addition, the smiles and 
excitement on their peers’ faces as the participants played the games in the common 
area also drew many curious on-lookers, which added to the social atmosphere.  This 
led to an additional two new NHRs requesting to learn how to play the computer 
games, one of whom was subsequently recruited for the study in Phase 3.  This effect 
was similar to that described by Weisman270 and Boulay et al.273  In addition, all the 
participants were motivated to schedule for the next day’s gameplay sessions, and 
were always punctual.  Four of the participants even continued to play computer 
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games after the study was completed.  These observations were in line with those 
reported by Whitcomb, that hands-on experience can stimulate interest, resulting in 
positive attitude towards learning and a continued use of computers,269 in this case, as 
a recreational tool.   
Among the four participants reported in Section 5.3.3, the participant who had 
the lowest ECAQ score was unable to move and click the mouse simultaneously, 
hence requiring constant assistance during the gameplay.  It seemed logical then that 
the severity of cognitive impairment may play a role in the successful use of the game 
controller.  In addition, the participant’s inability to use the mouse corresponded with 
that described by Boulay et al,273 who related this to deficiencies in the visual-spatial 
processing, episodic memory and the working memory.  On the other hand, the ability 
to overcome the initial difficulty in handling the computer mouse observed in the 
other three participants’ may be related to the presence of preserved implicit motor 
learning ability in dementing diseases, thus allowing the participants to pick up 
procedural skills by repeated exposure and subsequent revival from implicit 
memory.281 
Overall, the findings suggested that playing computer games may be a feasible 
diversional strategy in managing BPSD as suitable computer games such as Linyca 
and Jungle Tower were shown to have good accessibility and usability by the 
participants with dementia, and were able to arouse their interest and draw them to 
focus on the gameplay.  Although surveys such as the GEQ and LS could not be 
administered among these participants, the significant positive change in the 
psychological well-being of participants in Phase 2, the encouraging participants’ 
responses in Phase 3, and the examples reported by Boulay et al.273 on the effects of a 
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Wii game on elderly with dementia, led to the conclusion that playing computer 
games could improve the psychological well-being of some NHRs with dementia.   
As this pilot study was limited by time, resources and the sample size, the 
effects of playing computer games on BPSD should be further evaluated among more 
elderly with dementia and BPSD, with the inclusion of a control group to improve the 
external validity and generalizability of the results.  The impact of longer periods of 
exposure to computer games, the feasibility of playing computer games among elderly 
with more advanced cognitive impairment, and the impact of this non-
pharmacological intervention on pharmacological use trends in managing BPSD may 
be evaluated in future studies. 
In addition, although the six short-listed games complied with the JACLY 
criteria for elder-friendly games, games such as Simon, Mushroom Madness and 
Colour Breaker were found to be less user-friendly by five out of the seven 
participants in Phase 2.  Future studies could look at the development of a refinement 
of JACLY criteria, such as adding (1) a domain for the presence of animation and 
sounds that can help to illustrate game objectives and (2) quantifiable sub-domains 
under the domain for speed of gameplay, to define the time limits for the player to 
respond to cues, pause between multiple inputs, and complete each game stage levels.   
 
5.5 Summary 
  In this chapter, a pilot study to determine the feasibility of using computer 
games as a diversional strategy in managing BPSD was conducted at a NH in three 
phases; which began with short-listing of suitable computer games that were elder-
friendly, by using the JACLY criteria developed, followed by a further selection by 
NHRs without dementia, and finally the use of the selected games for testing of their 
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ability to engage, accessibility, and usability by NHRs with dementia.  The overall 
findings suggest that suitable games accepted by the participants with dementia could 
arouse their interests, and capture their attention on the gameplay for at least 30 
minutes per day during the 5-day study period.  From the survey responses of the 
NHRs without dementia and the investigators’ observations of those with dementia, 
the playing of computer games could plausibly lead to improved psychological well-
being of the NHRs in general.  Hence, it may be promising to further explore the use 








 Prescribing is the first and major decision-making stage in the medication use 
process.  Therefore, IP in the NHs can directly impact patient outcomes, especially 
when there is full compliance in the “administration” of medications for regular use or 
a lack in judicious “administration” of medications for short-term use by the NS.  
Interventions by pharmacists who play a primary role in the “monitoring” stage of the 
medication use process, were often focused on medication safety and limited in terms 
of improving the appropriateness of prescribing/use of medications.  This is of 
concern as there appears to be a continuously high prevalence of IP (Chapter 2).  
Although the role of the pharmacists in medication review is well established and 
valued (Table 1.3), such interventions were often general and lacked evidence of their 
impact on clinical outcomes of NHRs.  By leveraging on their role as the “advocator” 
of appropriate medication use and prescribing in the NHs, pharmacists can improve 
PA and bring positive impact on patient outcomes through engaging the physicians 
and NS in innovative inter-professional collaborative practices.  Such collaborative 
efforts can close the gap between individual efforts made by each healthcare 
professional towards PA and positive patient outcomes in the medication use process 
(Figure 6.1).  The work in this thesis demonstrated how two such innovative inter-
professional collaborative interventions can be developed, implemented and evaluated 





















































































































































































































































































































































To the author’s knowledge, the Pharmacist-Led Education on Appropriate 
Drug-use (PLEAD) program for laxatives is the first intervention led by a pharmacist, 
which was successfully implemented in a pilot study with collaborative efforts of the 
NS, physicians and key administrators through behavioral changes to improve the 
appropriateness of laxative use and patient outcome among the elderly NHRs 
(Chapter 3).  In conventional medication reviews, pharmacists’ recommendations are 
communicated to fellow healthcare professionals in the team through written notes in 
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the NHRs’ medical records, which may often be overlooked or misunderstood.  By 
comparison, the PLEAD program provides an effective platform for raising issues and 
identifying gaps, educating and communicating recommendations for appropriate 
laxative use.  Firstly, the educational nature of the workshop created a 
congenial/friendly learning environment which fosters open communication282 
between and among the health care professionals and administrators.  Secondly, the 
workshop provided recommendations with references to the research findings, which 
facilitated the understanding by the audience on how the attitudes and behaviors of 
NHRs and health care professionals could impact the appropriateness of laxative use 
and clinical outcomes.  As such, positive assertion283 of the issues and gaps was 
created which enhanced situational awareness and encouraged behavioral changes 
among the NS and administrators.  Thirdly, the discussion session at the end of the 
workshop also provided opportunities for the audience to seek clarification and to 
elicit commitment to action and behavioral changes towards appropriate laxative use 
by the NS.  Lastly, communication of the PLEAD workshop content to the physicians 
through the mail delivery of the “Dear Healthcare Professional Letters” was concise 
and relevant.  This was coupled with the efforts by the NS to bring about physician’s 
acceptance and adoption of these recommendations.  In addition, although 
recommendations made in conventional medication reviews and the PLEAD program 
are both retrospective in nature, the former is usually case-based and hence elicit 
actions that are once-off.  In contrast, the recommendations in the PLEAD program 
are coupled with educational information which allows the NS and physician to relate 
and apply to various uncomplicated case scenarios that require laxative use, hence, 
they may have wide-spreading effects through eliciting actions that are both 
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retrospective in correcting currently identified inappropriate laxative use and 
prospective in preventing future incidents of inappropriate practices.   
Thus, based on the results reported from the pilot study in this thesis, more 
NHs should be enrolled in a cluster randomized study to further evaluate the 
effectiveness of the PLEAD program.  Through this, more elderly NHRs can also 
potentially benefit from this program, especially when the current capacity increases 
by 50% to 14,000 by 2020.284  Updates to the program content can also be made 
pending on the emergence of new clinical practice evidence.  There may be a need to 
develop PLEAD programs for other medications, which use may be influenced by 
beliefs and attitudes of the prescriber, NS and NHRs, such as analgesics and 
hypnotics. 
Further to PLEAD, an Algorithm for Appropriate Laxative Use (AALU) was 
developed (Chapter 3).  The AALU (Table 6.2) adds to the list of PA instruments 
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The AALU fills the gap of the other PA instruments by addressing the 
prescribing and use of laxatives, which are the most prevalent and commonly misused 
medications at the NH (Chapters 2 and 3).  Compared to the PA instruments such as 
the NAI38 and the Nursing Home Prescribing Indicators40 written in the form of 
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algorithms that target specific pharmacological agents/groups, AALU provides a more 
comprehensive assessment of the PA by allowing the user to measure “under-
prescribing” of laxatives for regular use and “under-use” of laxatives when necessary.  
Similar to the MAI, AALU allows for both explicit and implicit assessments of the 
PA of laxatives.  While the use of MAI was mostly reported in retrospective MUE, 
there is potential to use the AALU as a guide for timely decision-making during the 
“prescribing” and “administration” stage of the laxative use process.  Hence, future 
work can evaluate the effectiveness and impact of AALU on laxative use trends and 
NHR outcomes for either retrospective MUEs or prospective intervention.   
Among the reported interventions that aimed to improve antipsychotic use for 
BPSD in the NH (Tables 1.4 and 4.1), the Psychotropic Use Monitoring (PUM) 
program reported in Chapter 4 is the first that synergizes the expertise of the 
pharmacist, NS and physician at the “monitoring” stage of the medication use process 
(Table 6.1).  After being trained to use the Appropriate Psychotropic Prescribing 
(APP) scale that was developed for the PUM program, standardized and reliable (1) 
identification of target symptoms for appropriate treatment/management strategy, (2) 
monitoring for pharmacological therapeutic outcomes and (3) onset of psychotropic 
SE can be achieved by the NS while they carry out their usual duties.  Based on 
timely feedback to the physicians by the NS, desirable outcomes which included 
increased antipsychotic dose adjustments, fewer psychiatric problems and fewer AEs 
among the elderly NHRs could be achieved without the need for prolonged case 
conferencing or lengthy medication reviews.  Through the positive outcomes of the 
preliminary study of the PUM program and the related training in a single NH, 
pharmacists can play an important role as the trainer and advocator for appropriate 
medication use, in this case, of antipsychotics.   
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Therefore, applications of the PUM program and the use of the APP scale and 
SE monitoring list through inter-professional collaborative efforts may be an effective 
intervention to improve PA of antipsychotics and patient outcomes among patients 
with dementia at other intermediate and long-term care institutions.  Such 
collaborative interventions and related training will become increasingly valuable 
with the impending need to grow and improve the quality of the healthcare 
professional workforce in the NHs, driven by the needs of Singapore’s ageing 
population.285  Future work on evaluating the PUM program in a cluster randomized 
study involving more NHs is needed, which will also include evaluating the 
application of PUM to improve the PA of other psychotropic drug classes commonly 
used for managing BPSD, such as antidepressants, antiepileptics, and benzodiazepines.  
In response to the MOH’s initiatives to enhance the quality of care and support 
provided to patients and their caregivers in the community,286-288 pharmacists can 
provide training of how to use the APP scale and PUM to caregivers such as family 
members and domestic helpers in the community setting.  Such training may fill their 
expressed gap to cope with their loved ones with BPSD under their care at home,289 
through improving their understanding of dementia, reducing caregiving stress, and 
BPSD and equipping them with skills to play a part in appropriate pharmacotherapy 
treatment for their loved when necessary,236 to achieve optimal treatment outcomes 
when applicable, prevent adverse outcomes from psychotropic use and defer 
hospitalization and/or institutionalization of their loved ones to the NH.   
This thesis also explored the feasibility of using computer games as a 
diversional strategy to engage elderly NHRs with BPSD (Chapter 4).  Outcomes from 
the pilot study suggest that the elderly with physical and/or mild cognitive impairment 
can play computer games and embrace this novelty.  Further studies will be needed to 
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evaluate the impact of longer periods of exposure to computer games, the feasibility 
of this non-pharmacological intervention on NHRs with a range of cognitive 
impairment, and the intervention’s impact on the changes in BPSD, trends of using 
pharmacologicals to manage BPSD and caregiver stress.  In the process of this work, 
a JACLY criteria for elder-friendly games was developed as a screening tool for 
selecting suitable computer games.  This criteria can be refined to better serve its 
original purpose or as a guide for the development of computer games for elderly with 
dementia and BPSD.  From the outcomes in Phase 2 of the pilot study, there is also 
potential to evaluate the use of suitable computer games as a recreational activity in 
NHs, day care centers and the community setting to create an inclusive environment, 
promote social integration and improve the quality of life and general well-being of 
elderly in general.  
The pharmacist has played critical role of an advocator for appropriate 
medication prescribing/use at the “monitoring” stage of the medication use process.  
Pharmacists can also provide interventions at the earlier “supply” stage to prevent the 
impact of IP from being carried forward to the “administration” stage.  However, the 
current lack of infrastructure linking the medical information of the NHRs to the 
dispensing pharmacists at other practice settings (community or hospital) poses a 
challenge for interventions to be made beyond checking of skill-based medication 
errors in prescribing.  Selected pharmacists should be allowed to gain access to the 
National Electronic Health Records system,290 which is set to link information 
between the primary, tertiary and long-term care institutions in Singapore, to allow 
interventions that may improve PA to be made at the “supply” stage, and add timely 
advice/recommendations to improve the appropriateness of medication use during the 
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“administration” stage, thus preventing any consequent adverse outcomes from such 
“first pass” effect.    
In conclusion, innovations to improve PA and direct patient outcome from the 
use of specific drug groups within certain diseases among the elderly NHRs in 
Singapore can be achieved, through inter-professional collaborative efforts, while 
leveraging on the pharmacists’ role as the “advocator” of appropriate medication use 
and prescribing.  The unique role of pharmacists and the dynamics of interaction with 
other healthcare professionals for medication management in the NH setting have also 
been redefined.  This could prompt more pharmacists to continue to fill the gaps in 
medication management and encourage fostering of a stronger team-based care model 
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 in Singapore 
 The population of persons aged 65 years and above will increase from the 8.7% 
(2008) to 19% (2030).   
 
Nursing Home Capacity 




 The total number of NHs is 63.  In all, they contribute 9265 beds (2010).3  Of 
all the NH, 31 are run by the commercial sector, and 32 are run by Volunteer 
Welfare Organizations (VWO).   
 The bed capacity will be increased by 50% to 14,000 by year 2020.4   
 
Expenditures and Fees of NH 
 NHs run by VWOs can receive 50-100% financial assistance from the 
government on various expenditures.
5
   
 Patients who are admitted to VWO-run and some privately-run NHs through 
referral by the Agency for Integrated Care (AIC) and who meet the means test 
criteria
6
 may receive 10-75% subsidies
7
 for the NH fees.   
 Patients can also be admitted as a full-paying patient, without any subsidy for 
the NH fees. 
 
Standards of Care within NH 
 Currently, up to 70% of the 4,000 formal long-term care workers are 
foreigners from the Philippines, Sri Lanka and Myanmar.  A third of these 




 The standards of care and service of all NHs are presented in a set of 
guidelines that was updated in 2004.
2
  The different aspects of medication 
management, including purchasing, storage, packaging, prescription, 
administration and quality assurance are covered in a separate set of guidelines 
updated in 2005.
9
   
 The roles of the visiting physician and NS (including registered nurse, enrolled 
nurse, nursing aide, and health care assistant) and defined in the Guidebook on 
Nursing Homes
2
 while that of the visiting pharmacist is spelled out in the 




Guidelines on Medication Management in Nursing Homes
9
.   These are 
summarized in the Table below. 
 However, there are no regulations or enticements in place to enforce 
compliance by the NHs.   Hence, the standard of care varies among the NHs. 
Roles of Healthcare Professions 
Physicians 
- Provide medical care to residents 
- Perform medical and medication reviews (within 48 hours at first admission 
and at least every 6 monthly) 
- Involve in education and training of nurses and allied health personnel 
Registered Nurse 
- Provide nursing care 
- Develop nursing care plan and implement nursing interventions, includes 
evaluation of residents’ response to care interventions 
- Supervise, educate and train NS 
- Prepare clinical documentation (including reporting incidents of falls, deaths, 
accidents, injuries, transfers to hospitals and categorization of residents  and 
maintaining the residents’ medication records) 
Enrolled Nurse 
- Assist registered nurse 
- Provide nursing care and patient assessments 
Nursing Aide / Health Care Assistant 
- Assists and supervises individual resident’s activities of daily living  
- Attends to residents’ complaints 
- Identifies and reports residents’ needs to the registered nurse 
- Maintains accurate documentation of care given 
Pharmacist 
- Identify, prevent and resolve medication-related problems (at least 6 monthly) 
- Evaluate residents’ progress toward achieving therapeutic outcomes from drug 
therapies and ensure that these are appropriately indicated, effective, safe and 
convenient 
- Develop policies, procedures and guidelines for the use of medicines in the 
facility, minimum standards and quality assurance standards 
- Educate NS on pharmaceutical policies and procedures, medication 
administration, pharmacology and drug therapy, and monitoring of drug 
therapy for possible adverse effects and the attainment of therapeutic objectives 
- Provide drug information services to health professionals of the NH 
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PCNE Classification for DRPs (V5.01) Appendix 2.2 
A9 
 
PCNE Classification for DRPs (V5.01) 
 
Primary Domains Sub-domains 
Problems 
[P1]  Adverse reaction(s)  [P1.1] – side effect suffered (non-allergic) 
 [P1.2] – side effect suffered (allergic) 
 [P1.3] – toxic effects suffered 
[P2]  Drug choice problem  [P2.1] – inappropriate drug (not most appropriate for indication) 
 [P2.2] – inappropriate drug form (not most appropriate for 
indication) 
 [P2.3] Inappropriate duplication of therapeutic group or active 
ingredient 
 [P2.4] Contra-indication for drug (including pregnancy/breast 
feeding) 
 [P2.5] No clear indication for drug use 
 [P2.6] No drug prescribed but clear indication 
[P3]  Dosing problem  [P3.1] – drug dose too low or dosage regime not frequent 
enough 
 [P3.2] – drug dose too high or dosage regime too frequent 
 [P3.3] – duration of treatment too short 
 [P3.4] – duration of treatment too long 
[P4]  Drug use problem  [P4.1] – drug not taken/administered at all 
 [P4.2] – wrong drug taken/administered 
[P5]  Interactions  [P5.1] – potential interaction 
 [P5.2] – manifest interaction 
[P6] Other  [P6.1] – patient dissatisfied with therapy despite taking drug(s) 
correctly 
 [P6.2] – insufficient awareness of health and diseases (possibly 
leading to future problems) 
 [P6.3] – unclear complaints. Further clarification necessary 
 [P6.4] – therapy failure (reason unknown) 
Causes 
[C1] Drug/Dose selection  [C1.1] – inappropriate drug selection 
 [C1.2] – inappropriate dosage selection 
 [C1.3] – more cost-effective drug available 
 [C1.4] – pharmacokinetic problems, including 
ageing/deterioration in organ function and interactions 
 [C1.5] – synergistic/preventive drug required and not given 
 [C1.6] – deterioration/improvement of disease state 
 [C1.7] – new symptom or indication revealed/presented 
 [C1.8] – manifest side effect, no other cause 
[C2] Drug use process  [C2.1] – inappropriate timing of administration and/or dosing 
intervals 
 [C2.2] drug underused/ under-administered 
 [C2.3] drug overused/ under-administered 
 [C2.4] therapeutic drug level not monitored 
 [C2.5] drug abused (unregulated overuse) 
 [C2.6] patient unable to use drug/form as directed 
[C3] Information  [C3.1] – instructions for use/taking not known 
 [C3.2] – patient unaware of reason for drug treatment 
PCNE Classification for DRPs (V5.01) Appendix 2.2 
A10 
 
 [C3.3] – patient has difficulties reading/understanding Patient 
Information Form/Leaflet 
 [C3.4] – patient unable to understand local language 
 [C3.5] – lack of communication between healthcare 
professionals 
[C4] Patient/Psychological  [C4.1] – patient forgets to use/take drug 
 [C4.2] – patient has concerns with drugs 
 [C4.3] – patient suspects side effects 
 [C4.4] – patient unwilling to carry financial costs 
 [C4.5] – patient unwilling to bother physician 
 [C4.6] – patient unwilling to change drugs 
 [C4.7] – patient unwilling to adapt life-style 
 [C4.8] – burden of therapy 
 [C4.9] – treatment not in line with health beliefs 
 [C4.10] patient takes food that interacts with drugs 
[C5] (Pharmacy) logistics  [C5.1] – prescribed drug not available (anymore) 
 [C5.2] – prescribing error (only in case of slip of the pen) 
 [C5.3] – dispensing error (wrong drug or dose dispensed) 
[C6] Other  [C6.1] – other causes; specify 
 [C6.2] – no obvious cause 
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Algorithms for Appropriate Laxative Use (AALU) 
AALU (1): Was “when-needed” laxative used appropriately? 
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AALU (2): Was the “regular” laxative prescribed appropriately?
 




















 Feb  1 hour Introduction 
to PUM  
Understand: 
- Role of nursing staff in the 
management of BPSD 
- Use of psychotropics in managing 
BPSD: 
o pharmacotherapy brief of all 
common psychotropics used 
o issues of concern over 
antipsychotic use 
- Significance of monitoring to 
improve appropriate antipsychotic 
use 
- Aim and objectives of PUM 
 
Gain ability to perform PUM  
- know when and how to observe,  
recognize, and document: 
o different BPSD types and 
symptom severity 
o therapeutic response to 
psychotropic use 
o psychotropic side effects 







 Feb  
2 weeks Pilot the 
PUM form 
Practice observation skills and 
documentation on PUM form 
Week ‘1’ 28th Feb  Implementation of PUM 
Week ‘4’ 21st Mar ½ hour Review  Case discussions 
Week ‘8’ 18th Apr ½ hour Review and 
further 
learning  
Case discussions  
 
Understand the brief etiology, clinical 
significance on falls, and know how to 
assess, recognize and manage drug-
induced postural hypotension 
Week ‘12’ 16th May 1hour Review and 
further 
learning  
Case discussions  
 
Understand the brief etiology, clinical 
significance on falls, and know how to 
assess, recognize and manage extra-
pyramidal side effects (EPSE) 
 











































































Scoring Guidelines: GEQ In-Game version 
The In-game Module consists of seven components, identical to the core Module.  However, 
only two items are used for every component.  The items for each are listed below. 
Components scores are computed as the average value of its items. 
 
Competence: Items 2 and 9 
Sensory and Imaginative Immersion: Items 1 and 4 
Flow: Items 5 and 10 
Tension: Items 6 and 8 
Challenge: Items 12 and 13 
Negative Affect: Items 3 and 7 
Positive Affect: Items 11 and 14 
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 This is a puzzle bubble shooter game 
that requires players to shoot bubbles of 
similar colours into groups of three or more in 
order to make them disappear.  The objective 
of this 12-level game is to burst all the bubbles 
before they grow towards and touch the 
surrounding wall. [Available at: 
http://juegosya.org/bubble-pandy/] Last 







This is a relatively easy to play puzzle-type 
game in which the goal is to remove as many 
rows of coloured blocks as possible, by clicking 
on blocks with a matching colour in the same 
row; clicking on blocks without a match results 
in a deduction of points.  Each successful blocks 
removed will trigger a musical tone that 
corresponds to its color.  The resulting melody 
is then played back when the game is completed.  [Available at: 
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Jungle Tower  
 
  This game requires the player to balance 
dropping blocks on a plank.  The objective is to 
build a tower of blocks as high as possible without 
tipping the plank or letting any blocks fall off.  
[Available at: http://www.kingofgames.net/free-
games/Jungle_Tower_2_The_Balancer]  Last 














 This is a Mahjong type of game that 
requires the player to click on matching coloured 
blocks exposed at the extreme right and left of the 
grid to make them explode.  The objective of this 
game is to clear the grid of blocks as much as 
possible within a 60-second time limit.  [Available 
at: http://www.fupa.com/play/Action-free-









 This is an arcade shooter game 
where the player needs to protect their 
mushroom fields from hungry animals 
by using various tools such as a fly 
swatter to make the latter go away.  
[Available at: 
http://www.miniclip.com/games/mushr
oom-madness/en/ ]  Last accessed: 








 This is a memory game that requires the 
player to follow color (with light and sound) 
sequences, which gets longer in length with 
each correct sequence followed.  A wrong input 
will render a game over.  [Available at: 
http://www.free-coloring-
pages.com/game/simon/index.html ]  Last 
accessed: August 2012. 
 
